"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT04202341","Registry of Participants With Generalized Myasthenia Gravis Treated With C5 Inhibition Therapies",,"Recruiting","No Results Available","Generalized Myasthenia Gravis",,"Collect Real-world Effectiveness Data In Participants Using Alexion C5IT Therapy|Collect Real-world Data On Other Outcomes Of Interest In Alexion C5IT-treated Participants","Alexion Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)",,"500","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ALXN-MG-501","December 11, 2019","November 2024","November 2024","December 17, 2019",,"December 17, 2020","Clinical Trial Site, Phoenix, Arizona, United States|Clinical Trial Site, Fresno, California, United States|Clinical Trial Site, Rancho Mirage, California, United States|Clinical Trial Site, Clearwater, Florida, United States|Clinical Trial Site, Augusta, Georgia, United States|Clinical Trial Site, Lake Barrington, Illinois, United States|Clinical Trial Site, Las Vegas, Nevada, United States|Clinical Trial Site, Durham, North Carolina, United States|Clinical Trial Site, Houston, Texas, United States|Clinical Trial Site, Burlington, Vermont, United States",,"https://ClinicalTrials.gov/show/NCT04202341"
2,"NCT04463056","Efficacy and Safety of Elizaria® vs. Soliris® in Patients With PNH",,"Completed","No Results Available","Paroxysmal Nocturnal Hemoglobinuria|Marchiafava-Micheli Syndrome|Paroxysmal Hemoglobinuria","Biological: Elizaria®|Biological: Soliris®","Area under the LDH concentration-time curve (LDH AUC) during the maintenance therapy with the test drug or the reference drug|Area under the LDH concentration-time curve (LDH AUC) during 26-week therapy with the test product or the reference product|Hemoglobin level change during the maintenance therapy with the test drug or the reference drug|Number/proportion of the patients with stable hemoglobin level during the maintenance therapy with the test drug or the reference drug|Number/proportion of patients with various thrombotic complications developing during treatment with the test product or the reference product.|Number/proportion of patients who needed donor red blood cell transfusions during treatment with the test product or the reference product.|Number of donor red blood cell transfusions during treatment with the test product or the reference product.|Number/proportion of patients with breakthrough hemolysis","AO GENERIUM","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","32","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ECU-PNH-III|#546 eff date 17.10.2017","November 29, 2017","October 16, 2018","October 16, 2018","July 9, 2020",,"September 1, 2021","Federal State Budget Funded Institution National Medical Research Center of Hematology, Ministry of Health of the Russian Federation (MoH of Russia), Moscow, Russian Federation|Moscow State Budget Funded Healthcare Institution S. P. Botkin City Clinical Hospital, Moscow Department of Healthcare, Moscow, Russian Federation|State Budget Funded Institution of Higher Education Academician I. P. Pavlov Saint-Petersburg State Medical University of the Ministry of Health of the Russian Federation, Saint Petersburg, Russian Federation|State Budgetary Educational Institution of Higher Professional Education Samara State Medical University, Ministry of Health of the Russian Federation., Samara, Russian Federation",,"https://ClinicalTrials.gov/show/NCT04463056"
3,"NCT01374360","Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry",,"Recruiting","No Results Available","Paroxysmal Nocturnal Hemoglobinuria",,"Evaluate safety data specific to the use of Soliris and Ultomiris|Collect data to characterize the progression of PNH as well as clinical outcomes, mortality and morbidity in Soliris or Ultomiris and non-Soliris or non- Ultomiris treated patients","Alexion Pharmaceuticals","All","Child, Adult, Older Adult",,"5000","Industry","Observational","Observational Model: Other|Time Perspective: Prospective","M07-001","January 2007","December 2025","December 2025","June 16, 2011",,"December 15, 2021","Contact the PNH Registry at Alexion Pharmaceuticals, Inc. for worldwide locations., Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01374360"
4,"NCT05047523","Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson Disease",,"Recruiting","No Results Available","Wilson Disease","Drug: ALXN1840|Drug: Standard of Care","Percentage Change From Baseline To Week 48 In Non-ceruloplasmin-bound Copper (NCC) In Plasma|Area Under The Effect Versus Time Curve (AUEC) For NCC And Plasma Total Copper|Observed Change From Baseline To Week 48 Of Ceruloplasmin-bound Copper And Ceruloplasmin|NCC Responder Rate|Change From Baseline To Week 48 In The UWDRS Part II Total Score|Change From Baseline To Week 48 In The UWDRS Part III Total Score|PK: Maximum Observed Concentration (Cmax) Of ALXN1840 For Plasma Total Molybdenum And Plasma Ultrafiltrate Molybdenum Concentrations|PK: Time To Maximum Concentration (Tmax) Of ALXN1840 For Plasma Total Molybdenum And Plasma Ultrafiltrate Molybdenum Concentrations|PK: Area Under The Plasma Concentration Versus Time Curve From Time 0 To The End Of The Dosing Interval (AUCtau) Of ALXN1840 For Plasma Total Molybdenum And Plasma Ultrafiltrate Molybdenum Concentrations|Clinical Global Impression-improvement (CGI-I), As Assessed By The Investigator|Change From Baseline To Week 48 In Clinical Global Impression-severity (CGI-S), As Assessed By The Investigator|Change From Baseline To Week 48 In Model For End-stage Liver Disease (MELD) Score (Ages 12 Years And Older) Or Pediatric End-stage Liver Disease (PELD) Score (Ages 3 To < 12 Years)|Change From Baseline To Week 48 In Modified Nazer Score","Alexion Pharmaceuticals","All","3 Years to 17 Years   (Child)","Phase 3","48","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","ALXN1840-WD-302|2021-001015-82","October 6, 2021","October 31, 2023","May 31, 2024","September 17, 2021",,"March 2, 2022","Clinical Trial Site, Parkville, Australia|Clinical Trial Site, South Brisbane, Australia|Clinical Trial Site, Chiba, Japan|Clinical Trial Site, Kumamoto, Japan|Clinical Trial Site, Kurume, Japan|Clinical Trial Site, Meguro-Ku, Japan|Clinical Trial Site, Sapporo, Japan|Clinical Trial Site3, Seoul, Korea, Republic of|Clinical Trial Site, Seoul, Korea, Republic of|Clinical Trial Site 2, Seoul, Korea, Republic of|Clinical Trial Site, Warsaw, Poland|Clinical Trial Site, Barcelona, Spain|Clinical Trial Site, Barcelona, Spain|Clinical Trial Site, Las Palmas de Gran Canaria, Spain|Clinical Trial Site, Madrid, Spain|Clinical Trial Site, Pamplona, Spain",,"https://ClinicalTrials.gov/show/NCT05047523"
5,"NCT02763215","The Assessment of Copper Parameters in Wilson Disease Participants on Standard of Care Treatment",,"Completed","Has Results","Wilson Disease","Drug: Standard of Care Medications","Percentage Of Participants Who Achieved Or Maintained Normalized Concentrations Of Non-ceruloplasmin-bound Copper (NCC) Or Reached A Reduction Of ≥ 25% In NCC During 6 Months Of Treatment|Percentage Of Participants Who Achieved Or Maintained Normalized Concentrations Of NCC Or Reached A Reduction Of ≥ 25% In NCC Through Last Assessment|Change From Baseline In NCC Concentrations At Month 6, Month 24, And Last Assessment|Time To Normalization Of NCC If Above The Reference Range At The Time Of Enrollment|Change From Baseline In Exchangeable Copper At Month 6, Month 24, And Last Assessment|Change From Baseline In Copper Plasma Ultrafiltrate At Month 6, Month 24, And Last Assessment|Change From Baseline In Plasma Total Copper Used To Calculate NCC At Month 6, Month 24, And Last Assessment|Change From Baseline In Serum Total Ceruloplasmin (Nephelometry) Used To Calculate NCC At Month 6, Month 24, And Last Assessment|Change From Baseline In 24-Hour Urinary Copper At Month 6, Month 24, And Last Assessment|Change From Baseline In Plasma Total Molybdenum At Month 6 And Month 24|Change From Baseline In Molybdenum Plasma Ultrafiltrate At Month 6 And Month 24|Change From Baseline In 24-Hour Urinary Molybdenum At Month 6 And Month 24|Change From Baseline In Hepatic Laboratory Measures For Alanine Aminotransferase (ALT) At Month 6, Month 24, And Last Assessment|Change From Baseline In Hepatic Laboratory Measures For Aspartate Aminotransferase (AST) At Month 6, Month 24, And Last Assessment|Change From Baseline In Hepatic Laboratory Measures For Bilirubin At Month 6, Month 24, And Last Assessment|Change From Baseline In Hepatic Laboratory Measures For International Normalized Ratio (INR) At Month 6, Month 24, And Last Assessment|Change From Baseline In Clinical Global Impression (CGI) Scale Item 1 (Severity Of Illness) At Month 6, Month 24, And Last Assessment|CGI Scale Item 2 (Global Improvement) At Month 6, Month 24, And Last Assessment","Alexion Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)",,"64","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","WTX101-203","May 19, 2016","January 21, 2019","January 21, 2019","May 5, 2016","October 26, 2020","December 1, 2020","Clinical Trial Site, New Haven, Connecticut, United States|Clinical Trial Site, Chicago, Illinois, United States|Clinical Trial Site, Ann Arbor, Michigan, United States|Clinical Trial Site, Nashville, Tennessee, United States|Clinical Trial Site, Seattle, Washington, United States|Clinical Trial Site, Vienna, Austria|Clinical Trial Site, Heidelberg, Germany|Clinical Trial Site, Warszawa, Poland|Clinical Trial Site, Birmingham, United Kingdom|Clinical Trial Site, Guildford, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/15/NCT02763215/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/15/NCT02763215/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02763215"
6,"NCT02598583","Dose-Escalation Study of ALXN1210 IV in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)",,"Active, not recruiting","Has Results","PNH","Biological: ALXN1210","Percent Change In Lactate Dehydrogenase (LDH) Levels From Baseline To Day 169|Percent Change In Free Hemoglobin Levels From Baseline To Day 169|Percent Change In Haptoglobin Levels From Baseline To Day 169|Percent Change In Reticulocyte/Erythrocyte Count From Baseline To Day 169|Percent Change In Paroxysmal Nocturnal Hemoglobinuria (PNH) Red Blood Cell (RBC) Clones From Baseline To Day 169|Percent Change In D-dimer Levels From Baseline To Day 169|Change In Clinical Manifestations Of PNH From Baseline To Day 169","Alexion Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","13","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ALXN1210-PNH-103","November 2015","July 2016","June 2021","November 6, 2015","January 30, 2018","August 7, 2020","Clinical Trial Site, Liverpool, New South Wales, Australia|Clinical Trial Site, Woolloongabba, Queensland, Australia|Clinical Trial Site, Ulsan, Gyeonggi-do, Korea, Republic of|Clinical Trial Site, Daejeon, Korea, Republic of|Clinical Trial Site, Seoul, Korea, Republic of|Clinical Trial Site, Seoul, Korea, Republic of|Clinical Trial Site, Seoul, Korea, Republic of|Clinical Trial Site, Seoul, Korea, Republic of|Clinical Trial Site, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02598583"
7,"NCT00485576","Safety and Efficacy Study of Eculizumab in Patients With Mild Allergic Asthma",,"Completed","No Results Available","Allergic Asthma","Drug: eculizumab","Allergen-induced late asthmatic response as measured by the AUC of FEV1 from 3 to 7 hours post-allergen challenge|At 24 hours post-allergen challenge; treatment comparison of allergen-induced changes from baseline in sputum eosinophils and metachromatic cells|Allergen-induced airway responsiveness 24 hours post-allergen challenge as primary interest; 72 hour assessment timepoint will be supportive|Maximum % decrease in FEV1 from 3 to 7 hours post-allergen challenge|% decrease of FEV1 at 24 hours post-allergen challenge|AUC and maximum % fall of FEV1 from 0-3 hours post-allergen challenge","Alexion Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","21","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","C07-002","September 2007","September 2008","November 2008","June 13, 2007",,"January 15, 2009","McMaster University, Hamilton, Ontario, Canada|Hospital Laval, Ste-Foy, Quebec, Canada",,"https://ClinicalTrials.gov/show/NCT00485576"
8,"NCT04752566","A Study to Evaluate the Efficacy and Safety of Eculizumab in Guillain-Barré Syndrome",,"Recruiting","No Results Available","Guillain-Barre Syndrome","Biological: Eculizumab|Drug: Placebo","Time To First Reaching A Hughes FG Score ≤ 1|Proportion Of Participants With A Hughes FG Score ≤ 1|Proportion Of Participants With A Hughes FG Score Improvement Of ≥ 3|Incidence Of Treatment-emergent Adverse Events|Free Complement Component 5 In Serum|Hemolytic Complement Activity In Serum|Length Of Stay In The Hospital|Duration Of Ventilator Support|Concentration Of Eculizumab In Serum|Incidence Of Antidrug Antibodies","Alexion Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","57","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","ECU-GBS-301","March 8, 2021","October 31, 2022","October 31, 2022","February 12, 2021",,"February 18, 2022","Clinical Trial Site, Bunkyo-ku, Japan|Clinical Trial Site, Chiba, Japan|Clinical Trial Site, Fuchu, Japan|Clinical Trial Site, Fukuoka, Japan|Clinical Trial Site, Gifu, Japan|Clinical Trial Site, Hiroshima, Japan|Clinical Trial Site, Kagoshima, Japan|Clinical Trial Site, Kawagoe, Japan|Clinical Trial Site, Kawasaki, Japan|Clinical Trial Site, Kitakyushu, Japan|Clinical Trial Site, Kobe, Japan|Clinical Trial Site, Kumamoto, Japan|Clinical Trial Site, Kurashiki, Japan|Clinical Trial Site, Kyoto, Japan|Clinical Trial Site, Matsumoto, Japan|Clinical Trial Site, Mibu, Japan|Clinical Trial Site, Mitaka, Japan|Clinical Trial Site, Nagoya, Japan|Clinical Trial Site, Niigata, Japan|Clinical Trial Site, Nishinomiya, Japan|Clinical Trial Site, Osakasayama, Japan|Clinical Trial Site, Sagamihara, Japan|Clinical Trial Site, Sapporo, Japan|Clinical Trial Site, Sendai, Japan|Clinical Trial Site, Ube, Japan|Clinical Trial Site, Yokohama, Japan",,"https://ClinicalTrials.gov/show/NCT04752566"
9,"NCT01633489","Lysosomal Acid Lipase (LAL) Deficiency Registry","ALX-LALD-501","Recruiting","No Results Available","Lysosomal Acid Lipase Deficiency|Cholesterol Ester Storage Disease|Wolman Disease|Acid Cholesteryl Ester Hydrolase Deficiency, Type 2|Acid Lipase Deficiency|LIPA Deficiency|LAL-Deficiency",,"Understanding of the variability, progression, identification and natural history of LAL Deficiency.","Alexion Pharmaceuticals","All","Child, Adult, Older Adult",,"1000","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ALX-LALD-501","December 2012","June 2029","June 2029","July 4, 2012",,"January 12, 2021","Stanford, California, United States|Decatur, Georgia, United States|Chicago, Illinois, United States|Boston, Massachusetts, United States|Detroit, Michigan, United States|Bronx, New York, United States|New York, New York, United States|Providence, Rhode Island, United States|Houston, Texas, United States|Fairfax, Virginia, United States|Bron, France|Nancy, France|Berlin, Germany|Mainz, Germany|Genova, Italy|Milano, Italy|Turin, Italy|Amsterdam, Netherlands|Albacete, Spain|Oviedo, Spain|Valladolid, Spain|Zaragoza, Spain|Zürich, Switzerland|Birmingham, United Kingdom|Cambridge, United Kingdom|London, United Kingdom|Manchester, United Kingdom|Salford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01633489"
10,"NCT01770951","A Retrospective, Observational, Non-interventional Trial to Assess Eculizumab Treatment Effect in Patients With Atypical Hemolytic Uremic Syndrome (aHUS)",,"Completed","No Results Available","Atypical Hemolytic Uremic Syndrome (aHUS)",,"Overall safety and tolerability of eculizumab based on Adverse Events of Special Interest/Adverse Drug Reactions and Additional Adverse Events.|Assess eculizumab treatment affect based on change in laboratory parameters (platelets, hemoglobin, LDH and parameters associated with renal function and intravascular hemolysis) and reduction of thrombotic microangiopathy (TMA).","Alexion Pharmaceuticals","All","Child, Adult, Older Adult",,"30","Industry","Observational","Time Perspective: Retrospective","C09-001r","August 2009","November 2010","November 2010","January 18, 2013",,"January 18, 2013","Dunwoody, Georgia, United States|Chicago, Illinois, United States|Portland, Maine, United States|Boston, Massachusetts, United States|Durham, North Carolina, United States|Cincinnati, Ohio, United States|Oklahoma City, Oklahoma, United States|Corpus Christi, Texas, United States|Salt Lake City, Utah, United States|Seattle, Washington, United States|Spokane, Washington, United States|Appleton, Wisconsin, United States|Graz, Austria|Innsbruck, Austria|Montreal, Quebec, Canada|Caen, France|Le Kremlin Bicetre, France|Paris, France|Berlin, Germany|Heidelberg, Germany|Amsterdam, Netherlands|Barcelona, Spain|Bern, Switzerland",,"https://ClinicalTrials.gov/show/NCT01770951"
11,"NCT00867932","Eculizumab Pharmacokinetics/Pharmacodynamics Study in Pediatric/Adolescent Paroxysmal Nocturnal Hemoglobinuria (PNH)",,"Completed","Has Results","Hemoglobinuria, Paroxysmal","Drug: Eculizumab","Peak And Trough Concentrations Of Eculizumab In Serum At Week 12|Number Of Participants With Treatment-emergent Adverse Events (TEAEs)|Area Under The Curve (AUC) Of The Change From Baseline To Week 12 In Levels Of Lactate Dehydrogenase (LDH)|Concentration Of Plasma-free Hemoglobin At Baseline And Week 12|Change From Baseline In LDH Levels","Alexion Pharmaceuticals","All","2 Years to 17 Years   (Child)","Phase 4","7","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","M07-005|2009-010402-11","October 2, 2009","May 12, 2011","May 12, 2011","March 24, 2009","October 31, 2018","October 31, 2018","Orange, California, United States|Pensacola, Florida, United States|Memphis, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT00867932"
12,"NCT04256148","ALXN1830 in Patients With Warm Autoimmune Hemolytic Anemia",,"Withdrawn","No Results Available","Warm Autoimmune Hemolytic Anemia","Biological: ALXN1830|Other: Placebo","Percentage Of Participants With ≥ 2 Grams (g)/Deciliter (dL) Increase In Hemoglobin (Hgb) From Baseline|Total Number Of Units Of Packed Red Blood Cells (pRBCs) Transfused|Mean Change From Baseline To Day 92 In Quality Of Life, Assessed Via EuroQoL 5 Dimension 5 Level (EQ-5D-5L) Questionnaire|Mean Change From Baseline To Day 92 In Quality Of Life, Assessed Via Functional Assessment Of Cancer Therapy Anemia (FACT-AN) Questionnaire|Number Of Weekly Hgb Measurements With Change From Baseline ≥ 2 g/dL|Number Of Participants Needing New WAIHA Rescue Medication Or Increase In Dose Of WAIHA Medication","Alexion Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","ALXN1830-WAI-201","July 2021","October 30, 2022","April 30, 2023","February 5, 2020",,"July 13, 2020","Alexion Study Site, Whittier, California, United States",,"https://ClinicalTrials.gov/show/NCT04256148"
13,"NCT02496689","Expanded Access Program for Asfotase Alfa Treatment for Patients With Infantile- or Juvenile-onset Hypophosphatasia (HPP)",,"Approved for marketing","No Results Available","Hypophosphatasia","Biological: asfotase alfa",,"Alexion Pharmaceuticals","All","Child, Adult, Older Adult",,,"Industry","Expanded Access",,"AA-HPP-405",,,,"July 14, 2015",,"March 29, 2019","Colorado Center for Bone Research, Lakewood, Colorado, United States|Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States|Hôpital Bicêtre, Le Kremlin-Bicêtre, France|Hôpital Necker - Enfants Malades, Paris, France|Hôpital des Enfants, Toulouse Cedex 9, France",,"https://ClinicalTrials.gov/show/NCT02496689"
14,"NCT04422431","Copper Concentration and Histopathologic Changes in Liver Biopsy in Participants With Wilson Disease Treated With ALXN1840",,"Active, not recruiting","No Results Available","Wilson Disease","Drug: Bis-Choline Tetrathiomolybdate","Change From Baseline At Week 48 In Liver Cu Concentration|Change From Baseline At Week 48 In Liver Histopathology As Assessed by Liver Biopsy|Pre-dose Trough ALXN1840 Concentrations In Plasma At Each Study Site Visit|Clinical Global Impression-Improvement Scale At Week 48|Change From Baseline At Week 48 In The Clinical Global Impression-Severity Scale","Alexion Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","31","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ALXN1840-WD-205|2019-003711-60","December 2, 2020","August 2022","August 2023","June 9, 2020",,"June 15, 2021","UC Davis Health System - UC Davis Medical Center - Liver Clinic, Sacramento, California, United States|University of Michigan, Ann Arbor, Michigan, United States|UT Southwestern, Dallas, Texas, United States|Aarhus Universitetshospital, Aarhus, Denmark|Auckland Public Hospital, Auckland, New Zealand|Clinic of Rheumatology, Internal and Occupational Diseases named after EM. Tareeva, Moscow, Russian Federation|Federal State Budgetary Institution of Health Care St Petersburg Clinical Hospital of the Russian Academy of Sciences, St. Petersburg, Russian Federation|Singapore General Hospital, Singapore, Singapore|Hospital Clínic I Provincial de Barcelona, Barcelona, Spain|Hospital Universitario La Fe, Valencia, Spain|King's College, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04422431"
15,"NCT03403205","Efficacy and Safety of ALXN1840 (Formerly Named WTX101) Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease With an Extension Period of up to 60 Months",,"Active, not recruiting","No Results Available","Wilson Disease","Drug: ALXN1840|Drug: SoC Therapy","Daily Mean Area Under The Effect-time Curve (AUEC) Of Directly Measured Non-ceruloplasmin-bound Copper (dNCC)|Change From Baseline In cNCC In Plasma.|Number Of Participants With Treatment-emergent Adverse Events|Effects of ALXN1840 on hepatic status|Effects of ALXN1840 on disability status|Effects of ALXN1840 on neurological status, as assessed by UWDRS Part III individual items/subscales (arising from a chair, gait, handwriting, and speech)|Global effects of ALXN1840 on clinical symptoms as assessed by the Investigator on the Clinical Global Impression-Improvement Scale (CGI-I) and the Clinical Global Impression-Severity Scale (CGI-S)|Effects of ALXN1840 on NCC responder rate|Change From Baseline In The Unified Wilson Disease Rating Scale (UWDRS) Part II Total Score|Change From Baseline In UWDRS Part III Total Score And Individual Items/Subscales (Arising From A Chair, Gait, Handwriting, And Speech)|Clinical Global Impression-Improvement Scale (CGI-I)|Change From Baseline In Clinical Global Impression Severity Scale (CGI-S)|Change From Baseline In Model For End-Stage Liver Disease (MELD) Score|Change From Baseline In Calculated NCC (cNCC) In Plasma|cNCC Responder Rate","Alexion Pharmaceuticals","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","215","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","WTX101-301","February 15, 2018","February 24, 2021","February 28, 2026","January 18, 2018",,"January 25, 2022","Clinical Study Site, Los Angeles, California, United States|Clinical Study Site, New Haven, Connecticut, United States|AdventHealth Medical Group Pediatric Gastroenterology at Orlando, Orlando, Florida, United States|Clinical Study Site, Chicago, Illinois, United States|Clinical Study Site, Ann Arbor, Michigan, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Clinical Study Site, Nashville, Tennessee, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Clinical Study Site, Houston, Texas, United States|Texas Children's Hospital, Houston, Texas, United States|Clinical Study Site, Seattle, Washington, United States|Clinical Study Site, Camperdown, New South Wales, Australia|Clinical Study Site, Adelaide, South Australia, Australia|Clinical Study Site, Heidelberg, Victoria, Australia|Clinical Study Site, Melbourne, Victoria, Australia|Clinical Study Site, Parkville, Victoria, Australia|Clinical Study Site, Parkville, Victoria, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|Clinical Study Site, Concord, Australia|Clinical Study Site, Graz, Austria|Clinical Study Site, Innsbruck, Austria|Clinical Study Site, Vienna, Austria|Ghent University Hospital (Universitair Ziekenhuis Gent), Gent, Oost-Vlaanderen, Belgium|University Hospitals Leuven - Gasthuisberg, Leuven, Belgium|Clinical Study Site, Toronto, Ontario, Canada|Clinical Study Site, Prague, Czechia|Aarhus Universitetshospital, Aarhus, Denmark|Clinical Study Site, Aarhus, Denmark|Clinical Study Site, Bron, France|Clinical Study Site, Paris, France|Centre Hospitalier Universitaire (CHU) de Toulouse - Hopital Pierre-Paul Riquet, Toulouse, France|Clinical Study Site, Dresden, Germany|Clinical Study Site, Hamburg, Germany|Clinical Study Site, Heidelberg, Germany|Clinical Study Site, Leipzig, Germany|Clinical Study Site, Hong Kong, Hong Kong|Queen Mary Hospital, Hong Kong, Hong Kong|Clinical Study Site, Budapest, Hungary|Clinical Study Site, Haifa, Israel|Clinical Study Site, Jerusalem, Israel|Clinical Study Site, Ramat Gan, Israel|Clinical Study Site, Matsuyama, Ehime, Japan|Clinical Study Site, Kurume, Fukuoka, Japan|Clinical Study Site, Sapporo, Hokkaido, Japan|Clinical Study Site, Yokohama, Kanagawa, Japan|Clinical Study Site, Chiba, Japan|Clinical Study Site, Kumamoto, Japan|Clinical Study Site, Osaka, Japan|Clinical Study Site, Tokyo, Japan|Clinical Study Site, Daegu, Korea, Republic of|Clinical Study Site, Seoul, Korea, Republic of|Clinical Study Site, Seoul, Korea, Republic of|Clinical Study Site, Auckland, New Zealand|Clinical Study Site, Warszawa, Woj. Mazowieckie, Poland|Clinical Study Site, Warsaw, Poland|Clinical Study Site, Moscow, Russian Federation|Clinical Study Site, Moscow, Russian Federation|Clinical Study Site, Nizhny Novgorod, Russian Federation|Clinical Study Site, Saint Petersburg, Russian Federation|Federal State Budgetary Institution ""Child Research Clinical Infectious Disease Center"" of the Medical Biology Agency, Saint Petersburg, Russian Federation|Clinical Study Site, Belgrade, Serbia|National University Hospital, Singapore, Singapore|Clinical Study Site, Singapore, Singapore|KK Women's and Children's Hospital, Singapore, Singapore|Hospital Sant Joan de Déu Barcelona, Esplugues De Llobregat, Bareclona, Spain|Hospital Materno-Infantil Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Las Palmas, Spain|Clinical Study Site, Barcelona, Spain|Hospital Universitari Vall Hebron Barcelona, Barcelona, Spain|Clinical Study Site, Barcelona, Spain|Clinical Study Site, Barcelona, Spain|Clinical Study Site, Madrid, Spain|Clinical Study Site, Málaga, Spain|Hospital Materno Infantil de Málaga, Málaga, Spain|Clinical Study Site, Kaohsiung, Taiwan|Clinical Study Site, Taipei, Taiwan|Clinical Study Site, Taoyuan, Taiwan|Ege University School of Medicine, Izmir, Bornova, Turkey|Clinical Study Site, Bornova, Izmir, Turkey|Ege Universitesi Tip Fakultesi Çocuk Hastanesi (Ege University Medical Faculty Pediatric Hospital), Bornova, Izmir, Turkey|Clinical Study Site, Ankara, Turkey|Clinical Study Site, Istanbul, Turkey|Koc University Medical Faculty, Istanbul, Turkey|Bezmialem Foundation University Medical Faculty, Istanbul, Turkey|Clinical Study Site, Istanbul, Turkey|Istanbul Uni. Istanbul Medical Faculty Hospital, Istanbul, Turkey|Clinical Study Site, Birmingham, England, United Kingdom|Clinical Study Site, Cambridge, England, United Kingdom|Clinical Study Site, Guildford, England, United Kingdom|Clinical Study Site, Brixton, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03403205"
16,"NCT02301624","Extension Study of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis",,"Completed","Has Results","Refractory Generalized Myasthenia Gravis","Biological: Eculizumab|Drug: Placebo","Count Of Participants With Treatment-Emergent Adverse Events|Change From Baseline In Myasthenia Gravis Activities Of Daily Living Profile (MG-ADL) Total Score At Week 4 And Week 130","Alexion Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","117","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ECU-MG-302|2013-002191-41","November 12, 2014","January 15, 2019","January 15, 2019","November 26, 2014","February 5, 2020","February 5, 2020","Birmingham, Alabama, United States|Los Angeles, California, United States|Orange, California, United States|Palo Alto, California, United States|San Francisco, California, United States|New Haven, Connecticut, United States|Jacksonville, Florida, United States|Miami, Florida, United States|Tampa, Florida, United States|Springfield, Illinois, United States|Indianapolis, Indiana, United States|Iowa City, Iowa, United States|Kansas City, Kansas, United States|Baltimore, Maryland, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|Burlington, Massachusetts, United States|Las Vegas, Nevada, United States|Chapel Hill, North Carolina, United States|Charlotte, North Carolina, United States|Durham, North Carolina, United States|Columbus, Ohio, United States|Portland, Oregon, United States|San Antonio, Texas, United States|Burlington, Vermont, United States|Seattle, Washington, United States|Buenos Aires, Argentina|Edegem, Belgium|Gent, Belgium|Leuven, Belgium|São Paulo, Brazil|Edmonton, Canada|Ostrava - Poruba, Czechia|Praha 2, Czechia|Arhus C, Denmark|Kobenhavn, Denmark|Turku, Finland|Szeged, Hungary|Milano, Italy|Napoli, Italy|Roma, Italy|Chiba, Japan|Fukuoka, Japan|Hanamaki, Japan|Hokkaido, Japan|Miyagi, Japan|Nagasaki, Japan|Osaka-Fu, Japan|Osaka, Japan|Seoul, Korea, Republic of|Amsterdam, Netherlands|Barcelona, Spain|Madrid, Spain|Stockholm, Sweden|Ankara, Turkey|İzmir, Turkey|Kocaeli, Turkey|Birmingham, United Kingdom|Liverpool, United Kingdom|London, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/24/NCT02301624/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/24/NCT02301624/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02301624"
17,"NCT02273596","Efficacy and Safety Study of WTX101 (ALXN1840) in Adult Wilson Disease Patients",,"Completed","Has Results","Wilson Disease","Drug: ALXN1840","Percentage Of Participants With Normalized Concentrations Of NCC|Change From Baseline In NCC Concentrations Adjusted For Mo Plasma Concentration At Week 24|Time To Normalization Of NCC Adjusted For Mo Plasma Concentration In Participants With Elevated Baseline NCC|Change From Baseline In Neurological Status Using The Unified Wilson's Disease Rating Scale (UWDRS) (Neurological Subscore; Part I) At Week 24|Change From Baseline In Neurological Status Using The UWDRS (Neurological Subscore; Parts II, III, And Total Score) At Week 24|Change From Baseline In Psychiatric Status Dimension Using Mini International Neuropsychiatric Interview (M.I.N.I.) Tracking Standardized Scores At Week 24|Clinical Global Impression-Improvement Scale (CGI-I) At Week 24|Change From Baseline In Clinical Global Impression Severity Scale (CGI-S) At Week 24|Change From Baseline In Quality Of Life (QoL)/Patient Reported Outcome (PRO) Assessed By The European Quality Of Life 5 Dimensions (EQ-5D) Visual Analogue Scale (VAS) At Week 24|Change From Baseline In Quality Of Life (QoL)/Patient Reported Outcome (PRO) Assessed By The EQ-5D Descriptive System UK Health Index Scores At Week 24|QoL/PRO Assessed By The 8-Item Medication Adherence Scale (MMAS-8) At Week 24|QoL/PRO Assessed By The Treatment Satisfaction Questionnaire For Medication (TSQM-9) At Week 24|Change From Baseline In Hepatic Laboratory Measure Alanine Aminotransferase (ALT) At Week 24|Change From Baseline In Hepatic Laboratory Measure Aspartate Aminotransferase (AST) At Week 24|Change From Baseline In Hepatic Laboratory Measure International Normalized Ratio (INR) At Week 24|Change From Baseline In Hepatic Laboratory Measure Bilirubin At Week 24|Change From Baseline In Exchangeable Cu At Week 24|Change From Baseline In Speciation Profiling (Mo, Cu, And Protein Complex Profiling Using Size Exclusion Chromatography) At Week 24|Change From Baseline In 24-Hour Urinary Mo And Cu At Week 24|Pharmacokinetics (PK): Area Under The Curve From Time 0 to 24 (AUC0-24) Of Plasma Total Mo|PK: Maximum Concentration (Cmax) Of Plasma Total Mo|Extension Period: Percentage Of Participants With Normalized Concentrations Of NCC|Extension Period: Change From Baseline In NCC Levels Adjusted For Mo Plasma Concentration","Alexion Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","29","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","WTX101-201","November 24, 2014","October 27, 2016","November 7, 2018","October 24, 2014","September 29, 2021","September 29, 2021","Clinical Trial Site, Los Angeles, California, United States|Clinical Trial Site, New Haven, Connecticut, United States|Clinical Trial Site, Chicago, Illinois, United States|Clinical Trial Site, Ann Arbor, Michigan, United States|Clinical Trial Site, Vienna, Austria|Clinical Trial Site, Heidelberg, Germany|Clinical Trial Site, Warsaw, Poland|Clinical Trial Site, Guildford, Surrey, United Kingdom|Clinical Trial Site, Birmingham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02273596"
18,"NCT04743804","Ravulizumab in Thrombotic Microangiopathy Associated With a Trigger",,"Recruiting","No Results Available","Thrombotic Microangiopathy","Biological: Ravulizumab|Other: Placebo|Other: Best Supportive Care","Complete TMA Response|Time to Complete TMA Response|Hematologic Response|Renal Response|On Dialysis|Change in Kidney Function as measured by estimated glomerular filtration rate (eGFR) in mL/min/1.73m^2","Alexion Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","100","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ALXN1210-TMA-315","July 1, 2021","January 31, 2024","June 30, 2024","February 8, 2021",,"March 3, 2022","Clinical Trial Site, Tucson, Arizona, United States|Clinical Trial Site, Orange, California, United States|Clinical Trial Site, Lexington, Kentucky, United States|Clinical Trial Site, Boston, Massachusetts, United States|Clinical Trial Site, Boston, Massachusetts, United States|Clinical Trial Site, Boston, Massachusetts, United States|Clinical Trial Site, New York, New York, United States|Clinical Trial Site, Valhalla, New York, United States|Clinical Trial Site, Cleveland, Ohio, United States|Clinical Trial Site, Columbus, Ohio, United States|Clinical Trial Site, Philadelphia, Pennsylvania, United States|Clinical Trial Site, Salt Lake City, Utah, United States|Clinical Trial Site, Morgantown, West Virginia, United States|Clinical Trial Site, Bruxelles, Belgium|Clinical Trial Site, Leuven, Belgium|Clinical Trial Site, Liege, Belgium|Clinical Trial Site, Montreal, Canada|Clinical Trial Site, Bordeaux, France|Clinical Trial Site, Lille, France|Clinical Trial Site, Montpellier, France|Clinical Trial Site, Paris, France|Clinical Trial Site, Bergamo, Italy|Clinical Trial Site, Rome, Italy|Clinical Trial Site, Iruma-gun, Japan|Clinical Trial Site, Miyagi, Japan|Clinical Trial Site, Miyazaki City, Japan|Clinical Trial Site, Nagoya, Japan|Clinical Trial Site, Osaka, Japan|Clinical Trial Site, Sapporo, Japan|Clinical Trial Site, Shinjuku-ku, Japan|Clinical Trial Site, Tokyo, Japan|Clinical Trial Site, Daegu, Korea, Republic of|Clinical Trial Site, Gwangju, Korea, Republic of|Clinical Trial Site, Seoul, Korea, Republic of|Clinical Trial Site, Nijmegen, Netherlands|Clinical Trial Site, Barcelona, Spain|Clinical Trial Site, Granada, Spain|Clinical Trial Site, Madrid, Spain|Clinical Trial Site, Kaohsiung, Taiwan|Clinical Trial Site, Taichung, Taiwan|Clinical Trial Site, Taipei, Taiwan|Clinical Trial Site, London, United Kingdom|Clinical Trial Site, Newcastle, United Kingdom|Clinical Trial Site, Nottingham, United Kingdom|Clinical Trial Site, Oxford, United Kingdom|Clinical Trial Site, Salford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04743804"
19,"NCT04573309","Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840",,"Recruiting","No Results Available","Wilson Disease","Drug: ALXN1840","Mean Daily Copper Balance|Change From Baseline In Mean Daily Copper Balance|Copper Quantified In Food, Drink, Feces, And Urine, Including Plasma Total And Labile Bound copper (LBC)|Molybdenum Specified In ALXN1840 Doses Given And Quantified In Food, Drink, Feces, And Urine, Including Plasma At Steady State|Change From Baseline In Total Molybdenum Excretion In Urine And Feces|Mean Daily Molybdenum Balance At Steady State|Accumulation Of Molybdenum As Determined By Molybdenum Balance","Alexion Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","10","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ALXN1840-WD-204|2020-001104-41","September 7, 2020","May 22, 2022","May 22, 2022","October 5, 2020",,"March 3, 2022","Clinical Study Site, Lincoln, Nebraska, United States|Clinical Study Site, Grafton, Auckland, New Zealand|Clinical Study Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04573309"
20,"NCT04557735","Study of Ravulizumab in Pediatric Participants With HSCT-TMA",,"Recruiting","No Results Available","Thrombotic Microangiopathy","Drug: Ravulizumab|Other: Best Supportive Care","Proportion of Participants with TMA Response|Time To TMA Response|Proportion of Participants with TMA Relapse|Overall Survival|Proportion of Participants who die due to any cause during the study, with the exception of death due to underlying disease progression or relapse|Proportion of Participants with Platelet Response ≥ 100,000/mm^3 without transfusion support","Alexion Pharmaceuticals","All","1 Month to 17 Years   (Child)","Phase 3","40","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ALXN1210-TMA-314|2020-000761-16","November 6, 2020","August 2023","February 2024","September 22, 2020",,"July 22, 2021","Clinical Trial Site, Birmingham, Alabama, United States|Clinical Trial Site, Tucson, Arizona, United States|Clinical Trial Site, Duarte, California, United States|Clinical Trial Site, Chicago, Illinois, United States|Clinical Trial Site, Minneapolis, Minnesota, United States|Clinical Trial Site, Portland, Oregon, United States|Clinical Trial Site, Fort Worth, Texas, United States|Clinical Trial Site, Bron, France|Clinical Trial Site, Nantes, France|Clinical Trial Site, Paris, France|Clinical Trial Site, Strasbourg, France|Clinical Trial Site, Vandœuvre-lès-Nancy, France|Clinical Trial Site, Bologna, Italy|Clinical Trial Site, Firenze, Italy|Clinical Trial Site, Genova, Italy|Clinical Trial Site, Pavia, Italy|Clinical Trial Site, Verona, Italy|Clinical Trial Site, Fukuoka, Japan|Clinical Study Site, Fukushima, Japan|Clinical Trial Site, Kobe, Japan|Clinical Trial Site, Nagoya, Japan|Clinical Trial Site, Osakasayama, Japan|Clinical Trial Site, Osaka, Japan|Clinical Trial Site, Saitama, Japan|Clinical Trial Site, Setagaya-Ku, Japan|Clinical Trial Site, Goyang, Korea, Republic of|Clinical Trial Site, Seoul, Korea, Republic of|Clinical Trial Site, Barcelona, Spain|Clinical Trial Site, Esplugues De Llobregat, Spain|Clinical Trial Site, Madrid, Spain|Clinical Trial Site, Salamanca, Spain|Clinical Trial Site, Valencia, Spain|Clinical Trial Site, Bristol, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04557735"
21,"NCT04543591","Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant",,"Recruiting","No Results Available","Thrombotic Microangiopathy","Drug: Ravulizumab|Drug: Placebo|Other: Best supportive care","TMA Response|Time To TMA Response|TMA Relapse|Overall Survival|Non-relapse Mortality|Platelet Response","Alexion Pharmaceuticals","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","184","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ALXN1210-TMA-313|2020-000144-61","September 16, 2020","August 2023","February 2024","September 10, 2020",,"July 22, 2021","Clinical Trial Site, Atlanta, Georgia, United States|Clinical Trial Site, Chicago, Illinois, United States|Clinical Trial Site, Grosse Pointe Farms, Michigan, United States|Clinical Trial Site, Pittsburgh, Pennsylvania, United States|Clinical Trial Site, Angers, France|Clinical Trial Site, La Tronche, France|Clinical Trial Manager, Lille, France|Clinical Trial Site, Nice, France|Clinical Trial Site, Paris, France|Clinical Trial Site, Pierre-Bénite, France|Clinical Trial Site, Toulouse, France|Clinical Study Site, Milano, Italy|Clinical Trial Site, Milano, Italy|Clinical Trial Site, Roma, Italy|Clinical Trial Site, Salerno, Italy|Clinical Trial Site, San Giovanni Rotondo, Italy|Clinical Trial Site, Akita, Japan|Clinical Study Site, Chiba, Japan|Clinical Study Site, Fukushima, Japan|Clinical Trial Site, Isehara, Japan|Clinical Study Site, Kanazawa, Japan|Clinical Trial Site, Kobe, Japan|Clinical Trial Site, Kumamoto, Japan|Clinical Trial Site, Kurashiki, Japan|Clinical Trial Site, Nagaizumi-chō, Japan|Clinical Trial Site, Okayama, Japan|Clinical Trial Site, Osakasayama, Japan|Clinical Trial Site, Osaka, Japan|Clinical Trial Site, Sapporo, Japan|Clinical Trial Site, Suita, Japan|Clinical Trial Site, Tsukuba, Japan|Clinical Trial Site, Wakayama, Japan|Clinical Trial Site, Goyang, Korea, Republic of|Clinical Trial Site, Seoul, Korea, Republic of|Clinical Trial Site, Suwon, Korea, Republic of|Clinical Trial Site, Barcelona, Spain|Clinical Trial Site, Granada, Spain|Clinical Trial Site, Madrid, Spain|Clinical Trial Site, Majadahonda, Spain|Clinical Trial Site, Málaga, Spain|Clinical Trial Site, Oviedo, Spain|Clinical Trial Site, Palma De Mallorca, Spain|Clinical Trial Site, Pamplona, Spain|Clinical Trial Site, Salamanca, Spain|Clinical Trial Site, San Sebastián, Spain|Clinical Trial Site, Sevilla, Spain|Clinical Trial Site, Valencia, Spain",,"https://ClinicalTrials.gov/show/NCT04543591"
22,"NCT04469465","Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobinuria (PNH) Participants Who Have Clinically Evident Extravascular Hemolysis (EVH)(ALPHA)",,"Recruiting","No Results Available","Paroxysmal Nocturnal Hemoglobinuria","Drug: Danicopan|Drug: Placebo|Drug: C5 Inhibitor","Change From Baseline In Hemoglobin (Hgb) At Week 12|Percentage Of Participants With Transfusion Avoidance|Change From Baseline In Functional Assessment Of Chronic Illness Therapy (FACIT) Fatigue Scores At Week 12|Change From Baseline In Absolute Reticulocyte Count At Week 12","Alexion Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","84","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ALXN2040-PNH-301|2019-003829-18","December 16, 2020","October 31, 2022","December 31, 2023","July 14, 2020",,"February 7, 2022","Clinical Trial Site, Los Angeles, California, United States|Clinical Trial Site, Chicago, Illinois, United States|Clinical Trial Site, Kalamazoo, Michigan, United States|Clinical Trial Site, New York, New York, United States|Clinical Trial Site, Durham, North Carolina, United States|Clinical Trial Site, Dallas, Texas, United States|Clinical Trial Site, Salvador, Bahia, Brazil|Clinical Trial Site, Fortaleza, Ceara, Brazil|Clinical Trial Site, Goiania, Goias, Brazil|Clinical Trial Site, Curitiba, Parana, Brazil|Clinical Trial Site, Belem, Para, Brazil|Clinical Trial Site, Porto Alegre, Rio Grande Do Sul, Brazil|Clinical Trial Site, Rio de Janeiro, Brazil|Clinical Trial Site, Edmonton, Alberta, Canada|Clinical Trial Site, Toronto, Ontario, Canada|Clinical Trial Site, Saint-Quentin cedex, Aisne, France|Clinical Trial Site, Nice, Alpes Maritimes, France|Clinical Trial Site, Marseille Cedex 9, Bouches-du-Rhone, France|Clinical Trial Site, Lille cedex, Nord, France|Clinical Trial Site, Paris cedex 10, Paris, France|Clinical Trial Site, Pierre-Bénite, Rhone, France|Clinical Trial Site, Pessac, France|Clinical Trial Site, Aachen, Germany|Clinical Trial Site, Ulm, Germany|Clinical Trial Site, Reggio Calabria, Calabria, Italy|Clinical Trial Site, Avellino, Campagnia, Italy|Clinical Trial Site, Roma, Lazio, Italy|Clinical Trial Site, Milano, Lombardia, Italy|Clinical Trial Site, Firenze, Toscana, Italy|Clinical Trial Site, Bassano Del Grappa, Vicenza, Italy|Clinical Trial Site, Toyoake, Aichi, Japan|Clinical Trial Site, Kashiwa-shi, Chiba, Japan|Clinical Trial Site, Fukuoka-shi, Fukuoka, Japan|Clinical Trial Site, Fukushima-shi, Fukushima-ken, Japan|Clinical Trial Site, Ogaki-shi, Gifu, Japan|Clinical Trial Site, Tsukuba-shi, Ibaraki, Japan|Clinical Trial Site, Osakasayama-shi, Osaka, Japan|Clinical Trial Site, Suita-shi, Osaka, Japan|Clinical Trial Site, Bunkyo-ku, Tokyo, Japan|Clinical Trial Site, Shinjuku-Ku, Tokyo, Japan|Clinical Trial Site, Tanabe-shi, Wakayama, Japan|Clinical Trial Site, Suwon-si, Gyeonggi-do, Korea, Republic of|Clinical Trial Site, Daegu, Korea, Republic of|Clinical Trial Site, Daejeon, Korea, Republic of|Clinical Trial Site, Seoul, Korea, Republic of|Clinical Trial Site, Seoul, Korea, Republic of|Clinical Trial Site, Seoul, Korea, Republic of|Clinical Trial Site, Seoul, Korea, Republic of|Clinical Trial Site, Kota Kinabalu, Sabah, Malaysia|Clinical Trial Site, Kuching, Sarawak, Malaysia|Clinical Trial Site, Miri, Sarawak, Malaysia|Clinical Trial Site, Maastricht, Limburg, Netherlands|Clinical Trial Site, Gdansk, Poland|Clinical Trial Site, Badalona, Barcelona, Spain|Clinical Trial Site, L'Hospitalet de Llobregat, Barcelona, Spain|Clinical Trial Site, Majadahonda, Madrid, Spain|Clinical Trial Site, Málaga, Malaga, Spain|Clinical Trial Site, Barcelona, Spain|Clinical Trial Site, Barcelona, Spain|Clinical Trial Site, Madrid, Spain|Clinical Trial Site, Sevilla, Spain|Clinical Trial Site, Pathum Wan, Bangkok, Thailand|Clinical Trial Site, London, Greater London, United Kingdom|Clinical Trial Site, Airdrie, North Lanarkshire, United Kingdom|Clinical Trial Site, Leeds, West Yorkshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04469465"
23,"NCT05259085","Study of ALXN2050 in Participants With Hepatic Impairment",,"Not yet recruiting","No Results Available","Impaired Hepatic Function|Healthy","Drug: ALXN2050","Area Under The Concentration-time Curve From Time 0 To The 12-hour Time Point (AUC0-12) Of Plasma ALXN2050 After Steady-state|Area Under The Concentration-time Curve Calculated To The Last Observable Concentration At Time t (AUCt) Of Plasma ALXN2050 After Steady-state|Maximum (Peak) Steady-state Plasma Concentration Of ALXN2050 (Cmax,ss)|Time To Reach Maximum (Peak) Plasma Concentration Following ALXN2050 Administration At Steady-state (Tmax,ss)|Number Of Participants Receiving ALXN2050 With Treatment-emergent Adverse Events","Alexion Pharmaceuticals","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","36","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","ALXN2050-HV-109","March 31, 2022","May 4, 2023","October 3, 2023","February 28, 2022",,"February 28, 2022","Clinical Trial Site, Hialeah, Florida, United States|Clinical Trial Site, Orlando, Florida, United States",,"https://ClinicalTrials.gov/show/NCT05259085"
24,"NCT01757184","Acid Lipase Replacement Investigating Safety and Efficacy (ARISE) in Participants With Lysosomal Acid Lipase Deficiency","ARISE","Completed","Has Results","Lysosomal Acid Lipase Deficiency","Drug: Sebelipase Alfa|Drug: Placebo","Percentage Of Participants Achieving Alanine Aminotransferase Normalization|Percent Change From Baseline In Low-density Lipoprotein Cholesterol (LDL-C)|Percent Change From Baseline In Non-high Density Lipoprotein Cholesterol (Non-HDL-C)|Percentage Of Participants Achieving Aspartate Aminotransferase Normalization|Percent Change From Baseline In Triglycerides|Percent Change From Baseline In High-density Lipoprotein Cholesterol (HDL-C)|Percent Change From Baseline In Liver Fat Content|Participants With Improvement In Liver Histopathology (Decrease Of > 5% In Hepatic Steatosis Score)|Percent Change From Baseline In Liver Volume","Alexion Pharmaceuticals","All","4 Years and older   (Child, Adult, Older Adult)","Phase 3","66","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","LAL-CL02","January 22, 2013","May 30, 2014","December 11, 2018","December 28, 2012","April 18, 2016","December 29, 2020","Tucson, Arizona, United States|Palo Alto, California, United States|San Francisco, California, United States|Wilmington, Delaware, United States|Chicago, Illinois, United States|Boston, Massachusetts, United States|Buffalo, New York, United States|Manhasset, New York, United States|New York, New York, United States|Cincinnati, Ohio, United States|Philadelphia, Pennsylvania, United States|Córdoba, Argentina|Brisbane, Australia|New Lambton, Australia|Parkville, Australia|Perth, Australia|Zagreb, Croatia|Olomouc, Czechia|Prague, Czechia|Paris, France|Vandoeuvre les Nancy, France|Freiburg, Germany|Mainz, Germany|Munich, Germany|Bergamo, Italy|Genoa, Italy|Padova, Italy|Tokyo, Japan|Tottori, Japan|Mexico City, Mexico|Warsaw, Poland|Moscow, Russian Federation|Elche, Spain|Madrid, Spain|Oviedo, Spain|Ankara, Turkey|Izmir, Turkey|Cambridge, United Kingdom|London, United Kingdom|Plymouth, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01757184"
25,"NCT05234567","A Prospective Sub-Study of the Global Hypophosphatasia Registry",,"Not yet recruiting","No Results Available","Hypophosphatasia","Biological: Asfotase Alfa","Occurrence Of Immune-mediated Loss Of Effectiveness According To The Treating Physician|Occurrence Of Immune-mediated Serious Adverse Events","Alexion Pharmaceuticals","All","Child, Adult, Older Adult",,"40","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ALX-HPP-501s","February 17, 2022","June 30, 2028","June 30, 2028","February 10, 2022",,"February 10, 2022","Clinical Trial Site, Little Rock, Arkansas, United States|Clinical Trial Site, Centennial, Colorado, United States|Clinical Trial Site, Decatur, Georgia, United States|Clinical Trial Site, Minneapolis, Minnesota, United States|Clinical Trial Site, Kansas City, Missouri, United States|Clinical Trial Site, Syracuse, New York, United States|Clinical Trial Site, Durham, North Carolina, United States|Clinical Trial Site, Cincinnati, Ohio, United States|Clinical Trial Site, Columbus, Ohio, United States|Clinical Trial Site, Pittsburgh, Pennsylvania, United States|Clinical Trial Site, Nashville, Tennessee, United States|Clinical Trial Site, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT05234567"
26,"NCT05218096","Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis",,"Recruiting","No Results Available","Generalized Myasthenia Gravis|Myasthenia Gravis","Drug: ALXN2050|Drug: Placebo","Proportion Of Participants With A Myasthenia Gravis Activities of Daily Living (MG-ADL) Total Score Reduction Of ≥ 2 Points In Any 4 Consecutive Weeks During The First 8 Weeks And Who Did Not Receive Rescue Therapy|Change From Baseline In Quantitative Myasthenia Gravis (QMG) Total Score At Week 8|Proportion Of Participants Meeting Prespecified Threshold In The QMG Total Score At Week 8|Proportion Of Participants Meeting Prespecified Threshold In The QMG Total Score In Any 4 Consecutive Weeks During The First 8 Weeks And Who Did Not Receive Rescue Therapy|Change From Baseline In MG-ADL Total Score At Week 8|Proportion Of Participants Meeting Prespecified Threshold In The MG-ADL Total Score In Any 4 Consecutive Weeks During The First 8 Weeks And Who Did Not Receive Rescue Therapy|Proportion Of Participants Meeting Prespecified Threshold In The MG-ADL Total Score At Week 8|Change From Baseline In Quality Of Life In Neurological Disorders Fatigue Questionnaire (Neuro-QoL) Fatigue Score At Week 8|Maximum Peak Plasma Concentration (Cmax) Of ALXN2050 Over Time|Pre-dose Concentration (Ctrough) Of ALXN2050 Over Time|Absolute Values And Change From Baseline In Plasma Concentration Of Bb Fragment Of Complement Factor B At Week 8|Absolute Values And Change From Baseline In Serum Alternative Pathway (AP) Activity At Week 8 As Measured By Wieslab Assay|Plasma Factor D Concentration Over Time|Serum Complement Component 3 Concentration Over Time|Serum Classical Pathway Activity Over Time As Measured By CH50","Alexion Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","70","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","ALXN2050-MG-201","December 30, 2021","February 28, 2023","February 28, 2025","February 1, 2022",,"February 1, 2022","Clinical Trial Site, Allentown, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT05218096"
27,"NCT04170023","Study of the Oral Factor D (FD) Inhibitor ALXN2050 in PNH Patients as Monotherapy",,"Recruiting","No Results Available","Paroxysmal Nocturnal Hemoglobinuria (PNH)","Drug: ALXN2050","Change In HgB Relative To Baseline|Number Of Patients Who Have Transfusion Avoidance|Number Of RBC Units Transfused and Transfusion Instances|Change In LDH Relative To Baseline|Change From Baseline In Absolute Reticulocyte Count|Change From Baseline In Direct Bilirubin|Change From Baseline In Total Bilirubin|Change From Baseline In PNH RBC Clone Size|Change From Baseline In C3 Complement Protein Fragment Deposition On PNH RBCs|Incidence of TEAEs, SAEs, and Events Leading To Discontinuation Of Study Medication|Change in HgB Relative To Baseline|Change in LDH Relative To Baseline|Change in FACIT Fatigue Scale (Version 4) Scores Relative To Baseline","Alexion Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","26","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACH228-110","December 16, 2019","July 31, 2022","July 31, 2025","November 20, 2019",,"January 31, 2022","Clinical Study Site, Toronto, Ontario, Canada|Clinical Study Site, Sainte-Marie, Quebec, Canada|Clinical study Site, Essen, Germany|Clinical Study Site, Ulm, Germany|Clinical Study Site, Avellino, Italy|Clinical Study Site, Florence, Italy|Clinical Study Site, Milano, Italy|Clinical Study Site, Hwasun-gun, Korea, Republic of|Clinical Study Site, Seoul, Korea, Republic of|Clinical Study Site, Auckland, New Zealand|Clinical Study Site, Christchurch, New Zealand|Clinical Study Site, Albacete, Spain|Clinical Study Site, Bilbao, Spain|Clinical Study Site, Salamanca, Spain|Clinical Study Site, Fatih, Istanbul, Turkey|Clinical Study Site, Bornova, Izmir, Turkey|Clinical Study Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04170023"
28,"NCT05202145","Drug-Drug Interaction (DDI) Study of ALXN2050 in Healthy Adult Participants",,"Not yet recruiting","No Results Available","Healthy","Drug: ALXN2050|Drug: Cyclosporine|Drug: Tacrolimus|Drug: MMF","Part 1 Cyclosporine: Area Under The Concentration-Time Curve From Time Zero To The 12-hour Time Point (AUC0-12) Following Multiple Dose Cyclosporine Alone Versus When Dosed In The Presence Of Steady-state ALXN2050|Part 1: ALXN2050 AUC0-12 Following Multiple Dose ALXN2050 When Dosed Alone Versus When Dosed In The Presence Of Steady-state Cyclosporine|Part 1: Cyclosporine Maximum Observed Concentration (Cmax) Following Multiple Dose Cyclosporine When Dosed Alone Versus When Dosed In The Presence Of Steady-state ALXN2050|Part 1: ALXN2050 Cmax Following Multiple Dose ALXN2050 When Dosed Alone Versus When Dosed In The Presence Of Steady-state Cyclosporine|Part 1: Cyclosporine Time To Maximum Plasma Concentration (Tmax) Following Multiple Dose Cyclosporine When Dosed Alone Versus When Dosed In The Presence Of Steady-state ALXN2050|Part 1: ALXN2050 Tmax Following Multiple Dose ALXN2050 When Dosed Alone Versus When Dosed In The Presence Of Steady-state Cyclosporine|Part 2: Tacrolimus Area Under The Concentration-Time Curve From Time Zero To The Last Observed Concentration (AUC0-t) Following Single Dose Tacrolimus When Dosed Alone Versus When Dosed In The Presence Of Steady-state ALXN2050|Part 2: Tacrolimus Area Under the Concentration-Time Curve From Time Zero To Infinity (AUC0-inf) Following Single Dose Tacrolimus When Dosed Alone Versus When Dosed In The Presence of Steady-state ALXN2050|Part 2: Tacrolimus Cmax Following Single Dose Tacrolimus When Dosed Alone Versus When Dosed In The Presence Of Steady-state ALXN2050|Part 2: Tacrolimus Tmax Following Single Dose Tacrolimus When Dosed Alone Versus When Dosed In The Presence Of Steady-state ALXN2050|Part 3: Mycophenolic Acid (MPA) And Mycophenolic Acid Glucuronide (MPAG) (Active Metabolites Of MMF) AUC0-t Following Single Dose MMF When Dosed Alone Versus When Dosed In The Presence Of Steady-state ALXN2050|Part 3: MPA and MPAG AUC0-inf Following Single Dose MMF When Dosed Alone Versus When Dosed In The Presence Of Steady-State ALXN2050|Part 3: MPA And MPAG Cmax Following Single Dose MMF When Dosed Alone Versus When Dosed In The Presence Of Steady-state ALXN2050|Part 3: MPA And MPAG Tmax Following Single Dose MMF When Dosed Alone Versus When Dosed In The Presence Of Steady-state ALXN2050|Parts 1-3: Number of Participants Experiencing Treatment-emergent Adverse Events","Alexion Pharmaceuticals","All","18 Years to 55 Years   (Adult)","Phase 1","60","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","ALXN2050-HV-110","January 2022","February 2022","February 2022","January 21, 2022",,"January 21, 2022","Clinical Study Site, Tempe, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT05202145"
29,"NCT05097989","Study of ALXN2050 in Proliferative Lupus Nephritis (LN) and Immunoglobulin A Nephropathy (IgAN)",,"Not yet recruiting","No Results Available","Lupus Nephritis|Immunoglobulin A Nephropathy|IgAN","Drug: ALXN2050|Drug: Placebo","Both Cohorts: Percentage Change In Proteinuria From Baseline To Week 26|Both Cohorts: Percentage Change In Proteinuria From Baseline To Week 50|Both Cohorts: Participants Achieving > 30% And > 50% Reduction In Proteinuria At Week 26 And Week 50 Compared To Baseline|Both Cohorts: Change From Baseline In Estimated Glomerular Filtration Rate (eGFR) At Week 26 And Week 50|LN Cohort: Participants Meeting The Criteria For Complete Renal Response At Week 26 And Week 50|LN Cohort: Participants Meeting The Criteria For Partial Renal Response At Week 26 And Week 50|LN Cohort: Time To The First Occurrence Of Urine Protein To Creatinine Ratio (UPCR) ≤ 0.5 Gram/Gram (g/g) As Measured By Spot Urine Sample|LN Cohort: Participants Achieving Corticosteroid Taper|LN Cohort: Participants Experiencing A Renal Flare Through Week 50|LN Cohort: Participants Experiencing An Extrarenal Systemic Lupus Erythematosus (SLE) Flare Through Week 50|LN Cohort: Participants Meeting The Criteria For Treatment Failure Through Week 50|LN Cohort: Absolute Values And Change From Baseline In Serum Albumin At Week 26 And Week 50|IgAN Cohort: Participants Meeting The Criteria For Partial Remission At Week 26 And Week 50|Both Cohorts: Observed Plasma Concentrations Of ALXN2050 Over Time|Both Cohorts: Absolute Values And Change From Baseline In Plasma Concentration Of Bb Fragment Of Complement Factor B At Week 50|Both Cohorts: Absolute Values And Change From Baseline In Serum Alternative Pathway Activity At Week 50","Alexion Pharmaceuticals","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","126","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ALXN2050-NEPH-201","November 2021","February 2023","February 2026","October 28, 2021",,"October 28, 2021",,,"https://ClinicalTrials.gov/show/NCT05097989"
30,"NCT05019521","A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration",,"Recruiting","No Results Available","Geographic Atrophy","Drug: Danicopan|Drug: Placebo","Mean Rate Of Change From Baseline At Week 52 In The Square Root (sqrt) Of Total GA Lesion Area In The Study Eye As Measured By Fundus Autofluorescence (FAF)|Mean Rate Of Change From Baseline At Week 104 In The Sqrt Of The Total GA Lesion Area In The Study Eye And From Baseline At Week 52 And Week 104 In The Fellow Eye And Both Eyes Combined (Regardless Of Baseline GA Status) As Measured By FAF|Mean Rate Of Change From Baseline At Week 52 And Week 104 In The Total GA Lesion Area In The Study Eye, The Fellow Eye, And Both Eyes Combined (Regardless Of Baseline GA Status) As Measured By FAF|Mean Change From Baseline At Week 52 And Week 104 In The Total GA Lesion Area In The Study Eye, The Fellow Eye, And Both Eyes Combined (Regardless Of Baseline GA Status) As Measured By FAF|Percent Change From Baseline At Week 52 And Week 104 In The Total GA Lesion Area In The Study Eye, The Fellow Eye, And Both Eyes Combined (Regardless Of Baseline GA Status) As Measured By FAF|Mean Change From Baseline At Week 52 And Week 104 In The Sqrt Of The Total GA Lesion Area In The Study Eye, The Fellow Eye, And Both Eyes Combined (Regardless Of Baseline GA Status) As Measured By FAF|Percent Change From Baseline At Week 52 And Week 104 In The Sqrt Of The Total GA Lesion Area In The Study Eye, The Fellow Eye, And Both Eyes Combined (Regardless Of Baseline GA Status) As Measured By FAF|Mean Change From Baseline At Week 52 And Week 104 In Monocular Best-corrected Visual Acuity (BCVA) Scores In The Study Eye And Fellow Eye As Assessed By The Early Treatment Diabetic Retinopathy Study (ETDRS) Chart At Four Meters|Mean Change From Baseline At Week 52 And Week 104 In Monocular Low Luminance Visual Acuity (LLVA) Scores In The Study Eye And Fellow Eye As Assessed By The ETDRS Chart At Four Meters|Mean Change From Baseline At Week 52 And Week 104 In Low Luminance Deficit In The Study Eye And Fellow Eye|Mean Change In National Eye Institute Visual Function Questionnaire, 25-item Version (NEI VFQ 25) Scores From Baseline At Week 52 And Week 104|Plasma Concentration Of Danicopan Over Time|Ex Vivo Serum Alternative Pathway Activity|Plasma Concentration Of Bb Fragment Of Complement Factor B|Incidence Of Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), And Ocular TEAEs, SAEs, And Clinical Laboratory Abnormalities, And Events Leading To Discontinuation Of Study Drug","Alexion Pharmaceuticals","All","70 Years and older   (Older Adult)","Phase 2","330","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ALXN2040-GA-201","August 20, 2021","February 29, 2024","February 28, 2025","August 25, 2021",,"March 7, 2022","Clinical Study Site, Encino, California, United States|Clinical Study Site, Sacramento, California, United States|Clinical Study Site, Waterford, Connecticut, United States|Clinical Study Site, Coral Springs, Florida, United States|Clinical Study Site, Deerfield Beach, Florida, United States|Clinical Study Site, Augusta, Georgia, United States|Clinical Study Site, West Des Moines, Iowa, United States|Clinical Study Site, Baltimore, Maryland, United States|Clinical Study Site, Baltimore, Maryland, United States|Clinical Study Site, Hagerstown, Maryland, United States|Clinical Study Site, Minneapolis, Minnesota, United States|Clinical Study Site, Kingston, Pennsylvania, United States|Clinical Study Site, Austin, Texas, United States|Clinical Study Site, Bellaire, Texas, United States",,"https://ClinicalTrials.gov/show/NCT05019521"
31,"NCT04999020","Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis",,"Recruiting","No Results Available","Dermatomyositis","Drug: Ravulizumab|Drug: Placebo","Part A: Proportion Of Participants With A ≥ 20-point Improvement Response On International Myositis Assessment And Clinical Studies-Total Improvement Score (IMACS-TIS) (TIS20) At Week 26 Of The Randomized Controlled Period|Part B: Proportion Of Participants With A ≥ 20-point Improvement Response On TIS20 At Week 50|Part A: Mean TIS At Week 26|Part A: Mean Change From Baseline In Cutaneous Dermatomyositis Disease Area And Severity Index (CDASI) Activity Score At Week 26|Part A: Change From Baseline Of Each Of The IMACS Core Set Measures At Week 26|Part A: Time To First CDASI Activity Score Improvement|Part A: Proportion Of Participants With CDASI MCID Improvement At Week 26|Part A: Change In Cutaneous Dermatomyositis Activity Physician's Global Assessment (CDA-IGA) At Week 26|Part A: Proportion Of Participants With TIS20 At Each Visit|Part A: Proportion Of Participants With A ≥ 40-point Improvement Response On IMACS-TIS (TIS40) At Each Visit|Part A: Proportion Of Participants With A ≥ 60-point Improvement Response On IMACS-TIS (TIS60) At Each Visit|Part A: Time To First Response Of TIS20, TIS40, Or TIS60|Part A: Time To First IMACS Myositis Core Set Measure Improvements|Part B: Mean TIS At Week 50|Part B: Mean Change From Baseline In Manual Muscle Testing Subset Of 8 Muscles (MMT-8) At Week 50|Part B: Mean Change From Baseline In Extra-muscular Disease Activity Based On Myositis Disease Activity Assessment Tool (MDAAT) At Week 50|Part B: Mean Change From Baseline In CDASI Activity Score At Week 50|Part B: Mean Change From Baseline In Patient Global Activity Assessment At Week 50|Part B: Mean Change From Baseline In Physician Global Activity Assessment At Week 50|Part B: Mean Change From Baseline In Health Assessment Questionnaire (HAQ) At Week 50|Part B: Mean Change From Baseline In Muscle Enzyme Values At Week 50|Part B: Mean TIS At Each Visit From Week 2 Through Week 50|Part B: Proportion Of Participants With TIS20 At Each Visit|Part B: Proportion Of Participants With TIS40 At Each Visit|Part B: Proportion Of Participants With TIS60 At Each Visit|Part B: Time To First Response Of TIS20, TIS40, Or TIS60|Part B: Time To First IMACS Myositis Core Set Measure Improvements|Part B: Time To First CDASI Activity Score Improvement|Part B: Proportion Of Participants With CDASI MCID Improvement At Week 50|Part B: Change In CDA-IGA At Week 50","Alexion Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","180","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ALXN1210-DM-310|2021-001200-15","December 2, 2021","August 31, 2022","August 31, 2024","August 10, 2021",,"February 24, 2022","Clinical Trial Site, Orange, California, United States|Clinical Trial Site, Kansas City, Kansas, United States|Clinical Trial Site, Toulouse Cedex 9, France|Clinical Trial Site, Essen, Germany|Clinical Trial Site, Freiburg, Germany|Clinical Trial Site, Brescia, BS, Italy|Clinical Trial Site, Pavia, PV, Italy|Clinical Trial Site, Roma, Italy|Clinical Trial Site, Incheon, Korea, Republic of|Clinical Trial Site, Seoul, Korea, Republic of|Clinical Trial Site, Seoul, Korea, Republic of|Clinical Trial Site, Seoul, Korea, Republic of|Clinical Trial Site, L'Hospitalet de Llobregat, Barcelona, Spain|Clinical Trial Site, Bilbao, Vizcaya, Spain|Clinical Trial Site, Barcelona, Spain|Clinical Trial Site, Barcelona, Spain|Clinical Trial Site, Madrid, Spain|Clinical Trial Site, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT04999020"
32,"NCT04980248","Study of ALXN1850 in Participants With Hypophosphatasia (HPP)",,"Recruiting","No Results Available","Hypophosphatasia","Biological: ALXN1850","Incidence Of Treatment-emergent Adverse Events And Treatment-emergent Serious Adverse Events|Area Under The Plasma Concentration Versus Time Curve (AUC) Of Single IV And Multiple SC Doses Of ALXN1850|Maximum Observed Plasma Concentration (Cmax) Of Single IV And Multiple SC Doses Of ALXN1850|Area Under The Plasma Concentration Versus Time Curve Within The Dosing Interval (AUCtau) Values Of The First SC Versus IV Administration|Change From Baseline In Plasma Concentrations Of Inorganic Pyrophosphate (PPi)|Change From Baseline In Plasma Concentrations Of Pyridoxal-5'-Phosphate (PLP)|Change From Baseline In Plasma Concentrations Of PLP/Pyridoxal (PL) Ratio","Alexion Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 1","15","Industry","Interventional","Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","ALXN1850-HPP-101","July 22, 2021","July 31, 2022","July 31, 2022","July 28, 2021",,"September 22, 2021","Clinical Trial Site, Nashville, Tennessee, United States",,"https://ClinicalTrials.gov/show/NCT04980248"
33,"NCT04970004","Retrospective Observational Study in Adult and Pediatric Patients With HSCT-TMA",,"Recruiting","No Results Available","Stem Cell Transplant Complications|Thrombotic Microangiopathies","Other: No intervention","Proportion of patients achieving TMA Response|Proportion of patients achieving TMA response|Changes in individual components of TMA response|Overall survival|Nonrelapse mortality","Alexion Pharmaceuticals","All","1 Month and older   (Child, Adult, Older Adult)",,"170","Industry","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","ALX-TMA-501","July 12, 2021","June 2022","June 2022","July 21, 2021",,"July 21, 2021","Clinical Trial Site, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT04970004"
34,"NCT01522183","Atypical Hemolytic-Uremic Syndrome (aHUS) Registry",,"Recruiting","No Results Available","Atypical Hemolytic-Uremic Syndrome",,"Proportion of patients who experience specified events|Time to first and subsequent occurrence of specified events.","Alexion Pharmaceuticals|Syneos Health","All","Child, Adult, Older Adult",,"2000","Industry|Other","Observational","Observational Model: Other|Time Perspective: Other","M11-001","April 2012","December 2023","December 2025","January 31, 2012",,"May 18, 2020","Georgetown University Hospital, Washington, District of Columbia, United States|University of Florida, Division of Nephrology, Gainesville, Florida, United States|Emory Children's Center Emory University, Atlanta, Georgia, United States|Children's Memorial Hospital, Chicago, Illinois, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Brookview Hills Research Associates LLC, Winston-Salem, North Carolina, United States|Arthur James Cancer Hospital, Columbus, Ohio, United States|Nepean Hospital, Penrith, New South Wales, Australia|The Children's Hospital at Westmead, Westmead, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Cairns Base Hospital, Cairns, Queensland, Australia|Royal Brisbane & Women's Hospital, Herston, Queensland, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Austin Health, Heidelberg, Victoria, Australia|The Royal Children's Hospital, Parkville, Victoria, Australia|The Royal Melbourne Hospital, Parkville, Victoria, Australia|Fiona Stanley Hospital, Murdoch, Western Australia, Australia|Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia|Hopital Erasme, Brussels, Belgium|Hopital Universitaire des Enfants Reine, Brussels, Belgium|UZ Brussels, Brussels, Belgium|UZA (Adult), Edegem, Belgium|UZA (Pediatric), Edegem, Belgium|UZ Gent (pediatric), Gent, Belgium|University Hospital Leuven (Adult), Leuven, Belgium|University Hospital Leuven (pediatric), Leuven, Belgium|CHU de Liege - Clinique de l'Esperance (pediatric), Liège, Belgium|CHU de Liege - Sart Tilman, Liège, Belgium|Cliniques Universitaires Saint-Luc (adult), Woluwe-Saint-Lambert, Belgium|Cliniques Universitaires Saint-Luc (Pediatric), Woluwe-Saint-Lambert, Belgium|London Health Science Center, London, Ontario, Canada|The Hospital for Sick Children, Toronto, Ontario, Canada|CHU Ste Justine, Montréal, Quebec, Canada|CHU de Quebec Hotel-Dieu de Quebec, Québec, Quebec, Canada|Odense University Hospital, Odense, Denmark|CH Amiens - Hopital Nord, Amiens, France|Hopital Sud, Amiens, France|CHU Angers, Angers, France|CHG Bayonne, Bayonne, France|CHU de Bordeaux Pellegrin, Bordeaux, France|CHRU Brest, Brest, France|Hopital Femme Mere Enfant, Bron, France|CHRU de Caen Hopital Clemenceau Service de Nephrologie, Caen, France|Centre Hospitialier Regional de Chambery, Chambéry, France|CHU Clermont Ferrand, Clermont-Ferrand, France|CHU Dijon, Dijon, France|CHU Grenoble, Grenoble, France|Le Kremlin Bicetre Hospital, Le Kremlin-Bicêtre, France|CHRU de Lille Hopital A Calmette, Lille, France|CHRU de Lille Hopital Jeanne de Flandre, Lille, France|Hopital Edouard Herriot (CHU Lyon), Lyon, France|Hopital de la Timone Enfants, Marseille, France|CHU de Montpellier, Montpellier, France|Hopital Brabois, Nancy, France|Hopital de Nancy, Nancy, France|CHU de Nantes-Hopital Hotel Dieu, Nantes, France|Hopital Enfants et Adolescents, Nantes, France|Le Centre Hospitialier Universitarie de Nice Hopital Pasteur, Nice, France|HEGP - Hopital Europeen Georges Pompidou, Paris, France|Hopital Necker, Enfants Malades Service de Nephrologie Pediatrique, Paris, France|Hopital Necker, Paris, France|Hopital Robert Debre Service de Nephrologie Pediatrique, Paris, France|Hopital Tenon, Paris, France|CH Perpignan, Perpignan, France|Hopital Poitiers, Poitiers, France|CHU de Pontoise, Pontoise, France|CHU de Rennes Ponchaillou, Rennes, France|CHU Rennes, Hopital Sud, Rennes, France|CHU-CH Charles Nicolle, Rouen, France|Hopital de Bois Guillaume CHU de Rouen, Rouen, France|Hopital Civil de Strasbourg, Strasbourg, France|Nouvel Hopital Civil, Strasbourg, France|CHU Rangueil, Toulouse, France|Hopital des Enfants, Toulouse, France|CHFU de Tours, Tours, France|CH Valenciennes, Valenciennes, France|Universitaetsklinikum Essen, Essen, Germany|Medizinische Hochschule Hannover Adult Nephrology, Hannover, Germany|Medizinische Hochschule Hannover Pediatric Nephrology, Hannover, Germany|Universitaet Heidelberg, Heidelberg, Germany|Universtaetskilinkum Schlkeswig-Holstein, Luebeck, Germany|Universitaetskilinikum Muenster, Münster, Germany|Universitaetsklinikum Tuebingen, Tübingen, Germany|Soroka University Medical Center, Be'er Sheva, Israel|Policlinico Consorziale de Bari, Bari, Italy|U O Nefrologia e Dialisi Pediatrica Ospedale Giovanni XXIII, Bari, Italy|Azienda Ospedaliero - Universitaria Careggi, Firenze, Italy|Istituto Giannina Gaslini, Genova, Italy|Fondazione IRCCS Ca Granda, Ospedale Maggiore Policlinico, Milano, Italy|Pad Croff Nefrologia Ospedale Maggiore Policlinico, Milano, Italy|S C Nefrologia - A O Ospedale Niguarda-Ca Granda, Milano, Italy|Dipartmento di Nefrologia e Urologia Ospedale Pediatrico Bambin Gesu, Roma, Italy|Ospediale Pediatrico Regina Margherita, Torino, Italy|CHA Bundang Medical Center, CHA University, Gyeonggi-do, Korea, Republic of|The Catholic University of Korea, Uijeongnu St Mary's Hospital, Gyeonggi-do, Korea, Republic of|Pusan National University Yangsan Hospital, Gyeongsang, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Esha Womans University Medical Center, Seoul, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Severance Hospital Yonsei University Health System, Seoul, Korea, Republic of|NZOZ - TRI Medica, Łódź, Poland|Samodzielny Publiczny Zaklad Opieki Zdrowotnej Centralny Szpital Klinkzny, Łódź, Poland|Sverdlovsk Regional Clinical Hospital No. 1, Ekaterinburg, Russian Federation|Regional Clinical Hospital No. 1, Khabarovsk, Russian Federation|Children's City Clinical Hospital of Saint Vladimir, Moscow, Russian Federation|City Clinical Hospital #52, Moscow, Russian Federation|First Moscow State Medical University, Moscow, Russian Federation|Saint Petersburg Medical University, Saint Petersburg, Russian Federation|H. Valle Hebron, Barcelona, Spain|Complejo Hospitalario de Navarra, Pamplona, Spain|Hospital Virgen del Rocio, Sevilla, Spain|Veteran's General Hospital - Kaohsiung (VGH-KS), Kaohsiung, Taiwan|Chang Cung Memorial Hospital - LK (CGMH-LK), New Taipei City, Taiwan|China Medical University Hospital (CMUH), Taichung, Taiwan|National Taiwan University Hospital (NTUH), Taipei, Taiwan|Royal Devon & Exeter NHS Foundation Trust, Exeter, United Kingdom|Great Ormond Street Hospital, London, United Kingdom|Royal Free Hospital, London, United Kingdom|University College London Hospitals NHS Foundation Trust, London, United Kingdom|Royal Manchester Children's Hospital, Manchester, United Kingdom|Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle, United Kingdom|Southampton General Hospital, Southampton, United Kingdom|Morriston Hospital, Wales, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01522183"
35,"NCT04757259","Expanded Access Program for Participants Who Completed Study 13-601 and Continue to Clinically Benefit From Cerdulatinib",,"Available","No Results Available","Relapsed/Refractory Chronic Lymphocytic Leukemia|Non-hodgkin's Lymphoma","Drug: cerdulatinib",,"Alexion Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)",,,"Industry","Expanded Access:Treatment IND/Protocol",,"20-605",,,,"February 17, 2021",,"February 17, 2021",,,"https://ClinicalTrials.gov/show/NCT04757259"
36,"NCT04631562","Study of ALXN1820 in Healthy Adult Participants",,"Recruiting","No Results Available","Healthy","Drug: ALXN1820 SC|Drug: ALXN1820 IV|Drug: Placebo SC|Drug: Placebo IV","Participants With Treatment-related Adverse Events (TEAEs) For ALXN1820 SC And ALXN1820 IV|Area Under The Concentration-time Curve From Time 0 (Dosing) To Time Infinity (AUC0-inf) And AUC During The Dosing Interval (AUCtau) Of Serum ALXN1820 For Single And Multiple Ascending Doses|Maximum Observed Serum Concentration (Cmax) Of Serum ALXN1820 For Single And Multiple Ascending Doses|Change From Baseline In Serum Concentrations Of Total And Free Properdin For ALXN1820 SC And ALXN1820 IV|Change From Baseline In Complement Alternative Pathway (CAP) Activity Using The Wieslab Alternative Pathway (AP) Assay For ALXN1820 SC And ALXN1820 IV|Incidence Of Antidrug Antibodies (ADAs) To ALXN1820 SC And ALXN1820 IV|Absolute Bioavailability Of ALXN1820 SC|Comparison Of Incidence Of TEAEs For ALXN1820 SC For Multiple Ascending Doses Between Healthy Non-Japanese Participants And Participants Of Japanese Descent|Comparison Of AUCtau Of Serum ALXN1820 SC For Multiple Ascending Doses Between Healthy Non-Japanese Participants And Participants Of Japanese Descent|Comparison Of Cmax Of Serum ALXN1820 SC For Multiple Ascending Doses Between Healthy Non-Japanese Participants And Participants Of Japanese Descent|Comparison Of Incidence of ADAs To ALXN1820 SC Between Healthy Non-Japanese Participants And Participants Of Japanese Descent|Comparison Of The Change From Baseline In CAP Activity Using The Wieslab AP Assay Between Healthy Non-Japanese Participants And Participants Of Japanese Descent For Multiple Ascending Doses Of ALXN1820 SC|Comparison In The Change From Baseline In Serum Concentrations Of Total And Free Properdin Between Healthy Non-Japanese Participants And Participants Of Japanese Descent For Multiple Ascending Doses Of ALXN1820 SC","Alexion Pharmaceuticals|Syneos Health","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","80","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","ALXN1820-HV-101","January 8, 2021","March 31, 2022","March 31, 2022","November 17, 2020",,"November 9, 2021","Clinical Study Site, Herston, Australia|Clinical Study Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04631562"
37,"NCT04623710","Study of ALXN2050 in Participants With Renal Impairment",,"Not yet recruiting","No Results Available","Renal Impairment|Healthy","Drug: ALXN2050","Area Under The Concentration-time Curve From Time 0 To The 12-hour Time Point (AUC0-12) Of Plasma ALXN2050 After Steady-state|Area Under The Concentration-time Curve Calculated To The Last Observable Concentration At Time t (AUCt) Of Plasma ALXN2050 After Steady-state|Maximum (Peak) Steady-state Plasma Concentration (Cmax,ss) Of Plasma ALXN2050|Time To Reach Maximum (Peak) Plasma Concentration Following ALXN2050 Administration At Steady-state (Tmax,ss)|Change From Baseline In Complement Factor D Concentration At 24, 48, And 72 Hours Postdose|Change From Baseline In Plasma b Fragment Of Complement Factor B Concentration|Change From Baseline In Complement Alternative Pathway Hemolysis Activity|Number Of Participants Receiving ALXN2050 With Treatment-emergent Adverse Events","Alexion Pharmaceuticals","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","40","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","ALXN2050-HV-108","January 2021","December 2021","December 2021","November 10, 2020",,"November 10, 2020","Clinical Trial Site, Hialeah, Florida, United States|Clinical Trial Site, Orlando, Florida, United States",,"https://ClinicalTrials.gov/show/NCT04623710"
38,"NCT04564339","Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)",,"Recruiting","No Results Available","Lupus Nephritis|Immunoglobulin A Nephropathy","Drug: Ravulizumab|Drug: Placebo|Other: Background Therapy","Both Cohorts: Percentage Change In Proteinuria From Baseline To Week 26 Assessed Using 24-hour Urine Collections|Both Cohorts: Percentage Change In Proteinuria From Baseline To Week 50 Assessed Using 24-hour Urine Collections|Both Cohorts: Change In Estimated Glomerular Filtration Rate (eGFR) From Baseline At Week 26 And Week 50|LN Cohort: Percentage Of Participants Meeting The Criteria For Complete Renal Response|LN Cohort: Percentage Of Participants Meeting The Criteria For Partial Renal Response|LN Cohort: Time To Urine Protein To Creatinine Ratio < 0.5 g/g|LN Cohort: Percentage Of Participants Achieving Corticosteroid Taper To 7.5 mg/day|LN Cohort: Percentage Of Participants With Renal Flare|LN Cohort: Percentage Of Participants With Extrarenal Systemic Lupus Erythematosus Flare|IgAN Cohort: Percentage Of Participants Meeting The Criteria For Partial Remission","Alexion Pharmaceuticals","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","120","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ALXN1210-NEPH-202|2020-001537-13","December 11, 2020","June 30, 2023","July 31, 2024","September 25, 2020",,"December 16, 2021","Clinical Study Site, Los Angeles, California, United States|Clinical Study Site, S. Gate, California, United States|Clinical Study Site, San Dimas, California, United States|Clinical Study Site, Hollywood, Florida, United States|Clinical Study Site, Orlando, Florida, United States|Clinical Study Site, Lawrenceville, Georgia, United States|Clinical Study Site, Lexington, Kentucky, United States|Clinical Study Site, Boston, Massachusetts, United States|Clinical Study Site, Kansas City, Missouri, United States|Clinical Study Site, New York, New York, United States|Clinical Study Site, Chapel Hill, North Carolina, United States|Clinical Study Site, Columbus, Ohio, United States|Clinical Study Site, Dallas, Texas, United States|Clinical Study Site, El Paso, Texas, United States|Clinical Study Site, Fort Worth, Texas, United States|Clinical Study Site, Houston, Texas, United States|Clinical Study Site, Houston, Texas, United States|Clinical Study Site, Salt Lake City, Utah, United States|Clinical Study Site, Milwaukee, Wisconsin, United States|Clinical Study Site, Parkville, Melbourne, Australia|Clinical Study Site, Westmead, New South Wales, Australia|Clinical Study Site, Herston, Queensland, Australia|Clinical Study Site, Quebec, Canada|Clinical Study Site, Strasbourg, Bas-Rhin, France|Clinical Study Site, Clermont-Ferrand, France|Clinical Study Site, Créteil, France|Clinical Study Site, Le Kremlin-Bicêtre, France|Clinical Study Site, Montpellier, France|Clinical Study Site, Paris, France|Clinical Study Site, Saint-Étienne, France|Clinical Study Site, Toulouse, France|Clinical Study Site, Hannover, Niedersachsen, Germany|Clinical Study Site, Essen, North Rhine-Westphalia, Germany|Clinical Study Site, Berlin, Germany|Clinical Study Site, Essen, Germany|Clinical Study Site, Lubeck, Germany|Clinical Study Site, Bologna, Italy|Clinical Study Site, Brescia, Italy|Clinical Study Site, Firenze, Italy|Clinical Study Site, Monza, Italy|Clinical Study Site, Anyang-si, Gyeonggi-do, Korea, Republic of|Clinical Study Site, Seongnam, Gyeonggi-do, Korea, Republic of|Clinical Study Site, Seoul, Korea, Republic of|Clinical Study Site, Seoul, Korea, Republic of|Clinical Study Site, Seoul, Korea, Republic of|Clinical Study Site, Seoul, Korea, Republic of|Clinical Study Site, Maastricht, Netherlands|Clinical Study Site, Bydgoszcz, Poland|Clinical Study Site, Lodz, Poland|Clinical Study Site, Singapore, Singapore|Clinical Study Site, Santiago De Compostela, A Coruña, Spain|Clinical Study Site, Sevilla, Andalucia, Spain|Clinical Study Site, Valencia, Comunidad, Spain|Clinical Study Site, Palma, Illes Balears, Spain|Clinical Study Site, Alicante, Spain|Clinical Study Site, Barcelona, Spain|Clinical Study Site, Barcelona, Spain|Clinical Study Site, Lleida, Spain|Clinical Study Site, Madrid, Spain|Clinical Study Site, Madrid, Spain|Clinical Study Site, Madrid, Spain|Clinical Study Site, Malaga, Spain|Clinical Study Site, Zaragoza, Spain|Clinical Study Site, Orebro, Sweden|Clinical Study Site, Uppsala, Sweden|Clinical Study Site, Kaohsiung City, Taiwan|Clinical Study Site, New Taipei City, Taiwan|Clinical Study Site, Taichung City, Taiwan|Clinical Study Site, London, United Kingdom|Clinical Study Site, Nottingham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04564339"
39,"NCT01412047","Paroxysmal Nocturnal Hemoglobinuria Human Anti-Human Antibodies Study",,"Completed","No Results Available","Paroxysmal Nocturnal Hemoglobinuria|PNH",,"To summarize the proportion of patients with neutralizing HAHA antibodies.|To summarize the proportion of patients with non-neutralizing HAHA antibodies.|To summarize the proportion of patients with increased hemolysis in setting of neutralizing HAHA antibodies.","Alexion Pharmaceuticals","All","Child, Adult, Older Adult",,"75","Industry","Observational","Observational Model: Other|Time Perspective: Prospective","M07-003","March 2012","June 2013","June 30, 2013","August 8, 2011",,"October 18, 2017","University Park Hematology Oncology, Englewood, Colorado, United States|Cleveland Clinic Florida, Weston, Florida, United States|Maine Cancer Center of Medicine, Scarborough, Maine, United States|Melbourne, Australia|Brussels, Belgium|Paris, France|Universitatsklinikum Essen, Essen, Germany|Institut fur Klinische Transfusionmedizin und Immungenetick, Ulm, Germany|Dublin, Ireland|Azienda Ospediliera Universitatia Careggi, Firenze, Italy|Universita degli Studi di Napoli, Napoli, Italy|Nijmegen, Netherlands|Basel, Switzerland|London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01412047"
40,"NCT01399593","Safety & Efficacy of Eculizumab to Prevent AMR in Living Donor Kidney Transplant Recipients Requiring Desensitization",,"Terminated","Has Results","Antibody Mediated Rejection","Drug: Eculizumab","Treatment Failure Rate","Alexion Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","102","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","C10-001|2010-019630-28|BB-IND: 100,003","November 2, 2011","May 13, 2014","November 13, 2015","July 22, 2011","April 19, 2017","October 3, 2017","Birmingham, Alabama, United States|La Jolla, California, United States|Los Angeles, California, United States|San Francisco, California, United States|Washington, D.C., District of Columbia, United States|Atlanta, Georgia, United States|Chicago, Illinois, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|Rochester, Minnesota, United States|Saint Louis, Missouri, United States|Livingston, New Jersey, United States|New York, New York, United States|Chapel Hill, North Carolina, United States|Cincinnati, Ohio, United States|Oklahoma City, Oklahoma, United States|Houston, Texas, United States|North Terrace, South Australia, Australia|Camperdown, Australia|Clayton VIC, Australia|Parkville VIC, Australia|Paris, France|Paris, France|Toulouse Cedex, France|Tours Cedex, France|Dresden, Germany|Heidelberg, Germany|Milan, Italy|Padova, Italy|Rotterdam, Netherlands|Oslo, Norway|Barcelona, Spain|Göteborg, Sweden|Huddinge, Sweden|Uppsala, Sweden|London, England, United Kingdom|London, England, United Kingdom|Oxford, England, United Kingdom|Birmingham, United Kingdom|Cambridge, United Kingdom|Coventry, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01399593"
41,"NCT01335165","Safety and Pharmacokinetics of TT30 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)",,"Terminated","No Results Available","Paroxysmal Nocturnal Hemoglobinuria (PNH)","Drug: ALXN1102|Drug: ALXN1103","Assess the safety and tolerability of a single dose of TT30.|Characterize PK, PD and immunogenicity of a single dose of TT30.","Alexion Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 1","10","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TT30-PNH-002","April 2011","March 2014","March 2014","April 14, 2011",,"May 22, 2014","USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States|Institute of Hematology and Blood Transfusion / Institut Hematologie a krevní transfuze, U nemocnice 1, Prague 2, Czech Republic|Federico II University of Naples, Via Pansini 5, Naples, Italy|University Clinical Centre, Dębinki 7, Gdańsk, Poland|King's College Hospital NHS Foundation Trust, Denmark Hill, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01335165"
42,"NCT02128269","Phase IIa Trial of ALXN1007 for the Treatment of Non-criteria Manifestations of Antiphospholipid Syndrome",,"Terminated","Has Results","Antiphospholipid (aPL)-Positive","Biological: Study Drug- ALXN1007","Safety and Tolerability of Intravenous (IV) ALXN1007 as Measured by Percentage of Patients Reporting Adverse Events","Alexion Pharmaceuticals","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","9","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ALXN1007-APS-201|2013-003588-73","April 2014","June 2016","June 2016","May 1, 2014","July 13, 2017","July 13, 2017","Hospital for Special Surgery, New York, New York, United States|University of Texas Medical Branch, Galveston, Texas, United States|O & O Alpan, LLC, Fairfax, Virginia, United States|Hospital das Clínicas da Faculdade de Medicina da USP, São Paulo, Sao Paulo, Brazil|Hôpital Cochin, Paris, France 75679, France|Hopital Claude Huriez - CHU Lille, Lille, Nord, France|Azienda Ospedaliera di Padova, Padova, Italy|Hokkaido University Hospital, Sapporo-shi, Hokkaido 060-8648, Japan|University College London Hospitals, London, Greater London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02128269"
43,"NCT03406507","A Phase 3, Open-Label Study of ALXN1210 in Children and Adolescents With Paroxysmal Nocturnal Hemoglobinuria (PNH)",,"Recruiting","No Results Available","Paroxysmal Nocturnal Hemoglobinuria (PNH)","Biological: ALXN1210","Cmax (pharmacokinetic parameter)|Ctrough (pharmacokinetic parameter)|accumulation ratio (pharmacokinetic parameter)|free C5 concentrations (pharmacodynamic parameter)|cRBC (pharmacodynamic parameter)|Change in lactate dehydrogenase ( LDH) level|Proportion of patients who achieve transfusion avoidance (TA)","Alexion Pharmaceuticals","All","up to 18 Years   (Child, Adult)","Phase 3","13","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ALXN1210-PNH-304|2017-002820-26","February 22, 2018","June 2021","June 2025","January 23, 2018",,"July 31, 2020","Clinical Trial Site, Atlanta, Georgia, United States|Clinical Trial Site, Milwaukee, Wisconsin, United States|Clinical Trial Site, Paris, France|Clinical Trial Site, Utrecht, Netherlands|Clinical Trial Site, Oslo, Norway|Clinical Trial Site, Moscow, Russian Federation|Clinical Trial Site, Saint Petersburg, Russian Federation|Clinical Trial Site, Leeds, United Kingdom|Clinical Trial Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03406507"
44,"NCT04155424","A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder",,"Recruiting","No Results Available","Neuromyelitis Optica|Neuromyelitis Optica Spectrum Disorder","Drug: Eculizumab","Change From Baseline In The Annualized Relapse Rate At 52/53 Weeks|Time To First Relapse|Change From Baseline In Expanded Disability Status Scale (EDSS) Score At 52/53 Weeks In Participants ≥5 Years Of Age|Change From Baseline In The Hauser Ambulatory Index Score At 52/53 Weeks|Change From Baseline In Pediatric Quality Of Life Inventory (PedsQL) At 52/53 Weeks In Participants ≥5 Years Of Age|Change From Baseline In Pediatric Quality Of Life Inventory Parent Proxy (PedsQL Parent Proxy) At 52/53 Weeks In Participants < 5 Years Of Age|Change From Baseline In Visual Acuity As Measured By The Snellen Or LEA Symbols Eye Chart Examination At 52/53 Weeks|Change From Baseline In Confrontational Visual Fields As Measured During Ophthalmologic Examination At 52/53 Weeks|Change From Baseline In Color Vision As Measured During Ophthalmologic Examination At 52/53 Weeks|Serum Eculizumab Concentration Over Time|Serum Free Complement Protein 5 Concentrations Over Time|In Vitro Hemolytic Activity Over Time","Alexion Pharmaceuticals","All","2 Years to 17 Years   (Child)","Phase 2|Phase 3","15","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ECU-NMO-303|2019-001829-26","January 14, 2020","November 2021","December 2024","November 7, 2019",,"July 14, 2021","University of California San Francisco (UCSF), San Francisco, California, United States|Georgetown University, Washington, District of Columbia, United States|University of Miami, Miami, Florida, United States|Children's Healthcare of Atlanta, Atlanta, Georgia, United States|Meridian Clinical Research, Rockville, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of North Carolina School of Medicine at Chapel Hill, Chapel Hill, North Carolina, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|The Stollery Childrens Hospital, Edmonton, Alberta, Canada|The Hospital for Sick Children SickKids, Toronto, Ontario, Canada|Georg-August-Universitaet Goettingen - Universitaetsmedizin Goettingen (UMG) Klinik fuer Kinder- und Jugendmedizin, Abt. Neuropaediatrie, Regensburger Straße, Goettingen, Germany|Ospedale Policlinico San Martino, Genoa, Italy|Neurological Centre of Latium, Rome, Italy|Yokohama City University Medical Center, Yokohama, Japan|Seoul National University Hospital, Seoul, Korea, Republic of|Hospital Sant Joan de Deu, Barcelona, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain",,"https://ClinicalTrials.gov/show/NCT04155424"
45,"NCT01192399","Safety and Efficacy Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients",,"Completed","Has Results","Paroxysmal Nocturnal Hemoglobinuria","Biological: Eculizumab","Change From Baseline in Lactate Dehydrogenase|Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale Total Score|Change From Baseline in Paroxysmal Nocturnal Hemoglobinuria (PNH) Red Blood Cell (RBC) Count|Number of Units of Packed Red Blood Cells (pRBCs) Transfused|Change From Baseline in Lactate Dehydrogenase (LDH) Area Under the Curve (AUC)|Change From Baseline in Plasma Free Hemoglobin|Change From Baseline in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30 Score (Global Health Status)","Alexion Pharmaceuticals","All","12 Years and older   (Child, Adult, Older Adult)","Phase 2","29","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","C07-001","November 2007","June 2008","June 2008","September 1, 2010","March 13, 2018","March 13, 2018",,,"https://ClinicalTrials.gov/show/NCT01192399"
46,"NCT01180790","Safety, Tolerability and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in HCV Positive Subjects",,"Completed","Has Results","Hepatitis C","Drug: ACH-0141625 (Sovaprevir)|Drug: Placebo|Drug: Pegylated Interferon alpha-2a|Drug: Ribavirin","Segment 1: Safety|Segment 1 : Rapid Viral Response at Week 4 (RVR4)|Segment 2: Safety|Segment 2: Complete Early Virologic Response (cEVR)|Segment 1: Complete Early Virologic Response (cEVR)|Segment 2: RVR4 (Rapid Viral Response at 4 Weeks)|Segment 1 and Segment 2: End of Treatment Response|Segment 1 and Segment 2: Sustained Virologic Response 12 Weeks ( Three Months Post Dosing) (SVR12)|Segment 1 and Segment 2: Sustained Virologic Response ( Six Months Post Dosing) (SVR24)|Segment 1 and Segment 2: HCV RNA Change From Baseline","Alexion Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","122","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ACH625-003|2010-022092-65","September 2010","March 2012","April 2013","August 12, 2010","September 10, 2014","September 10, 2014","Axis Clinical Trials, Los Angeles, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|Quest Clinical Research, San Francisco, California, United States|Pointe West Infectious Disease, Brandenton, Florida, United States|Orlando Immunology Center, Orlando, Florida, United States|Northwestern University, Chicago, Illinois, United States|Vince and Associates Clinical Research, Overland Park, Kansas, United States|St. Louis University, St. Louis, Missouri, United States|Impact Clinical Trials, Las Vegas, Nevada, United States|Weill Medical College of Cornell University, New York, New York, United States|Albert Einstein Medical Center, Philadelphia, Pennsylvania, United States|North Texas Research Institute, Arlington, Texas, United States|Alamo Medical Research, San Antonio, Texas, United States|Bon Secours St. Mary's Hospital of Richmond, Newport News, Virginia, United States|Digestive and Liver Diseas Specialists, Norfolk, Virginia, United States|Universitair Ziekenhuis Antwerpen, Edgem, Antwerp, Belgium|Centre Hospitalier de Jolimont-Lobbes, Haine-Saint-Paul, Hainaut, Belgium|Universitair Ziekenhuis Gent, Gent, Oost-Vlaanderen, Belgium",,"https://ClinicalTrials.gov/show/NCT01180790"
47,"NCT00675844","An Open Label Treatment Protocol to Provide Continued Elvucitabine Treatment",,"Completed","No Results Available","HIV Infections","Drug: elvucitabine","Determine the safety profile of elvucitabine as measured by the incidence of study discontinuations and the incidence, severity and type of AEs and clinically significant changes or abnormalities in the subject's clinical laboratory results.|Determination of the continued efficacy of elvucitabine as measured by the change in helper T cell (CD4) count.","Alexion Pharmaceuticals|Bellos, Nicholaos C., M.D.|Central Texas Primary Care Research Network|Orlando Immunology Center|Saint Michael|Center for the Prevention and Treatment of Infections","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","7","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACH443-904","May 2008","March 2010","March 2010","May 12, 2008",,"February 13, 2014","Orlando Immunology Center, Orlando, Florida, United States|Center for the Prevention and Treatment of Infections, Pensacola, Florida, United States|St Michael's Medical Center, Newark, New Jersey, United States|Central Texas Clinical Research, Austin, Texas, United States|Nicholaos Bellos, MD, Dallas, Texas, United States",,"https://ClinicalTrials.gov/show/NCT00675844"
48,"NCT00401947","A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ACH-0137171 in Subjects With Chronic Hepatitis C Infection",,"Terminated","No Results Available","HCV Infection","Drug: ACH-0137171","The primary objectives of this study are as follows:|To assess the short-term safety and tolerability of multiple, escalating, oral doses of ACH-0137171 in subjects with chronic hepatitis C infection.|To characterize the plasma pharmacokinetics of ACH-0137171 following administration of multiple, escalating, oral doses in subjects with chronic hepatitis C infection.|To assess the antiviral activity of ACH-0137171 as measured by plasma HCV RNA levels in subjects with chronic hepatitis C infection following administration of multiple, escalating, oral doses.|To assess the correlation between antiviral activity and pharmacokinetic parameters.|The secondary objective of this study is as follows:|To perform viral dynamic and pharmacodynamic modeling of ACH 0137171 virologic response.|To assess the biochemical response of ACH-0137171 as measured by the change from baseline of serum ALT and AST levels.","Alexion Pharmaceuticals","All","18 Years to 60 Years   (Adult)","Phase 2","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment","ACH171-002","November 2006",,"March 2007","November 22, 2006",,"December 30, 2015","Mayo Clinic Hospital, Phoenix, Arizona, United States|University of California, San Diego, LaJolla, California, United States|University of California, San Francisco, San Francisco, California, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Mt. Sinai Medical Center, New York, New York, United States|The Liver Institute at Methodist-Dallas, Dallas, Texas, United States|Alamo Medical Research, San Antonio, Texas, United States|Paraxel International GmbH, Berlin, Germany|Universitair Medisch Centrum Utrecht (AZU), Utrecht, Netherlands",,"https://ClinicalTrials.gov/show/NCT00401947"
49,"NCT00350272","Elvucitabine/Efavirenz/Tenofovir vs. Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects",,"Completed","Has Results","HIV Infections","Drug: elvucitabine|Drug: Lamivudine|Drug: Tenofovir|Drug: Efavirenz","The Proportion of Subjects With Virologic Response for 10 mg/Day Elvucitabine in HIV-1-infected Subjects by 12 Weeks Compared With the Proportion of Subjects With Lamivudine 300 mg/Day.|The Safety Profile of Elvucitabine.","Alexion Pharmaceuticals","All","18 Years to 60 Years   (Adult)","Phase 2","76","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ACH443-015","May 2006","August 2007","April 2009","July 10, 2006","March 22, 2016","June 17, 2016","Health for Life Clinic, Little Rock, Arkansas, United States|Living Hope Clinical Foundation, Inc., Long Beach, California, United States|Anthony Mills, Los Angeles, California, United States|Georgetown University, Washington, District of Columbia, United States|Clinical Research of West Florida, Clearwater, Florida, United States|Associates in Research, Inc., Fort Myers, Florida, United States|Steinhart Medical Associates, Miami, Florida, United States|University of Miami School of Medicine, Miami, Florida, United States|Orlando Immunology Center, Orlando, Florida, United States|Hillsborough County Health Department, Tampa, Florida, United States|Infectious Disease Research Institute, Inc., Tampa, Florida, United States|Triple O Medical Services, West Palm Beach, Florida, United States|Northwestern University, Chicago, Illinois, United States|University of Kansas School of Medicine Wichita, Wichita, Kansas, United States|Georgetown University, Washington D.C., Maryland, United States|CRI of New England, Boston, Massachusetts, United States|Saint Michael's Medical Center, Newark, New Jersey, United States|Beth Israel Medical Center, New York, New York, United States|Central Texas Clinical Research, Austin, Texas, United States|Nicholaos C. Bellos, MD, PA, Dallas, Texas, United States|Therapeutic Concepts, Houston, Texas, United States|Univ. of Texas Health Science Center, Houston, Texas, United States|Thomas Street Clinic, Houston, Texas, United States|Montrose Clinic, Houston, Texas, United States|Hampton Roads Medical Specialist, Hampton, Virginia, United States|Clinical Research Puerto Rico, San Juan, Puerto Rico",,"https://ClinicalTrials.gov/show/NCT00350272"
50,"NCT00438789","The Paroxysmal Nocturnal Hemoglobinuria Early Access Treatment Protocol","EMBRACE","Approved for marketing","No Results Available","Hemoglobinuria, Paroxysmal","Drug: eculizumab",,"Alexion Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)",,,"Industry","Expanded Access",,"C06-002",,,,"February 22, 2007",,"May 6, 2014","Anthony Botti, Livingston, New Jersey, United States",,"https://ClinicalTrials.gov/show/NCT00438789"
51,"NCT03075904","A Safety and Dose-Finding Study of SYNT001 in Subjects With Pemphigus (Vulgaris or Foliaceus)",,"Terminated","Has Results","Pemphigus|Pemphigus Vulgaris|Pemphigus Foliaceus","Drug: ALXN1830","Count Of Participants Reporting Treatment-emergent Adverse Events (TEAEs)|Maximum Percent Reduction Of Mean Total Immunoglobulin G (IgG) Levels From Baseline|Maximum Percent Reduction In Mean Pemphigus Disease Area Index (PDAI) Total Activity Score From Baseline|Maximum Percent Reduction Of Mean Circulating Immune Complexes (CIC) Levels From Baseline|Maximum Percent Reduction Of Mean Anti-Desmoglein (Dsg) 1 And 3 Antibodies From Baseline","Alexion Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","8","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SYNT001-103","July 18, 2017","January 16, 2019","January 16, 2019","March 9, 2017","February 5, 2020","February 5, 2020","Alexion Study Site, Chapel Hill, North Carolina, United States|Alexion Study Site, Durham, North Carolina, United States|Alexion Study Site, Philadelphia, Pennsylvania, United States","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/04/NCT03075904/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/04/NCT03075904/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT03075904"
52,"NCT01192425","Paroxysmal Nocturnal Hemoglobinuria (PNH), Level of CD59 on Red and White Blood Cells in Bone Marrow Failure Syndromes","EXPLORE","Completed","No Results Available","Hemoglobinuria",,,"Alexion Pharmaceuticals","All","10 Years and older   (Child, Adult, Older Adult)",,"5580","Industry","Observational","Time Perspective: Prospective","P06-001",,,,"September 1, 2010",,"September 1, 2010",,,"https://ClinicalTrials.gov/show/NCT01192425"
53,"NCT05109390","A Study of the Drug Interactions Between Danicopan and Cyclosporine, Tacrolimus, Antacids, and Omeprazole in Healthy Adults",,"Completed","No Results Available","Healthy","Drug: Danicopan|Drug: Cyclosporine|Drug: Tacrolimus|Drug: Calcium Carbonate|Drug: Aluminum/Magnesium Hydroxide/Simethicone|Drug: Omeprazole","Part 1: Cyclosporine Maximum Observed Concentration (Cmax) Following Single-dose Cyclosporine Alone Versus In The Presence Of Steady-state Danicopan|Part 1: Cyclosporine Time To Reach The Maximum Observed Concentration (Tmax) Following Single-dose Cyclosporine Alone Versus In The Presence Of Steady-state Danicopan|Part 1: Cyclosporine Area Under The Concentration-time Curve From Time 0 Extrapolated To Infinity (AUC0-inf) Following Single-dose Cyclosporine Alone Versus In The Presence Of Steady-state Danicopan|Part 2: Tacrolimus Cmax Following Single-dose Tacrolimus Alone Versus In The Presence Of Steady-state Danicopan|Part 2: Tacrolimus Tmax Following Single-dose Tacrolimus Alone Versus In The Presence Of Steady-state Danicopan|Part 2: Tacrolimus AUC0-inf Following Single-dose Tacrolimus Alone Versus In The Presence Of Steady-state Danicopan|Part 3: Steady-state Omeprazole Cmax Following Multiple-dose Omeprazole Alone Versus In The Presence Of Steady-state Danicopan|Part 3: Steady-state Omeprazole Tmax Following Multiple-dose Omeprazole Alone Versus In The Presence Of Steady-state Danicopan|Part 3: Steady-state Omeprazole Area Under The Concentration-time Curve From Time 0 To The 24-hour Time Point (AUC0-24) Following Multiple-dose Omeprazole Alone Versus In The Presence Of Steady-state Danicopan|Part 3: Steady-state Danicopan Cmax Alone Versus In The Presence Of Multiple-dose Omeprazole|Part 3: Steady-state Danicopan Tmax Alone Versus In The Presence Of Multiple-dose Omeprazole|Part 3: Steady-state Danicopan Area Under The Concentration-time Curve From Time 0 To The 8-hour Time Point (AUC0-8) Alone Versus In The Presence Of Multiple-dose Omeprazole|Part 3: Steady-state Danicopan Cmax Alone Versus In The Presence Of Single-dose Calcium Carbonate Or Aluminum/Magnesium Hydroxide/Simethicone|Part 3: Steady-state Danicopan Tmax Alone Versus In The Presence Of Single-dose Calcium Carbonate Or Aluminum/Magnesium Hydroxide/Simethicone|Part 3: Steady-state Danicopan AUC0-8 Alone Versus In The Presence Of Single-dose Calcium Carbonate Or Aluminum/Magnesium Hydroxide/Simethicone|Number Of Participants Experiencing Treatment-emergent Adverse Events","Alexion Pharmaceuticals|Achillion, a wholly owned subsidiary of Alexion","All","18 Years to 55 Years   (Adult)","Phase 1","72","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","ACH471-014","July 27, 2018","October 17, 2018","October 17, 2018","November 5, 2021",,"November 5, 2021","Clinical Trial Site, Tempe, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT05109390"
54,"NCT05047484","A Study of Multiple Doses of ALXN2050 in Healthy Adults",,"Completed","No Results Available","Healthy","Drug: ALXN2050|Drug: Placebo","Number Of Participants Experiencing Serious Adverse Events|Number Of Participants Experiencing Grade 3 Or 4 Adverse Events (AEs)|Number Of Participants Experiencing AEs Leading To Discontinuation From The Study|Number Of Participants Experiencing Grade 3 Or 4 Laboratory Abnormalities|Number Of Participants Experiencing Treatment-emergent Vital Signs, Physical Examination Results, And Electrocardiogram (ECG) Abnormalities|Maximum Steady-state Plasma Concentration (Cmax,ss) Of Multiple-dose ALXN2050|Time To Reach Maximum Steady-state Plasma Concentration (Tmax,ss) Of Multiple-dose ALXN2050|Area Under The Plasma Concentration Versus Time Curve Over The Dosing Interval (AUCtau) Of Multiple-dose ALXN2050|Maximum Plasma Concentration (Cmax) Of Single-dose ALXN2050|Time To Reach Maximum Plasma Concentration (Tmax) Of Single-dose ALXN2050|Area Under The Concentration-time Curve Extrapolated To Infinity (AUC0-inf) For Single-dose ALXN2050|Alternative Pathway (AP) Activity As Measured By Wieslab Assay|Plasma Bb Fragment Of Complement Factor B Concentration Over Time","Alexion Pharmaceuticals|Achillion, a wholly owned subsidiary of Alexion","All","25 Years to 55 Years   (Adult)","Phase 1","45","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","ACH228-002","January 7, 2019","July 23, 2019","July 23, 2019","September 17, 2021",,"September 17, 2021","Clinical Trial Site, Auckland, New Zealand",,"https://ClinicalTrials.gov/show/NCT05047484"
55,"NCT05047458","A Study of Single-dose ALXN2050 in Healthy Adults",,"Completed","No Results Available","Healthy","Drug: ALXN2050|Drug: Placebo","Number Of Participants Experiencing Serious Adverse Events|Number Of Participants Experiencing Grade 3 Or 4 Adverse Events (AEs)|Number Of Participants Experiencing AEs Leading To Discontinuation From The Study|Number Of Participants Experiencing Grade 3 Or 4 Laboratory Abnormalities|Number Of Participants Experiencing Treatment-emergent Vital Signs, Physical Examination Results, And Electrocardiogram (ECG) Abnormalities|Maximum Plasma Concentration (Cmax) Of ALXN2050|Time To Reach The Maximum Plasma Concentration (Tmax) Of ALXN2050|Area Under The Plasma Concentration-time Curve Extrapolated To Infinity (AUC0-inf) Of ALXN2050|Alternative Pathway (AP) Activity As Measured By Wieslab Assay|Plasma Bb Fragment Of Complement Factor B Concentration Over Time","Alexion Pharmaceuticals|Achillion, a wholly owned subsidiary of Alexion","All","25 Years to 55 Years   (Adult)","Phase 1","28","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","ACH228-001|ACTRN12617001521314|U1111-1203-1371","November 28, 2017","April 13, 2018","April 13, 2018","September 17, 2021",,"September 17, 2021","Clinical Trial Site, Auckland, New Zealand",,"https://ClinicalTrials.gov/show/NCT05047458"
56,"NCT05016206","A Study of the Cardiac Effects of Danicopan in Healthy Adults",,"Completed","No Results Available","Healthy","Drug: Danicopan|Drug: Moxifloxacin-matching Placebo|Drug: Danicopan-matching placebo|Drug: Moxifloxacin","Placebo-corrected Change From Baseline In QTc Intervals (ddQTc) For Danicopan|Change From Baseline In Heart Rate (HR) For Danicopan|Change From Baseline In QT Interval For Danicopan|Change From Baseline In Pulse Rate (PR) For Danicopan|Change From Baseline In RR Interval For Danicopan|Change From Baseline In QRS Interval For Danicopan|ddQTcF Of Moxifloxacin|Treatment-emergent T-wave Morphology Abnormalities And Pathologic U-waves|Area Under The Plasma Concentration Versus Time Curve From Time 0 To 24 Hours Post-dose (AUC0-24) Of Danicopan|Maximum Observed Plasma Concentration (Cmax) Of Danicopan|Time To Reach The Maximum Observed Plasma Concentration (Tmax) Of Danicopan|Number Of Participants Experiencing Treatment-emergent Adverse Events","Alexion Pharmaceuticals|Achillion, a wholly owned subsidiary of Alexion","All","18 Years to 55 Years   (Adult)","Phase 1","33","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","ACH471-013","July 26, 2018","October 12, 2018","October 12, 2018","August 23, 2021",,"August 23, 2021","Clinical Trial Site, Tempe, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT05016206"
57,"NCT04940559","Study of Different Forms of Danicopan (Tablet, Softgel Capsule, Liquid-filled Capsule) in Healthy Participants",,"Completed","No Results Available","Healthy","Drug: Danicopan - Tablet|Drug: Danicopan - Softgel|Drug: Danicopan - LFC","PK: Maximum Plasma Concentration (Cmax) Of Danicopan After Treatment With Each Of The Three Formulations|PK: Time To Reach The Maximum Plasma Concentration (Tmax) Of Danicopan After Treatment With Each Of The Three Formulations|PK: Area Under The Plasma Concentration-time Curve Extrapolated To Infinity (AUC0-Inf) Of Danicopan After Treatment With Each Of The Three Formulations|PK: Cmax Of Danicopan After Treatment With The Tablet Under Fed And Fasted Conditions|PK: Tmax Of Danicopan After Treatment With The Tablet Under Fed And Fasted Conditions|PK: AUC0-inf Of Danicopan After Treatment With The Tablet Under Fed And Fasted Conditions|Incidence Of Serious Adverse Events, Grade 3 Or 4 Adverse Events (AEs), And AEs Leading To Discontinuation","Alexion Pharmaceuticals|Achillion, a wholly owned subsidiary of Alexion","All","18 Years to 55 Years   (Adult)","Phase 1","26","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","ACH471-006|ACTRN12616001017415","August 2, 2016","October 5, 2016","October 5, 2016","June 25, 2021",,"June 25, 2021","Clinical Trial Site, Auckland, New Zealand",,"https://ClinicalTrials.gov/show/NCT04940559"
58,"NCT04935294","Study of Danicopan in Participants With Normal Kidney Function and Participants With Kidney Dysfunction",,"Completed","No Results Available","Healthy|Renal Dysfunction","Drug: Danicopan","Participants With Treatment-emergent Adverse Events|Area Under The Plasma Concentration-time Curve Extrapolated To Infinity (AUC0-inf) Of Danicopan|Maximum Observed Plasma Concentration (Cmax) Of Danicopan|Time To Reach The Maximum Observed Plasma Concentration (Tmax) Of Danicopan|Alternative Pathway Activity As Measured By Wieslab Assay|Change From Baseline In Plasma Bb Fragment Of Complement Factor B Concentration|Change From Baseline In Complement Factor D Concentration","Alexion Pharmaceuticals|Achillion, a wholly owned subsidiary of Alexion","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","16","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","ACH471-009","January 24, 2018","May 29, 2018","May 29, 2018","June 23, 2021",,"June 23, 2021","Clinical Trial Site, Miami, Florida, United States|Clinical Trial Site, Orlando, Florida, United States|Clinical Trial Site, Minneapolis, Minnesota, United States|Clinical Trial Site, Saint Paul, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT04935294"
59,"NCT04889690","Study of Multiple Doses of Danicopan in Healthy Participants",,"Completed","No Results Available","Healthy","Drug: Danicopan|Drug: Placebo","Incidence Of Serious Adverse Events, Grade 3 Or 4 Adverse Events (AEs), AEs Leading To Discontinuation, And Clinically Significant Laboratory Abnormalities And Electrocardiogram Abnormalities|Maximum Observed Plasma Concentration (Cmax) Of Danicopan|Time To Maximum Observed Plasma Concentration (Tmax) Of Danicopan|Area Under The Plasma Concentration Versus Time Curve Over The Dosing Interval (AUCtau) Of Danicopan|Activity Of Danicopan As Measured By Alternative Pathway (AP) Wieslab Assay|Relationship Between AP Inhibition And Danicopan Plasma Concentrations","Alexion Pharmaceuticals|Achillion, a wholly owned subsidiary of Alexion","All","25 Years to 55 Years   (Adult)","Phase 1","45","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","ACH471-002","May 21, 2016","January 11, 2017","January 11, 2017","May 17, 2021",,"May 17, 2021","Clinical Trial Site, Auckland, New Zealand",,"https://ClinicalTrials.gov/show/NCT04889690"
60,"NCT04889677","Study of a Single Dose of Danicopan in Healthy Participants",,"Completed","No Results Available","Healthy","Drug: Danicopan|Drug: Placebo","Incidence Of Serious Adverse Events, Grade 3 Or 4 Adverse Events (AEs), AEs Leading To Discontinuation, And Clinically Significant Laboratory Abnormalities And Electrocardiogram Abnormalities|Area Under The Plasma Concentration-time Curve Extrapolated To Infinity (AUC0-inf) Of Danicopan Under Both Fed And Fasted Conditions|Maximal Plasma Concentration (Cmax) Of Danicopan Under Both Fed And Fasted Conditions|Time To Reach The Maximal Plasma Concentration (Tmax) Of Danicopan Under Both Fed And Fasted Conditions|Relationship Between Alternative Pathway Inhibition And Danicopan Plasma Concentrations","Alexion Pharmaceuticals|Achillion, a wholly owned subsidiary of Alexion","All","21 Years to 55 Years   (Adult)","Phase 1","44","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","ACH471-001","February 4, 2016","June 21, 2016","June 21, 2016","May 17, 2021",,"May 17, 2021","Clinical Trial Site, Auckland, New Zealand",,"https://ClinicalTrials.gov/show/NCT04889677"
61,"NCT04889391","Study of Radiolabeled Danicopan in Healthy Male Participants",,"Completed","No Results Available","Healthy","Drug: [14C]-Danicopan","Mean Cumulative Percentages Of Total Radioactivity Recovered In Urine And Feces Following A Single Oral Dose Of [14C]-Danicopan|Whole Blood And Plasma Pharmacokinetics (PK) Of Total Radioactivity After A Single Oral Dose Of [14C]-Danicopan: Area Under The Concentration-time Curve From Time 0 To The Time Of Last Quantifiable Concentration (AUC0-t)|Whole Blood And Plasma PK Of Total Radioactivity After A Single Oral Dose Of [14C]-Danicopan: Area Under The Concentration-time Curve Extrapolated to Infinity (AUC0-inf)|Whole Blood And Plasma PK Of Total Radioactivity After A Single Oral Dose Of [14C]-Danicopan: Maximum Observed Concentration (Cmax)|Whole Blood And Plasma PK Of Total Radioactivity After A Single Oral Dose Of [14C]-Danicopan: Time To Maximum Observed Concentration (Tmax)|Plasma PK Of Danicopan After A Single Oral Dose Of [14C]-Danicopan: AUC0-t|Plasma PK Of Danicopan After A Single Oral Dose Of [14C]-Danicopan: AUC0-inf|Plasma PK Of Danicopan After A Single Oral Dose Of [14C]-Danicopan: Cmax|Plasma PK Of Danicopan After A Single Oral Dose Of [14C]-Danicopan: Tmax|[14C]-Danicopan Metabolites In Plasma, Urine, And Feces|Percentage Of Total Radioactivity Detected For Each [14C]-Danicopan Metabolite in Plasma, Urine, And Feces|Incidence Of Treatment-emergent Adverse Events","Alexion Pharmaceuticals|Achillion, a wholly owned subsidiary of Alexion","Male","18 Years to 55 Years   (Adult)","Phase 1","8","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","ACH471-005","September 14, 2017","October 15, 2017","October 15, 2017","May 17, 2021",,"May 17, 2021","Clinical Trial Site, Auckland, New Zealand",,"https://ClinicalTrials.gov/show/NCT04889391"
62,"NCT03555539","Study of Danicopan in Participants With Hepatic Impairment",,"Completed","No Results Available","Hepatic Impairment","Drug: Danicopan","Area Under The Plasma Concentration Versus Time Curve From Time 0 Extrapolated To Infinity (AUC0-inf) Of Danicopan|Area Under The Plasma Concentration Versus Time Curve From Time 0 To The Last Measurable Concentration (AUC0-t) Of Danicopan|Maximum Observed Plasma Concentration (Cmax) Of Danicopan|Time To Maximum Observed Plasma Concentration (Tmax) Of Danicopan|Participants Experiencing Treatment-emergent Adverse Events","Alexion Pharmaceuticals|Achillion, a wholly owned subsidiary of Alexion","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","16","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","ACH471-012","May 1, 2018","September 21, 2018","September 21, 2018","June 13, 2018",,"August 20, 2021","Clinical Trial Site, Miami, Florida, United States|Clinical Trial Site, Orlando, Florida, United States",,"https://ClinicalTrials.gov/show/NCT03555539"
63,"NCT03472885","Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria With Inadequate Response to Eculizumab","PNH","Active, not recruiting","Has Results","Paroxysmal Nocturnal Hemoglobinuria (PNH)","Drug: Danicopan|Drug: Eculizumab","Change From Baseline In Hemoglobin At Week 24|Number Of Units Of Red Blood Cells (RBCs) Transfused During 24 Weeks Of Treatment|Number Of Participants Without RBC Transfusions|Change From Baseline In Lactate Dehydrogenase At Week 24|Number Of Participants With Serious Adverse Events (SAEs), Grade 3 And Grade 4 Adverse Events (AEs), And Events Leading To Discontinuation Of Study Drug","Alexion Pharmaceuticals|Achillion, a wholly owned subsidiary of Alexion","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","12","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACH471-101|2016-003526-16|U1111-1209-4655","May 8, 2018","September 20, 2019","July 22, 2022","March 21, 2018","June 25, 2021","March 2, 2022","Clinical Study Site, Baltimore, Maryland, United States|Clinical Study Site, Cleveland, Ohio, United States|Clinical Study Site, Florence, Italy|Clinical Study Site, Naples, Italy|Clinical Study Site, London, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/85/NCT03472885/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/85/NCT03472885/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03472885"
64,"NCT03384186","A Study of Modified Release Formulations of Danicopan in Healthy Adult Participants",,"Completed","No Results Available","Healthy","Drug: Danicopan Modified Release Prototype 1|Drug: Danicopan Modified Release Prototype 2|Drug: Danicopan Modified Release Prototype 3","Time To Maximum Observed Concentration (Tmax) Of Danicopan After Treatment With Each Prototype Formulation|Maximum Observed Concentration (Cmax) Of Danicopan After Treatment With Each Prototype Formulation|Area Under The Concentration Versus Time Curve From Time 0 Extrapolated To Infinity (AUC0-inf) Of Danicopan After Treatment With Each Prototype Formulation|Participants Experiencing Treatment-emergent Adverse Events","Alexion Pharmaceuticals|Achillion, a wholly owned subsidiary of Alexion","All","18 Years to 55 Years   (Adult)","Phase 1","14","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","ACH471-011|2017-003525-15","December 1, 2017","March 21, 2018","March 21, 2018","December 27, 2017",,"August 20, 2021","Clinical Trial Site, Ruddington, Nottingham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03384186"
65,"NCT03181633","A Long-Term Treatment Study of ACH-0144471 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)",,"Active, not recruiting","No Results Available","Paroxysmal Nocturnal Hemoglobinuria","Drug: ACH-0144471","Serious Adverse Events (SAEs), Grade 3 And Grade 4 Adverse Events (AEs), And AEs Leading To Discontinuation|Serum Lactate Dehydrogenase (LDH) Levels|Hemoglobin (Hgb) Levels|Number Of Red Blood Cell (RBC) Transfusions|Reticulocyte Counts|Functional Assessment Of Chronic Illness Therapy (FACIT) Fatigue Scale Scores|European Organization For Research And Treatment (EORTC) Cancer Core Quality Of Life Questionnaire (QLQ-C30) Scores","Alexion Pharmaceuticals|Achillion, a wholly owned subsidiary of Alexion","All","18 Years and older   (Adult, Older Adult)","Phase 2","8","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACH471-103|2017-000665-79|U1111-1196-0653","June 22, 2017","January 3, 2022","March 24, 2022","June 9, 2017",,"February 22, 2022","Clinical Trial Site, Avellino, Italy|Clinical Trial Site, Naples, Italy|Clinical Trial Site, Seoul, Korea, Republic of|Clinical Trial Site, Auckland, New Zealand",,"https://ClinicalTrials.gov/show/NCT03181633"
66,"NCT03124368","A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN",,"Completed","Has Results","C3 Glomerulonephritis|Dense Deposit Disease|C3 Glomerulopathy|Immune Complex Mediated Membranoproliferative Glomerulonephritis|Membranoproliferative Glomerulonephritis Types I, II, and III","Drug: Danicopan","Change From Baseline In Serum C3 Complement Protein (C3) Levels On Day 15|Change From Baseline In Plasma Intact C3 Level On Day 15|Change From Baseline In Total Complement Classical Pathway (CP) Activity On Day 14|Change From Baseline In Total Complement Alternative Pathway (AP) Functional Activity (AP Wieslab) On Day 15|Time To Achieving Peak Serum C3 Levels|Number Of Participants With Serious Adverse Events (SAEs), Grade 3 And Grade 4 Treatment-emergent Adverse Events (TEAEs), And Adverse Events (AEs) Leading To Discontinuation|Pharmacokinetics (PK): Area Under The Plasma Concentration-time Curve From Time Of Administration To 8 Hours Postdose (AUC0-8)|PK: Maximum Plasma Concentration (Cmax)|PK: Time To Maximum Concentration (Tmax)|Change From Baseline In Bb Fragment Of Complement Factor B (Bb) At Day 15|Change From Baseline In Soluble Terminal Complement Complex (sC5b-9) At Day 15","Alexion Pharmaceuticals|Achillion, a wholly owned subsidiary of Alexion","All","16 Years to 65 Years   (Child, Adult, Older Adult)","Phase 2","6","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","ACH471-201|2016-003525-42","August 9, 2017","December 21, 2018","January 9, 2019","April 21, 2017","July 13, 2021","November 4, 2021","Clinical Trial Site, Melbourne, Australia|Clinical Trial Site, Antwerpen, Belgium|Clinical Trial Site, Leiden, Netherlands","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/68/NCT03124368/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/68/NCT03124368/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03124368"
67,"NCT03108274","A Drug Interaction Study Between Danicopan and Midazolam, Fexofenadine, and Mycophenolate Mofetil in Healthy Participants",,"Completed","No Results Available","Healthy","Drug: Danicopan|Drug: Midazolam|Drug: Fexofenadine|Drug: Mycophenolate Mofetil","Part 1: Midazolam Area Under The Plasma Concentration-time Curve From Time 0 To The Time Of The Last Observed Non-zero Concentration (AUC0-t) Following Single-dose Midazolam Alone Versus In The Presence of Steady-state Danicopan|Part 1: Midazolam Area Under The Plasma Concentration-time Curve From Time 0 Extrapolated To Infinity (AUC0-inf) Following Single-dose Midazolam Alone Versus In The Presence of Steady-state Danicopan|Part 1: Midazolam Maximum Observed Plasma Concentration (Cmax) Following Single-dose Midazolam Alone Versus In The Presence of Steady-state Danicopan|Part 1: Midazolam Time To Reach Maximum Observed Plasma Concentration (Tmax) Following Single-dose Midazolam Alone Versus In The Presence of Steady-state Danicopan|Part 2: Fexofenadine AUC0-t Following Single-dose Fexofenadine Alone Versus In The Presence of Steady-state Danicopan|Part 2: Fexofenadine AUC0-inf Following Single-dose Fexofenadine Alone Versus In The Presence of Steady-state Danicopan|Part 2: Fexofenadine Cmax Following Single-dose Fexofenadine Alone Versus In The Presence of Steady-state Danicopan|Part 2: Fexofenadine Tmax Following Single-dose Fexofenadine Alone Versus In The Presence of Steady-state Danicopan|Part 3: Mycophenolic Acid (MPA) and Mycophenolic Acid Glucuronide (MPAG) AUC0-t Following Single-dose Mycophenolate Mofetil (MMF) Alone Versus In The Presence of Steady-state Danicopan|Part 3: MPA and MPAG AUC0-inf Following Single-dose MMF Alone Versus In The Presence of Steady-state Danicopan|Part 3: MPA and MPAG Cmax Following Single-dose MMF Alone Versus In The Presence of Steady-state Danicopan|Part 3: MPA and MPAG Tmax Following Single-dose MMF Alone Versus In The Presence of Steady-state Danicopan|Parts 1-3: Participants Experiencing Treatment-emergent Adverse Events","Alexion Pharmaceuticals|Achillion, a wholly owned subsidiary of Alexion","All","18 Years to 60 Years   (Adult)","Phase 1","35","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","ACH471-010|U1111-1193-2774","April 18, 2017","June 2, 2017","June 16, 2017","April 11, 2017",,"June 24, 2021","Clinical Trial Site, Auckland, New Zealand",,"https://ClinicalTrials.gov/show/NCT03108274"
68,"NCT03053102","Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)",,"Completed","Has Results","Paroxysmal Nocturnal Hemoglobinuria (PNH)","Drug: Danicopan","Change From Baseline In Serum LDH Levels At Day 28|Change From Baseline In Hemoglobin (Hgb) At Days 28 And 84|Serious Adverse Events (SAEs), Grade 3 And Grade 4 Treatment-emergent Adverse Events (TEAEs), And Adverse Events (AEs) Leading To Discontinuation|Grade 3 And Grade 4 Laboratory Abnormalities|Pharmacokinetics (PK): Area Under The Plasma Concentration-time Curve From Time Of Administration To 8 Hours Post-dose (AUC0-8)|PK: Maximum Plasma Concentration (Cmax)|PK: Time To Maximum Concentration (Tmax)|Complement Alternative Pathway (AP) Functional Activity|Complement Bb","Alexion Pharmaceuticals|Achillion, a wholly owned subsidiary of Alexion","All","18 Years and older   (Adult, Older Adult)","Phase 2","10","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACH471-100|2016-002652-25|U1111-1190-3490","March 31, 2017","November 14, 2018","November 14, 2018","February 14, 2017","June 2, 2021","June 2, 2021","Clinical Trial Site, Florence, Italy|Clinical Trial Site, Naples, Italy|Clinical Trial Site, Seoul, Korea, Republic of|Clinical Trial Site, Auckland, New Zealand|Clinical Trial Site, London, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/02/NCT03053102/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/02/NCT03053102/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03053102"
69,"NCT00088179","Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)",,"Completed","No Results Available","Coronary Artery Disease","Drug: pexelizumab in conjunction with CABG","Reduction in mortality.|Reduction in MI incidence.","Alexion Pharmaceuticals|Procter and Gamble","All","18 Years and older   (Adult, Older Adult)","Phase 3","4000","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","2003141","July 2004","October 2005","October 2005","July 23, 2004",,"February 22, 2018","Brookwood Medical Center, Birmingham, Alabama, United States|Baptist Medical Center Princeton, Birmingham, Alabama, United States|Baptist Health Systems Montclair, Birmingham, Alabama, United States|Medical Center East Hospital, Birmingham, Alabama, United States|University of Alabama at Birmingham Hospital, Birmingham, Alabama, United States|Thomas Hospital, Fairhope, Alabama, United States|Huntsville Hospital, Huntsville, Alabama, United States|Mobile Infirmary Medical Center, Mobile, Alabama, United States|Banner Good Samaritan Medical Center, Phoenix, Arizona, United States|Arizona Health Sciences Center, Tucson, Arizona, United States|University Medical Center, Tucson, Arizona, United States|Southern Arizona Veterans Affairs Health Care System, Tucson, Arizona, United States|Sparks Regional Medical Center, Fort Smith, Arkansas, United States|Baptist Medical Center, Little Rock, Arkansas, United States|Bakersfield Heart Hospital, Bakersfield, California, United States|Seaton Medical Center, Daly City, California, United States|Palomar Medical Center, Escondido, California, United States|Saddleback Memorial Medical Center, Laguna Hills, California, United States|Los Angeles County-University of Southern California Medical Center, Los Angeles, California, United States|University of Southern California University Hospital, Los Angeles, California, United States|St. Vincent Medical Center, Los Angeles, California, United States|Veterans Administration Greater Los Angeles Healthcare Sysytem, Los Angeles, California, United States|Tri City Medical Center, Oceanside, California, United States|University of California Irvine Medical Center, Orange, California, United States|Veterans Administration Palo Alto Healthcare System, Palo Alto, California, United States|Huntington Memorial Hospital, Pasadena, California, United States|Mercy General Hospital, Sacramento, California, United States|Sharp Memorial Hospital, San Diego, California, United States|Kaiser Permanente Medical Center, San Francisco, California, United States|Porter Adventist Hospital, Denver, Colorado, United States|Presbyterian St.Luke's Medical Center, Denver, Colorado, United States|University of Colorado Health Sciences Center, Denver, Colorado, United States|St. Vincent's Medical Center, Bridgeport, Connecticut, United States|Hospital of Saint Raphael, New Haven, Connecticut, United States|Christiana Hospital, Newark, Delaware, United States|John F. Kennedy Medical Center, Atlantis, Florida, United States|Morton Plant Hospital, Clearwater, Florida, United States|Halifax Medical Center, Daytona Beach, Florida, United States|North Ridge Medical Center, Fort Lauderdale, Florida, United States|Shands Hospital at the University of Florida, Gainesville, Florida, United States|Regional Medical Center Bayonet Point, Hudson, Florida, United States|Baptist Medical Center, Jacksonville, Florida, United States|Memorial Hospital, Jacksonville, Florida, United States|Lakeland Regional Medical Center, Lakeland, Florida, United States|Health First Holmes Regional Medical Center, Melbourne, Florida, United States|Orlando Regional Medical Center, Orlando, Florida, United States|Florida Hospital, Orlando, Florida, United States|Sacred Heart Hospital, Pensacola, Florida, United States|Wuesthoff Hospital, Rockledge, Florida, United States|Northside Hospital and Heart Institute, Saint Petersburg, Florida, United States|Sarasota Memorial Hospital, Sarasota, Florida, United States|University Community Hospital, Tampa, Florida, United States|Piedmont Hospital, Atlanta, Georgia, United States|Emory University Hospital, Atlanta, Georgia, United States|Atlanta Veteran's Administration (VA) Medical Center, Decatur, Georgia, United States|Medical Center of Central Georgia, Macon, Georgia, United States|St. Joseph's/Candler Health System, Savannah, Georgia, United States|St. Joseph's/Candler Health System, Savannah, Georgia, United States|Kaiser Permanente Moanalua Medical Center, Honolulu, Hawaii, United States|OSF Saint Francis Medical Center, Peoria, Illinois, United States|Memorial Medical Center, Springfield, Illinois, United States|St. John's Hospital, Springfield, Illinois, United States|Indiana Ohio Heart, Fort Wayne, Indiana, United States|Clarian Health Partners, Inc. Methodist Hospital, Indianapolis, Indiana, United States|The Indiana Heart Hospital, Indianapolis, Indiana, United States|The Heart Center of Indiana, Indianapolis, Indiana, United States|Iowa Heart Center, Des Moines, Iowa, United States|Olathe Medical Center, Olathe, Kansas, United States|Galichia Heart Hospital, Wichita, Kansas, United States|Central Baptist Hospital, Lexington, Kentucky, United States|Veterans Affairs Medical Center, Lexington, Kentucky, United States|University of Kentucky, Lexington, Kentucky, United States|Jewish Hospital, Louisville, Kentucky, United States|Norton Hospital, Louisville, Kentucky, United States|University of Louisville Hospital, Louisville, Kentucky, United States|Terrebonne General Medical Center, Houma, Louisiana, United States|Louisiana Heart Hospital, Lacombe, Louisiana, United States|Tulane University Hospital and Clinic, New Orleans, Louisiana, United States|Oschner Clinic Foundation, New Orleans, Louisiana, United States|Pendleton Memorial Methodist Hospital, New Orleans, Louisiana, United States|Touro Infirmary, New Orleans, Louisiana, United States|Slidell Memorial Hospital, Slidell, Louisiana, United States|Maine Medical Center, Portland, Maine, United States|Sinai Hospital of Baltimore, Baltimore, Maryland, United States|Union Memorial Hospital, Baltimore, Maryland, United States|Peninusla Medical Center, Salisbury, Maryland, United States|St. Joseph Medical Center, Towson, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Cape Cod Hospital, Hyannis, Massachusetts, United States|Baystate Medical Center, Springfield, Massachusetts, United States|Veterans Administration (VA) Boston Healthcare System, West Roxbury, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|McLaren Regional Medical Center, Flint, Michigan, United States|Spectrum Health Hospitals, Grand Rapids, Michigan, United States|Borgess Medical Center, Kalamazoo, Michigan, United States|Ingham Regional Medical Center, Lansing, Michigan, United States|West Shore Cardiology Research Department, Muskegon, Michigan, United States|William Beaumont Hospital, Royal Oak, Michigan, United States|Covenant Medical Center, Saginaw, Michigan, United States|Mayo Clinic College of Medicine, Rochester, Minnesota, United States|St. Luke's Health System, Kansas City, Missouri, United States|Saint Louis University Hospital, Saint Louis, Missouri, United States|Saint Louis University, Saint Louis, Missouri, United States|Des Peres Hospital, Saint Louis, Missouri, United States|Nebraska Heart Hospital, Lincoln, Nebraska, United States|Cooper Hospital University Medical Center, Camden, New Jersey, United States|Cooper Health System/University Medical Center, Camden, New Jersey, United States|Our Lady Of Lourdes Medical Center, Camden, New Jersey, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Morristown Memorial Hospital, Morristown, New Jersey, United States|Montefiore Medical Center, Bronx, New York, United States|Maimondes Medical Center, Brooklyn, New York, United States|United Health Services Hospital, Johnson City, New York, United States|New York Presbyterian Hospital, New York, New York, United States|Mount Sinai Hospital, New York, New York, United States|Vassar Brothers Medical Center, Poughkeepsie, New York, United States|Rochester General Hospital, Rochester, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|Westchester Medical Center, Valhalla, New York, United States|University of North Carolina at Chapel Hill Hospitals, Chapel Hill, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Moses H. Cone Memorial Hospital, Greensboro, North Carolina, United States|Pitt County Memorial Hospital, Greenville, North Carolina, United States|Medcenter One, Bismarck, North Dakota, United States|Akron General Medical Center, Akron, Ohio, United States|The Christ Hospital, Cincinnati, Ohio, United States|Good Samaritan Hospital, Cincinnati, Ohio, United States|Bethesda North Hospital, Cincinnati, Ohio, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|University Hospitals Health System, Cleveland, Ohio, United States|The Cleveland Clinic Foundation, Cleveland, Ohio, United States|Riverside Methodist Hospital, Columbus, Ohio, United States|The Dayton Heart Hospital, Dayton, Ohio, United States|The Toledo Hospital, Toledo, Ohio, United States|Good Samaritan Hospital, Zanesville, Ohio, United States|Oklahoma University Medical Center, Oklahoma City, Oklahoma, United States|INTEGRIS Baptist Medical Center, Oklahoma City, Oklahoma, United States|Oklahoma Heart Hospital, Oklahoma City, Oklahoma, United States|St. Charles Medical Center, Bend, Oregon, United States|Legacy Good Samaritan Hospital, Portland, Oregon, United States|Doylestown Hospital, Doylestown, Pennsylvania, United States|St. Mary Medical Center, Langhorne, Pennsylvania, United States|Hahnemann University Hospital, Philadelphia, Pennsylvania, United States|Presbyterian Medical Center, Philadelphia, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Crozer Chester Medical Center, Upland, Pennsylvania, United States|The Chester County Hospital, West Chester, Pennsylvania, United States|Roper St. Francis Healthcare, Charleston, South Carolina, United States|Rapid City Regional Hospital, Rapid City, South Dakota, United States|The Chattanooga Heart Institute, Chattanooga, Tennessee, United States|Jackson-Madison County General Hospital, Jackson, Tennessee, United States|Baptist Memorial Hospital, Memphis, Tennessee, United States|Baptist Hospital, Nashville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Methodist Medical Center, Oak Ridge, Tennessee, United States|Heart Hospital of Austin, Austin, Texas, United States|Medical City Dallas Hospital, Dallas, Texas, United States|Christus Saint Joseph Hospital, Houston, Texas, United States|Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas, United States|Memorial Hermann Hospital, Houston, Texas, United States|Methodist Hospital, Houston, Texas, United States|St. Luke's Episcopal Hospital - Texas Heart, Houston, Texas, United States|The Methodist Hospital, Houston, Texas, United States|Covenant Medical Center, Lubbock, Texas, United States|TexSan Heart Hospital, San Antonio, Texas, United States|Northeast Baptist Hospital, San Antonio, Texas, United States|University of Utah Hospital, Salt Lake City, Utah, United States|Virginia Hospital Center, Arlington, Virginia, United States|University of Virginia Health System, Charlottesville, Virginia, United States|Inova Fairfax Hospital, Falls Church, Virginia, United States|Memorial Regional Medical Center, Mechanicsville, Virginia, United States|Sentara Norfolk General Hospital, Norfolk, Virginia, United States|CJW Medical Center, Richmond, Virginia, United States|Henrico Doctors' Hospital, Richmond, Virginia, United States|University of Washington Medical Center, Seattle, Washington, United States|Saint Joseph Medical Center, Tacoma, Washington, United States|Charleston Area Medical Center, Charleston, West Virginia, United States|Gundersen Lutheran Medical Center, La Crosse, Wisconsin, United States|St. Luke's Medical Center, Milwaukee, Wisconsin, United States|Hopital Minjoz, Besancon, France|Hopital du Bocage, Dijon, France|Hopital Albert Michallon, Grenoble, France|Hopital Europeen Georges Pompidou, Paris, France|Zentrum fuer Herzchirurgie der Frederick-Alexander-Universitaet, Erlangen, Germany|Leiden University Medical Center, Leiden, Netherlands",,"https://ClinicalTrials.gov/show/NCT00088179"
70,"NCT00040144","Safety and Antiviral Study of ACH126, 433 (b-L-Fd4C) in Adults With Lamivudine-resistant Chronic Hepatitis B",,"Terminated","No Results Available","Chronic Hepatitis B","Drug: ACH126, 433",,"Alexion Pharmaceuticals|Achillion, a wholly owned subsidiary of Alexion","All","18 Years and older   (Adult, Older Adult)","Phase 2","85","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","ACH443-005","July 2002",,"May 2003","June 25, 2002",,"February 18, 2021","Clinical Trial Site, Los Angeles, California, United States|Clinical Trial Site, Orange, California, United States|Clinical Trial Site, Pasadena, California, United States|Clinical Trial Site, San Francisco, California, United States|Clinical Trial Site, Miami, Florida, United States|Clinical Trial Site, Chicago, Illinois, United States|Clinical Trial Site, Chicago, Illinois, United States|Clinical Trial Site, Boston, Massachusetts, United States|Clinical Trial Site, New York, New York, United States|Clinical Trial Site, Dallas, Texas, United States|Clinical Trial Site, Dallas, Texas, United States|Clinical Trial Site, Fairfax, Virginia, United States|Clinical Trial Site, Seattle, Washington, United States|Clinical Trial Site, Vancouver, British Columbia, Canada|Clinical Trial Site, Toronto, Ontario, Canada|Clinical Trial Site, Toronto, Ontario, Canada|Clinical Trial Site, Montréal, Quebec, Canada|Clinical Trial Site, Hong Kong, China",,"https://ClinicalTrials.gov/show/NCT00040144"
71,"NCT00034359","Safety and Antiviral Activity Study of ACH-126,443 (Beta-L-Fd4C) in Treatment-naive Adults With Chronic Hepatitis B Virus Infection",,"Completed","No Results Available","Hepatitis B, Chronic","Drug: ACH-126,443|Drug: Lamivudine|Drug: Placebo",,"Alexion Pharmaceuticals|Achillion, a wholly owned subsidiary of Alexion","All","18 Years and older   (Adult, Older Adult)","Phase 2","79","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","ACH443-003","February 2002","January 2003","January 2003","April 29, 2002",,"February 18, 2021","Clinical Trial Site, Sofia, Bulgaria|Clinical Trial Site, Belgrade, Former Yugoslavia|Clinical Trial Site, Novi Sad, Former Yugoslavia",,"https://ClinicalTrials.gov/show/NCT00034359"
72,"NCT04709094","A Drug Interaction Study of Danicopan",,"Completed","No Results Available","Healthy","Drug: Danicopan|Drug: Warfarin|Drug: Bupropion|Drug: Ethinyl Estradiol/Norethindrone","Part 1: Area Under The Concentration Versus Time Curve From Time 0 Extrapolated To Infinity (AUC0-inf) Of Single-dose Warfarin Under Multiple Doses Of Danicopan|Part 1: Maximum Observed Concentration (Cmax) Of Single-dose Warfarin Under Multiple Doses Of Danicopan|Part 1: Time To Maximum Observed Concentration (Tmax) Of Single-dose Warfarin Under Multiple Doses Of Danicopan|Part 2: AUC0-inf Of Single-dose Bupropion Under Multiple Doses Of Danicopan|Part 2: Cmax Of Single-dose Bupropion Under Multiple Doses Of Danicopan|Part 2: Tmax Of Single-dose Bupropion Under Multiple Doses Of Danicopan|Part 3: AUC0-inf Of Single-dose EE/NET Under Multiple Doses Of Danicopan|Part 3: Cmax Of Single-dose EE/NET Under Multiple Doses Of Danicopan|Part 3: Tmax Of Single-dose EE/NET Under Multiple Doses Of Danicopan|Part 1: International Normalized Ratio (INR) Of Single-dose Warfarin Under Multiple Doses Of Danicopan|Part 1: Number Of Participants With Treatment-emergent Adverse Events (TEAEs) After Multiple Doses Of Danicopan Coadministered With A Single Dose Of Warfarin|Part 2: Number Of Participants With TEAEs After Multiple Doses Of Danicopan Coadministered With A Single Dose Of Bupropion|Part 3: Number Of Participants With TEAEs After Multiple Doses Of Danicopan Coadministered With A Single Dose Of EE/NET","Alexion Pharmaceuticals|Achillion, a wholly owned subsidiary of Alexion|Celerion","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","52","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","ACH471-017|CA27858","July 28, 2019","October 14, 2019","April 17, 2020","January 14, 2021",,"January 14, 2021","Clinical Study Site, Tempe, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT04709094"
73,"NCT04709081","A Drug Interaction Study of ACH-0145228",,"Completed","No Results Available","Healthy","Drug: ACH-0145228|Drug: Midazolam|Drug: Digoxin|Drug: Itraconazole","Part 1: Area Under The Concentration Versus Time Curve From Time 0 Extrapolated To Infinity (AUC0-inf) Of Single-dose Midazolam Under Multiple Doses Of ACH-0145228|Part 1: Maximum Observed Concentration (Cmax) Of Single-dose Midazolam Under Multiple Doses Of ACH-0145228|Part 1: Time To Maximum Observed Concentration (Tmax) Of Single-dose Midazolam Under Multiple Doses Of ACH-0145228|Part 1: AUC0-inf Of Single-dose Digoxin Under Multiple Doses Of ACH-0145228|Part 1: Cmax Of Single-dose Digoxin Under Multiple Doses Of ACH-0145228|Part 1: Tmax Of Single-dose Digoxin Under Multiple Doses Of ACH-0145228|Part 2: AUC0-inf Of Single-dose ACH-0145228 Under Multiple Doses Of Itraconazole|Part 2: Cmax Of Single-dose ACH-0145228 Under Multiple Doses Of Itraconazole|Part 2: Tmax Of Single-dose ACH-0145228 Under Multiple Doses Of Itraconazole|Part 1: Number Of Participants With Treatment-emergent Adverse Events (TEAEs) After Multiple Doses Of ACH-0145228 Coadministered With A Single Dose Of Midazolam|Part 1: Number Of Participants With TEAEs After Multiple Doses Of ACH-0145228 Coadministered With A Single Dose Of Digoxin|Part 2: Number Of Participants With TEAEs After A Single Dose Of ACH-0145228 Coadministered With Multiple Doses Of Itraconazole","Alexion Pharmaceuticals|Achillion, a wholly owned subsidiary of Alexion|Celerion","All","18 Years to 55 Years   (Adult)","Phase 1","38","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","ACH228-003|CA28776","December 22, 2019","April 16, 2020","April 16, 2020","January 14, 2021",,"January 14, 2021","Clinical Study Site, Tempe, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT04709081"
74,"NCT02329327","A Study in Participants With Acute Major Bleeding to Evaluate the Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Direct and Indirect Oral Anticoagulants (Extension Study)",,"Completed","Has Results","Bleeding","Biological: Andexanet","Percent Change From Baseline In Anti-fXa Activity By FXa Inhibitor|Participants Achieving Hemostatic Efficacy|Percent Change From Baseline In Anti-fXa Activity By Hemostatic Efficacy","Alexion Pharmaceuticals|Portola Pharmaceuticals, LLC (a wholly owned subsidiary of Alexion Pharmaceuticals)|Population Health Research Institute","All","18 Years and older   (Adult, Older Adult)","Phase 3","479","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","14-505","April 10, 2015","September 24, 2020","September 24, 2020","December 31, 2014","February 16, 2022","February 16, 2022","Clinical Study Site, Long Beach, California, United States|Clinical Study Site, Los Angeles, California, United States|Clinical Study Site, Orange, California, United States|Clinical Study Site, Fort Lauderdale, Florida, United States|Clinical Study Site, Jacksonville, Florida, United States|Clinical Study Site, Sarasota, Florida, United States|Clinical Study Site, Tampa, Florida, United States|Clinical Study Site, Annapolis, Maryland, United States|Clinical Study Site, Boston, Massachusetts, United States|Clinical Study Site, Detroit, Michigan, United States|Clinical Study Site, Royal Oak, Michigan, United States|Clinical Study Site, Troy, Michigan, United States|Clinical Study Site, Saint Louis, Missouri, United States|Clinical Study Site, Rochester, New York, United States|Clinical Study Site, Asheville, North Carolina, United States|Clinical Study Site, Chapel Hill, North Carolina, United States|Clinical Study Site, Raleigh, North Carolina, United States|Clinical Study Site, Cincinnati, Ohio, United States|Clinical Study Site, Cleveland, Ohio, United States|Clinical Study Site, Pittsburgh, Pennsylvania, United States|Clinical Study Site, Austin, Texas, United States|Clinical Study Site, Fort Worth, Texas, United States|Clinical Study Site, Huntington, West Virginia, United States|Clinical Study Site, Bruxelles, Belgium|Clinical Study Site, Genk, Belgium|Clinical Study Site, Leuven, Belgium|Clinical Study Site, Hamilton, Ontario, Canada|Clinical Study Site, Montreal, Quebec, Canada|Clinical Study Site, Clermont-Ferrand, France|Clinical Study Site, Grenoble, France|Clinical Study Site, Limoges, France|Clinical Study Site, Lyon, France|Clinical Study Site, Poitiers, France|Clinical Study Site, Altenburg, Germany|Clinical Study Site, Augsburg, Germany|Clinical Study Site, Berlin, Germany|Clinical Study Site, Bremen, Germany|Clinical Study Site, Celle, Germany|Clinical Study Site, Chemnitz, Germany|Clinical Study Site, Coburg, Germany|Clinical Study Site, Detmold, Germany|Clinical Study Site, Dresden, Germany|Clinical Study Site, Essen, Germany|Clinical Study Site, Greifswald, Germany|Clinical Study Site, Göttingen, Germany|Clinical Study Site, Halle, Germany|Clinical Study Site, Hamburg, Germany|Clinical Study Site, Hannover, Germany|Clinical Study Site, Heidelberg, Germany|Clinical Study Site, Hessen, Germany|Clinical Study Site, Jena, Germany|Clinical Study Site, Konstanz, Germany|Clinical Study Site, Leipzig, Germany|Clinical Study Site, Lubeck, Germany|Clinical Study Site, Ludwigshafen, Germany|Clinical Study Site, Mainz, Germany|Clinical Study Site, Minden, Germany|Clinical Study Site, Munich, Germany|Clinical Study Site, Münster, Germany|Clinical Study Site, Osnabrück, Germany|Clinical Study Site, Regensburg, Germany|Clinical Study Site, Sande, Germany|Clinical Study Site, Trier, Germany|Clinical Study Site, Tübingen, Germany|Clinical Study Site, Ulm, Germany|Clinical Study Site, Würzburg, Germany|Clinical Study Site, Fukuoka, Japan|Clinical Study Site, Gunma, Japan|Clinical Study Site, Hiroshima, Japan|Clinical Study Site, Ibaraki, Japan|Clinical Study Site, Izumisano, Japan|Clinical Study Site, Kobe, Japan|Clinical Study Site, Kumamoto, Japan|Clinical Study Site, Nagoya, Japan|Clinical Study Site, Sendai, Japan|Clinical Study Site, Shiwa-gun, Japan|Clinical Study Site, Suita, Japan|Clinical Study Site, Tokyo, Japan|Clinical Study Site, Yamaguchi, Japan|Clinical Study Site, Yokosuka, Japan|Clinical Study Site, Amsterdam, Netherlands|Clinical Study Site, Barcelona, Spain|Clinical Study Site, Caceres, Spain|Clinical Study Site, Madrid, Spain|Clinical Study Site, Cardiff, United Kingdom|Clinical Study Site, London, United Kingdom|Clinical Study Site, Stoke on Trent, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/27/NCT02329327/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/27/NCT02329327/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02329327"
75,"NCT04512235","A Study to Evaluate the Effectiveness and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis",,"Recruiting","No Results Available","AL Amyloidosis","Drug: CAEL-101|Other: Placebo|Drug: cyclophosphamide, bortezomib, and dexamethasone (CyBorD) regimen","Time from the date of randomization to date of death or end of study|Number of patients with treatment emergent adverse events as assessed by CTCAE v5.0|Change in distance walked (in meters) during a six-minute walk test|Quality of Life (QOL) by the Kansas City Cardiomyopathy Questionnaire-Overall Score (KCCQ-OS)|Quality of Life (QOL) by the Short Form-36 (SF-36) v2 Physical Component Score (PCS)|Cardiac Improvement by Global Longitudinal Strain (GLS%)","Caelum Biosciences, Inc.|Alexion Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","267","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CAEL101-302","August 25, 2020","August 2, 2022","February 24, 2023","August 13, 2020",,"December 7, 2021","Clinical Trial Site, Scottsdale, Arizona, United States|Clinical Trial Site, Duarte, California, United States|Clinical Trial Site, San Francisco, California, United States|Clinical Trial Site, Stanford, California, United States|Clinical Trial Site, Jacksonville, Florida, United States|Clinical Trial Site, Weston, Florida, United States|Clinical Trial Site, Indianapolis, Indiana, United States|Clinical Trial Site, Boston, Massachusetts, United States|Clinical Trial Site, Boston, Massachusetts, United States|Clinical Trial Site, Boston, Massachusetts, United States|Clinical Trial Site, Detroit, Michigan, United States|Clinical Trial Site, Rochester, Minnesota, United States|Clinical Trial Site, Saint Louis, Missouri, United States|Clinical Trial Site, New York, New York, United States|Clinical Trial Site, New York, New York, United States|Clinical Trial Site, Rochester, New York, United States|Clinical Trial Site, Chapel Hill, North Carolina, United States|Clinical Trial Site, Durham, North Carolina, United States|Clinical Trial Site, Winston-Salem, North Carolina, United States|Clinical Trial Site, Cleveland, Ohio, United States|Clinical Trial Site, Columbus, Ohio, United States|Clinical Trial Site, Portland, Oregon, United States|Clinical Trial Site, Philadelphia, Pennsylvania, United States|Clinical Trial Site, Nashville, Tennessee, United States|Clinical Trial Site, Dallas, Texas, United States|Clinical Trial Site, Houston, Texas, United States|Clinical Trial Site, Salt Lake City, Utah, United States|Clinical Trial Site, Seattle, Washington, United States|Clinical Trial Site, Milwaukee, Wisconsin, United States|Clinical Trial Site, Adelaide, Australia|Clinical Trial Site, Box Hill, Australia|Clinical Trial Site, Murdoch, Australia|Clinical Trial Site, Westmead, Australia|Clinical Trial Site, Woolloongabba, Australia|Clinical Trial Site, Bruxelles, Belgium|Clinical Trial Site, Bruxelles, Belgium|Clinical Trial Site, Leuven, Belgium|Clinical Trial Site, Calgary, Alberta, Canada|Clinical Trial Site, Edmonton, Alberta, Canada|Clinical Trial Site, Toronto, Ontario, Canada|Clinical Trial Site, Caen, France|Clinical Trial Site, Créteil, France|Clinical Trial Site, Lille, France|Clinical Trial Site, Limoges, France|Clinical Trial Site, Marseille, France|Clinical Trial Site, Paris, France|Clinical Trial Site, Pierre-Bénite, France|Clinical Trial Site, Poitiers, France|Clinical Trial Site, Rennes, France|Clinical Trial Site, Berlin, Germany|Clinical Trial Site, Düsseldorf, Germany|Clinical Trial Site, Essen, Germany|Clinical Trial Site, Hamburg, Germany|Clinical Trial Site, Heidelberg, Germany|Clinical Trial Site, Münster, Germany|Clinical Trial Site, Würzburg, Germany|Clinical Trial Site, Athens, Greece|Clinical Trial Site, Patras, Greece|Clinical Trial Site, Thessaloníki, Greece|Clinical Trial Site, Jerusalem, Israel|Clinical Trial Site, Tel Aviv-Yafo, Israel|Clinical Trial Site, Pavia, Italy|Clinical Trial Site, Chiba, Japan|Clinical Trial Site, Fukushima, Japan|Clinical Trial Site, Kanazawa, Japan|Clinical Trial Site, Kyoto, Japan|Clinical Trial Site, Nagoya, Japan|Clinical Trial Site, Tokyo, Japan|Clinical Trial Site, Warszawa, Poland|Clinical Trial Site, Petersburg, Russian Federation|Clinical Trial Site, Saint Petersburg, Russian Federation|Clinical Trial Site, Barcelona, Spain|Clinical Trial Site, Barcelona, Spain|Clinical Trial Site, Madrid, Spain|Clinical Trial Site, Pamplona, Spain|Clinical Trial Site, London, United Kingdom|Clinical Trial Site, London, United Kingdom|Clinical Trial Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04512235"
76,"NCT04504825","A Study to Evaluate the Effectiveness and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis",,"Recruiting","No Results Available","AL Amyloidosis","Drug: CAEL-101|Other: Placebo|Drug: cyclophosphamide, bortezomib, and Dexamethasone (CyBorD) regimen","Time from the date of randomization to date of death or end of study.|Number of patients with treatment emergent adverse events as assessed by CTCAE v5.0|Change in distance walked (in meters) during a six-minute walk test|Quality of Life (QOL) by the Kansas City Cardiomyopathy Questionnaire-Overall Score (KCCQ-OS)|Quality of Life (QOL) by the Short Form-36 (SF-36) v2 Physical Component Score (PCS)|Cardiac Improvement by Global Longitudinal Strain (GLS%)","Caelum Biosciences, Inc.|Alexion Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","111","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CAEL101-301","August 25, 2020","August 2, 2022","February 24, 2023","August 7, 2020",,"December 7, 2021","Clinical Trial Site, Scottsdale, Arizona, United States|Clinical Trial Site, Duarte, California, United States|Clinical Trial Site, San Francisco, California, United States|Clinical Trial Site, Stanford, California, United States|Clinical Trial Site, Jacksonville, Florida, United States|Clinical Trial Site, Weston, Florida, United States|Clinical Trial Site, Indianapolis, Indiana, United States|Clinical Trial Site, Boston, Massachusetts, United States|Clinical Trial Site, Boston, Massachusetts, United States|Clinical Trial Site, Boston, Massachusetts, United States|Clinical Trial Site, Detroit, Michigan, United States|Clinical Trial Site, Rochester, Minnesota, United States|Clinical Trial Site, Saint Louis, Missouri, United States|Clinical Trial Site, New York, New York, United States|Clinical Trial Site, New York, New York, United States|Clinical Trial Site, Rochester, New York, United States|Clinical Trial Site, Chapel Hill, North Carolina, United States|Clinical Trial Site, Durham, North Carolina, United States|Clinical Trial Site, Winston-Salem, North Carolina, United States|Clinical Trial Site, Cleveland, Ohio, United States|Clinical Trial Site, Columbus, Ohio, United States|Clinical Trial Site, Portland, Oregon, United States|Clinical Trial Site, Philadelphia, Pennsylvania, United States|Clinical Trial Site, Nashville, Tennessee, United States|Clinical Trial Site, Dallas, Texas, United States|Clinical Trial Site, Houston, Texas, United States|Clinical Trial Site, Salt Lake City, Utah, United States|Clinical Trial Site, Seattle, Washington, United States|Clinical Trial Site, Milwaukee, Wisconsin, United States|Clinical Trial Site, Adelaide, Australia|Clinical Trial Site, Box Hill, Australia|Clinical Trial Site, Murdoch, Australia|Clinical Trial Site, Westmead, Australia|Clinical Trial Site, Woolloongabba, Australia|Clinical Trial Site, Bruxelles, Belgium|Clinical Trial Site, Bruxelles, Belgium|Clinical Trial Site, Leuven, Belgium|Clinical Trial Site, Calgary, Alberta, Canada|Clinical Trial Site, Edmonton, Alberta, Canada|Clinical Trial Site, Toronto, Ontario, Canada|Clinical Trial Site, Caen, France|Clinical Trial Site, Créteil, France|Clinical Trial Site, Lille, France|Clinical Trial Site, Limoges, France|Clinical Trial Site, Marseille, France|Clinical Trial Site, Paris, France|Clinical Trial Site, Pierre-Bénite, France|Clinical Trial Site, Poitiers, France|Clinical Trial Site, Rennes, France|Clinical Trial Site, Berlin, Germany|Clinical Trial Site, Düsseldorf, Germany|Clinical Trial Site, Essen, Germany|Clinical Trial Site, Hamburg, Germany|Clinical Trial Site, Heidelberg, Germany|Clinical Trial Site, Münster, Germany|Clinical Trial Site, Würzburg, Germany|Clinical Trial Site, Athens, Greece|Clinical Trial Site, Patras, Greece|Clinical Trial Site, Thessaloníki, Greece|Clinical Trial Site, Jerusalem, Israel|Clinical Trial Site, Tel Aviv-Yafo, Israel|Clinical Trial Site, Pavia, Italy|Clinical Trial Site, Chiba, Japan|Clinical Trial Site, Fukushima, Japan|Clinical Trial Site, Ishikawa, Japan|Clinical Trial Site, Kanazawa, Japan|Clinical Trial Site, Kyoto, Japan|Clinical Trial Site, Nagoya, Japan|Clinical Trial Site, Tokyo, Japan|Clinical Trial Site, Warszawa, Poland|Clinical Trial Site, Petersburg, Russian Federation|Clinical Trial Site, Saint Petersburg, Russian Federation|Clinical Trial Site, Barcelona, Spain|Clinical Trial Site, Barcelona, Spain|Clinical Trial Site, Gijon, Spain|Clinical Trial Site, Madrid, Spain|Clinical Trial Site, Pamplona, Spain|Clinical Trial Site, Sevilla, Spain|Clinical Trial Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04504825"
77,"NCT03075878","A Safety Study of SYNT001 in Participants With Warm Autoimmune Hemolytic Anemia (WAIHA)",,"Terminated","Has Results","Warm Autoimmune Hemolytic Anemia","Drug: ALXN1830","Count Of Participants Reporting Treatment-emergent Adverse Events (TEAEs)|Maximum Serum Concentration (Cmax) On Day 0 And Day 28|Change From Baseline In Reticulocyte Count At Day 33|Change From Baseline In Hemoglobin At Day 33|Immunogenicity Of ALXN1830 At Day 112, As Assessed By Anti-ALXN1830 Antibody Level","Alexion Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","8","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SYNT001-102","January 10, 2018","April 15, 2019","August 6, 2019","March 9, 2017","May 13, 2020","May 13, 2020","Alexion Study Site, Los Angeles, California, United States|Alexion Study Site, San Francisco, California, United States|Alexion Study Site, Boston, Massachusetts, United States|Alexion Study Site, Pittsfield, Massachusetts, United States|Alexion Study Site, Rochester, Minnesota, United States|Alexion Study Site, Cleveland, Ohio, United States|Alexion Study Site, Philadelphia, Pennsylvania, United States|Alexion Study Site, Pittsburgh, Pennsylvania, United States|Alexion Study Site, Seattle, Washington, United States|Alexion Study Site, Amman, Jordan","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT03075878/SAP_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/78/NCT03075878/Prot_001.pdf","https://ClinicalTrials.gov/show/NCT03075878"
78,"NCT05254613","A Study of Single and Multiple SC Doses of ALXN1830 in Healthy Adult Participants",,"Terminated","No Results Available","Healthy","Drug: ALXN1830|Drug: Placebo","Number Of Participants With Treatment-emergent Adverse Events|Area Under The Plasma Concentration Versus Time Curve (AUC) Of Single And Multiple SC Doses Of ALXN1830|Maximum Observed Plasma Concentration (Cmax) Of Single And Multiple SC Doses Of ALXN1830|Change From Baseline In Serum Immunoglobulin G (IgG) Of Single And Multiple SC Doses Of ALXN1830|Change From Baseline In Antidrug Antibody (ADA) And Neutralizing Antibody (Nab) Levels OF Single And Multiple Doses Of ALXN1830","Alexion Pharmaceuticals","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","56","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","ALXN1830-HV-105|2019-003496-18","November 12, 2019","January 22, 2021","January 22, 2021","February 24, 2022",,"February 24, 2022","Clinical Trial Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT05254613"
79,"NCT04982289","Study of ALXN1830 Administered Subcutaneously in Adults With Generalized Myasthenia Gravis",,"Withdrawn","No Results Available","Generalized Myasthenia Gravis","Drug: ALXN1830|Other: Placebo","Adverse Events (AEs) And Serious Adverse Events (SAEs) Up To Week 24|AEs And SAEs Up To Week 82|Change From Baseline In Serum Total Immunoglobulin G (IgG)|Change From Baseline In Myasthenia Gravis Activities Of Daily Living Profile (MG-ADL) Total Score|Change From Baseline In Quantitative Myasthenia Gravis (QMG) Score|Number Of Participants With At Least A 2-point Improvement In The MG-ADL Score Over 4 Consecutive Weeks|Number Of Participants With At Least A 3-point Improvement In The QMG Score Over 4 Consecutive Weeks|Change From Baseline In Neurological Disorders Fatigue Questionnaire (Neuro-Qol) Fatigue Score|Serum Trough Concentrations Of ALXN1830|Change From Baseline In IgG Subtypes|Incidence Of Anti-drug Antibodies (ADA) And Neutralizing Antibodies (Nab) Against ALXN1830|Titers Of ADA And Nab Against ALXN1830","Alexion Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ALXN1830-MG-201","January 1, 2022","January 31, 2023","January 31, 2024","July 29, 2021",,"February 11, 2022","Clinical Study Site, Phoenix, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT04982289"
80,"NCT04958135","Study to Assess the Effect of Food on a Single Dose of Acoramidis in Healthy Adult Participants",,"Completed","No Results Available","Healthy","Drug: Acoramidis","Maximum Observed Plasma Concentration (Cmax) Of Acoramidis: Fed (Test) Versus Fasted (Reference) Conditions|Area Under The Plasma Concentration Versus Time Curve From Time 0 To The Last Quantifiable Concentration (AUC0-t) For Acoramidis: Fed (Test) Versus Fasted (Reference) Conditions|Area Under The Plasma Concentration Versus Time Curve From Zero To Infinity (AUC0-inf) For Acoramidis: Fed (Test) Versus Fasted (Reference) Conditions|Cmax Of Acoramidis-AG: Fed (Test) Versus Fasted (Reference) Conditions|AUC0-t For Acoramidis-AG: Fed (Test) Versus Fasted (Reference) Conditions|AUC0-inf For Acoramidis-AG: Fed (Test) Versus Fasted (Reference) Conditions","Alexion Pharmaceuticals|Celerion","All","18 Years to 55 Years   (Adult)","Phase 1","18","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","ALXN2060-HV-101","June 16, 2021","August 17, 2021","August 17, 2021","July 12, 2021",,"September 24, 2021","Celerion, Lincoln, Nebraska, United States",,"https://ClinicalTrials.gov/show/NCT04958135"
81,"NCT04956276","Subcutaneous ALXN1830 in Adult Participants With Warm Autoimmune Hemolytic Anemia",,"Withdrawn","No Results Available","Warm Autoimmune Hemolytic Anemia","Drug: ALXN1830|Drug: Placebo","Proportion Of Participants Achieving A ≥ 2 Grams/Deciliter (g/dL) Increase In Hemoglobin (Hgb) From Baseline To The End Of Primary Treatment|Total Number Of Units Of pRBCs Transfused|Number Of Hgb Measurements ≥ 2 g/dL From Baseline To The End Of Primary Treatment|Time To Hgb Increase By ≥ 2 g/dL From Baseline|Proportion Of Participants Who Require New WAIHA Rescue Medication Or Any Increase In The Dose Of An Existing WAIHA Medication Or pRBC Transfusions For The Treatment Of Anemia|Proportion Of Participants Achieving A ≥ 2 g/dL Increase In Hgb From Baseline Through Week 4|Change From Baseline To The End Of Primary Treatment In Serum Lactate Dehydrogenase (LDH) Levels|Change From Baseline To The End Of Primary Treatment In Absolute Reticulocyte Count|Change From Baseline To The End Of Primary Treatment In Serum Indirect Bilirubin|Change From Baseline To The End Of Primary Treatment In Serum Haptoglobin|Total Corticosteroid Usage From Baseline To The End Of Primary Treatment|Proportion Of Participants Who Require Any Increase In Corticosteroid Dose From Baseline To The End Of Follow Up After Primary Treatment|Change In Corticosteroid Dose From The End Of Primary Treatment To The End Of Follow Up|Number Of Days To Beginning Of Corticosteroid Taper During Follow Up After Primary Treatment|Number Of Days To Corticosteroid Maintenance Dose During Follow Up After Primary Treatment|Number Of Days To Reach Corticosteroid Discontinuation From The End Of Primary Treatment To The End Of Follow Up After Primary Treatment|Incidence And Titers Of Anti-drug Antibodies Against ALXN1830 Over Time|Incidence And Titers Of Neutralizing Antibodies Against ALXN1830 Over Time|Serum Trough Concentrations Of ALXN1830 Over Time|Change In Serum Total Immunoglobulin G (IgG) Levels By Dose Group And Time Point|Change From Baseline Of IgG Subtypes (IgG1 4) By Dose Group And Time Point|Change From Baseline Of IgA By Dose Group And Time Point|Change From Baseline Of IgM By Dose Group And Time Point|Change From Baseline Of Albumin By Dose Group And Time Point|Change From Baseline Of Circulating Immune Complexes By Dose Group And Time Point","Alexion Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ALXN1830-WAI-202","January 1, 2022","July 31, 2022","July 31, 2024","July 9, 2021",,"February 11, 2022","Clinical Study Site, Riverside, California, United States",,"https://ClinicalTrials.gov/show/NCT04956276"
82,"NCT04952545","Study of ALXN2050 in Healthy Adult Participants of Japanese Descent",,"Completed","No Results Available","Healthy","Drug: ALXN2050|Drug: Placebo","Number Of Participants With Treatment-emergent Adverse Events|Area Under The Concentration-time Curve From Time Zero To Infinity (AUCinf) For Single-dose ALXN2050|Maximum Plasma Concentration (Cmax) For Single-dose ALXN2050|Time To Maximum Plasma Concentration (Tmax) For Single-dose ALXN2050|Area Under The Concentration-time Curve From Time Zero To The 12-hour Time Point (AUC0-12) For Multiple-dose ALXN2050|Cmax For Multiple-dose ALXN2050|Tmax For Multiple-dose ALXN2050|Alternative Pathway Activity As Measured By Wieslab Assay|Complement Factor B Fraction b Levels","Alexion Pharmaceuticals","All","18 Years to 55 Years   (Adult)","Phase 1","20","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","ALXN2050-HV-113","July 9, 2021","September 7, 2021","September 7, 2021","July 7, 2021",,"December 10, 2021","Clinical Trial Site, Tempe, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT04952545"
83,"NCT04933682","Drug Interaction Study of ALXN2050 With Fluconazole and Rifampin in Healthy Adult Participants",,"Completed","No Results Available","Healthy","Drug: ALXN2050|Drug: Fluconazole|Drug: Rifampin","Part 1: Area Under The Concentration-time Curve From Time 0 To Infinity (AUC0-inf) For A Single Dose Of ALXN2050 When Dosed Alone Versus When Dosed In The Presence Of Steady-state Fluconazole|Part 1: Maximum Observed Concentration (Cmax) For A Single Dose Of ALXN2050 When Dosed Alone Versus When Dosed In The Presence Of Steady-state Fluconazole|Part 1: Time To Maximum Plasma Concentration (Tmax) For A Single Dose Of ALXN2050 When Dosed Alone Versus When Dosed In The Presence Of Steady-state Fluconazole|Part 1: Area Under The Concentration-time Curve From Time 0 To The 12-hour Point (AUC0-12) For Multiple Doses Of ALXN2050 When Dosed Alone Versus When Dosed In The Presence Of Steady-state Fluconazole|Part 1: Cmax For Multiple Doses Of ALXN2050 When Dosed Alone Versus When Dosed In The Presence Of Steady-state Fluconazole|Part 1: Tmax For Multiple Doses Of ALXN2050 When Dosed Alone Versus When Dosed In The Presence Of Steady-state Fluconazole|Part 2: AUC0-inf For A Single Dose Of ALXN2050 When Dosed Alone Versus When Dosed With A Single Dose Of Rifampin|Part 2: Cmax For A Single Dose Of ALXN2050 When Dosed Alone Versus When Dosed With A Single Dose Of Rifampin|Part 2: Tmax For A Single Dose Of ALXN2050 When Dosed Alone Versus When Dosed With A Single Dose Of Rifampin|Part 2: AUC0-inf For A Single Dose Of ALXN2050 When Dosed Alone Versus When Dosed In The Presence Of Steady-state Rifampin|Part 2: Cmax For A Single Dose Of ALXN2050 When Dosed Alone Versus When Dosed In The Presence Of Steady-state Rifampin|Part 2: Tmax For A Single Dose Of ALXN2050 When Dosed Alone Versus When Dosed In The Presence Of Steady-state Rifampin|Part 1: Area Under The Concentration-time Curve From Time Zero To The 4-hour Time Point (AUC0-4) For ALXN2050 When Dosed In The Morning Versus In The Evening|Participants Experiencing Treatment-emergent Adverse Events","Alexion Pharmaceuticals","All","18 Years to 55 Years   (Adult)","Phase 1","16","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","ALXN2050-HV-105","June 23, 2021","August 4, 2021","August 4, 2021","June 22, 2021",,"December 28, 2021","Clinical Trial Site, Tempe, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT04933682"
84,"NCT04920370","Study of Subcutaneous and Intravenous ALXN1720 With and Without rHuPH20 in Healthy Subjects",,"Completed","No Results Available","Healthy","Drug: ALXN1720 SC|Drug: ALXN1720 IV|Drug: rHuPH20|Drug: Placebo SC|Drug: Placebo IV","Incidence of Treatment-emergent and Serious Adverse Events (TEAEs, SAEs)|Maximum Observed Concentration (Cmax) of ALXN1720 SC, ALXN1720 SC/rHuPH20, and ALXN1720 IV|Area Under The Concentration-time Curve (AUC) of ALXN1720 SC, ALXN1720 SC/rHuPH20, and ALXN1720 IV|Change from Baseline in Serum Concentrations of Free Complement Component 5 (C5)|Change from Baseline in Serum Concentrations of Total C5|Change from Baseline in Ex Vivo Chicken Red Blood Cell (cRBC) Hemolysis Activity|Incidence of Antidrug Antibodies (ADAs) to ALXN1720|Absolute Bioavailability of ALXN1720|Comparison of Incidence of TEAEs and SAEs Between Healthy Non-Japanese Participants and Participants of Japanese Descent|Comparison of Cmax of ALXN1720 SC, ALXN1720 SC/rHuPH20, and ALXN1720 IV Between Healthy Non-Japanese Participants and Participants of Japanese Descent|Comparison of AUC of ALXN1720 SC, ALXN1720 SC/rHuPH20, and ALXN1720 IV Between Healthy Non-Japanese Participants and Participants of Japanese Descent|Comparison of Change from Baseline in Serum Concentrations of Free C5 Between Healthy Non-Japanese Participants and Participants of Japanese Descent|Comparison of Change from Baseline in Serum Concentrations of Total C5 Between Healthy Non-Japanese Participants and Participants of Japanese Descent|Comparison of Change from Baseline in Serum Concentrations in Ex Vivo cRBC Hemolysis Activity Between Healthy Non-Japanese Participants and Participants of Japanese Descent|Comparison of ADAs to ALXN1720 Between Healthy Non-Japanese Participants and Participants of Japanese Descent","Alexion Pharmaceuticals","All","18 Years to 45 Years   (Adult)","Phase 1","97","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ALXN1720-HV-101|2018-004500-19","September 4, 2019","November 16, 2021","November 16, 2021","June 9, 2021",,"February 11, 2022","Clinical Study Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04920370"
85,"NCT04802083","COVID-19 Soliris Expanded Access Protocol",,"No longer available","No Results Available","Covid19","Biological: Eculizumab",,"Alexion Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)",,,"Industry","Expanded Access:Intermediate-size Population",,"ECU-COV-402",,,,"March 17, 2021",,"October 4, 2021",,,"https://ClinicalTrials.gov/show/NCT04802083"
86,"NCT04730804","A Study of ALXN1830 in Healthy Adult Participants",,"Terminated","No Results Available","Healthy","Drug: ALXN1830|Drug: Placebo","Number Of Participants With Treatment-emergent Adverse Events|Area Under The Concentration-time Curve From Time 0 (Dosing) To Time Infinity (AUC0-inf) Of Serum ALXN1830 For Single And Multiple Doses|Change From Baseline In Serum Immunoglobulin G (IgG) For Single And Multiple Doses Of ALXN1830|Comparison Of Incidences Of Treatment-emergent Adverse Events Between Healthy Non-Japanese Participants And Participants Of Japanese Descent For Multiple HTDs Of ALXN1830|Comparison Of AUC0-inf Between Healthy Non-Japanese Participants And Participants Of Japanese Descent For Multiple HTDs Of ALXN1830|Comparison Of IgG Levels Between Healthy Non-Japanese Participants And Participants Of Japanese Descent For Multiple HTDs Of ALXN1830","Alexion Pharmaceuticals|Syneos Health","All","18 Years to 55 Years   (Adult)","Phase 1","48","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","ALXN1830-HV-108|2020-001081-11","March 17, 2021","December 14, 2021","January 4, 2022","January 29, 2021",,"February 23, 2022","Clinical Trial Site, Auckland, New Zealand",,"https://ClinicalTrials.gov/show/NCT04730804"
87,"NCT04660890","A Study of the Cardiac Effects of ALXN2050 in Healthy Adults",,"Completed","No Results Available","Healthy","Drug: ALXN2050|Drug: ALXN2050-matching Placebo|Drug: Moxifloxacin|Drug: Moxifloxacin-matching Placebo","Placebo-corrected Change From Baseline QTc Intervals (ddQTc) For ALXN2050|Change From Baseline PR Interval (dPR) For ALXN2050|ddQTc For Moxifloxacin|Area Under The Plasma Concentration-time Curve During A Dosing Interval (tau) At Steady-state (AUCtau) For ALXN2050|Maximum Observed Plasma Concentration Following Multiple Dosing (Cmax,ss) For ALXN2050|Time To Maximum Observed Plasma Concentration Following Multiple Dosing (Tmax,ss) For ALXN2050|Incidence Of Treatment-emergent Adverse Events","Alexion Pharmaceuticals|Celerion","All","18 Years to 55 Years   (Adult)","Phase 1","39","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","ALXN2050-HV-107","December 12, 2020","March 16, 2021","March 16, 2021","December 9, 2020",,"December 29, 2021","Clinical Trial Site, Tempe, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT04660890"
88,"NCT04622046","A Phase 3 Study of ALXN2060 in Japanese Participants With Symptomatic ATTR-CM",,"Active, not recruiting","No Results Available","Symptomatic Transthyretin Amyloid Cardiomyopathy","Drug: ALXN2060","Change From Baseline To Month 12 Of Treatment In Distance Walked During The Six-minute Walk Test (6MWT)|All-cause Mortality And Cardiovascular-related Hospitalization Over A 30-month Period|Change From Baseline To Month 30 Of Treatment In Distance Walked During The 6MWT|Change From Baseline To Month 12 Of Treatment In The Kansas City Cardiomyopathy Questionnaire Overall Score (KCCQ-OS)|Change From Baseline To Month 30 Of Treatment In The KCCQ-OS|Incidence Of Treatment-emergent Serious Adverse Events (SAEs) And Adverse Events (AEs)|Incidence Of Treatment-emergent SAEs And AEs|Change From Baseline To Day 28 In Transthyretin (TTR) Stabilization|Change From Baseline To Month 30 In TTR Stabilization","Alexion Pharmaceuticals|Eidos Therapeutics, a BridgeBio company","All","20 Years to 90 Years   (Adult, Older Adult)","Phase 3","22","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ALXN2060-TAC-302","November 1, 2020","November 2022","May 2024","November 9, 2020",,"May 25, 2021","Nagoya University Hospital, Aichi, Japan|Kurume University Hospital, Fukuoka, Japan|Kyushu University Hospital, Fukuoka, Japan|Sapporo Medical University Hospital, Hokkaido, Japan|Kitasato University Hospital, Kanagawa, Japan|Kochi Medical School Hospital, Kochi, Japan|Kumamoto University Hospital, Kumamoto, Japan|Shinshu University Hospital, Nagano, Japan|Okayama University Hospital, Okayama, Japan|National Cerebral and Cardiovascular Center, Osaka, Japan|Juntendo University Hospital, Tokyo, Japan|Keio University Hospital, Tokyo, Japan|The University of Tokyo Hospital, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT04622046"
89,"NCT04610580","Bioavailability Study of 2 Oral Formulations of ALXN1840",,"Completed","No Results Available","Healthy","Drug: ALXN1840","Relative Bioavailability Of ALXN1840 Test And Reference Formulations As Assessed By Maximum Observed Concentration (Cmax) For Plasma Total Molybdenum (Mo) and Plasma Ultrafiltrate (PUF) Mo|Relative Bioavailability Of ALXN1840 Test And Reference Formulations As Assessed By Area Under The Plasma Concentration Versus Time Curve From Time 0 To The Last Quantifiable Concentration (AUCt) For Plasma Total Mo and PUF Mo|Relative Bioavailability Of ALXN1840 Test And Reference Formulations As Assessed By Area Under The Plasma Concentration Versus Time Curve From Time 0 To Infinity (AUCinf) For Plasma Total Mo and PUF Mo|Extension Period: Dose-proportionality Between 4 Ascending Doses Of ALXN1840 As Assessed by Dose-normalized Cmax For Plasma Total Mo and PUF Mo|Extension Period: Dose-proportionality Between 4 Ascending Doses Of ALXN1840 As Assessed by Dose-normalized AUCt For Plasma Total Mo and PUF Mo|Extension Period: Dose-proportionality Between 4 Ascending Doses Of ALXN1840 As Assessed by Dose-normalized AUCinf For Plasma Total Mo and PUF Mo","Alexion Pharmaceuticals","All","18 Years to 55 Years   (Adult)","Phase 1","48","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ALXN1840-HV-109","January 31, 2021","March 24, 2021","April 26, 2021","October 30, 2020",,"July 28, 2021","Nucleus Network Pty Ltd., Melbourne, Victoria, Australia",,"https://ClinicalTrials.gov/show/NCT04610580"
90,"NCT04609696","Study of the Metabolism of Danicopan in Healthy Adults",,"Completed","No Results Available","Healthy","Drug: Danicopan: Powder-In-Capsule 1|Drug: Danicopan: Powder-In-Capsule 2|Drug: Danicopan: Tablet","Relative Bioavailability Of Danicopan Prototype PIC 1 Formulation And Tablet Formulation|AUC0-inf Of Danicopan Prototype PIC 1 Formulation Under Both Fed And Fasted Conditions|AUC0-t Of Danicopan Prototype PIC 1 Formulation Under Both Fed And Fasted Conditions|Cmax Of Danicopan Prototype PIC 1 Formulation Under Both Fed And Fasted Conditions|Time to maximum observed plasma concentration (Tmax) Of Danicopan Prototype PIC 1 Formulation Under Both Fed And Fasted Conditions|Relative Bioavailability Of Danicopan Prototype PIC 2 Formulation And Tablet Formulation|AUC0-inf Of Danicopan Prototype PIC 2 Formulation Under Both Fed And Fasted Conditions|AUC0-t Of Danicopan Prototype PIC 2 Formulation Under Both Fed And Fasted Conditions|Cmax Of Danicopan Prototype PIC 2 Formulation Under Both Fed And Fasted Conditions|Tmax Of Danicopan Prototype PIC 2 Formulation Under Both Fed And Fasted Conditions|Number Of Participants Receiving Prototype PIC 1 And Tablet With Treatment-emergent Adverse Events Under Fed Conditions|Number Of Participants Receiving Prototype PIC 1 With Treatment-emergent Adverse Events Under Fasted Conditions|Number Of Participants Receiving Prototype PIC 2 And Tablet With Treatment-emergent Adverse Events Under Fed Conditions|Number Of Participants Receiving Prototype PIC 2 With Treatment-emergent Adverse Events Under Fasted Conditions","Alexion Pharmaceuticals|Celerion","All","18 Years to 55 Years   (Adult)","Phase 1","24","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","ALXN2040-HV-119","October 20, 2020","December 1, 2020","December 1, 2020","October 30, 2020",,"February 15, 2021","Clinical Trial Site, Tempe, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT04609696"
91,"NCT04609670","Study of Radiolabeled ALXN2050 in Healthy Adult Males",,"Completed","No Results Available","Healthy","Drug: [14C]-ALXN2050","Mass Balance Recovery In Urine And Feces After a Single Oral Dose Of [14C]-ALXN2050|Plasma Pharmacokinetics (PK) Of Total Radioactivity After A Single Oral Dose Of [14C]-ALXN2050: Area Under The Concentration-time Curve From Time 0 Extrapolated To Infinity (AUC0-inf)|Plasma PK Of Total Radioactivity After A Single Oral Dose Of [14C]-ALXN2050: Area Under The Concentration Versus Time Curve, From Time 0 To The Time Of The Last Measurable Concentration (AUC0-last)|Plasma PK Of Total Radioactivity After A Single Oral Dose Of [14C]-ALXN2050: Maximum Observed Plasma Concentration (Cmax)|Plasma PK Of Total Radioactivity After A Single Oral Dose Of [14C]-ALXN2050: Time To Maximum Observed Plasma Concentration (Tmax)|Plasma PK Of ALXN2050 After A Single Oral Dose Of [14C]-ALXN2050: AUC0-inf|Plasma PK Of ALXN2050 After A Single Oral Dose Of [14C]-ALXN2050: AUC0-last|Plasma PK Of ALXN2050 After A Single Oral Dose Of [14C]-ALXN2050: Cmax|Plasma PK Of ALXN2050 After A Single Oral Dose Of [14C]-ALXN2050: Tmax|Percentage Of Total Radioactivity Detected For Each ALXN2050 Metabolite in Plasma, Urine, And Feces|Number Of Participants Receiving A Single Oral Administration Of [14C]-ALXN2050 With Treatment-emergent Adverse Events","Alexion Pharmaceuticals","Male","19 Years to 55 Years   (Adult)","Phase 1","9","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","ALXN2050-HV-106","April 12, 2021","August 13, 2021","August 13, 2021","October 30, 2020",,"February 14, 2022","Clinical Trial Site, Lincoln, Nebraska, United States",,"https://ClinicalTrials.gov/show/NCT04609670"
92,"NCT04594252","Copper Balance in Healthy Participants Administered ALXN1840",,"Completed","No Results Available","Healthy","Drug: ALXN1840","Change From Baseline In Mean Daily Copper Balance At Steady State|Mean Daily Copper Balance|Mean Daily Molybdenum Balance At Steady State|Change From Baseline In Total Molybdenum Excretion In Urine And Feces At Day 15|Mean Daily Molybdenum Balance|Copper Quantified In Food, Drink, Feces, And Urine, Including Plasma Total And Labile Bound Copper (LBC)|Copper Quantified In Food, Drink, Feces, And Urine|Molybdenum Specified In ALXN1840 Doses Given And Quantified In Food, Drink, Feces, And Urine|Pharmacokinetics (PK): Maximum Concentration (Cmax) Of Plasma Total Molybdenum|PK: Area Under The Curve (AUC) From Time 0 To The Time Of Last Measurable Concentration (AUCt) Of Plasma Total Molybdenum|PK: Trough (Predose) Concentration Observed At The Start Of The Dosing Interval (Ctrough)","Alexion Pharmaceuticals","All","18 Years to 45 Years   (Adult)","Phase 1","17","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ALXN1840-HV-108","July 1, 2020","November 17, 2020","November 17, 2020","October 20, 2020",,"February 15, 2021","Clinical Study Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04594252"
93,"NCT04560816","A Study of the Cardiac Effects of ALXN1840 in Healthy Adults",,"Enrolling by invitation","No Results Available","Healthy","Drug: ALXN1840|Drug: Placebo|Drug: Moxifloxacin","Placebo-corrected Change From Baseline QTc For ALXN1840 Using The By-time Point Analysis|Change From Baseline ΔΔQTcF For Moxifloxacin Using The By-time Point Analysis|Change From Baseline Heart Rate (ΔHR) For ALXN1840|Change From Baseline PR Interval (ΔPR) For ALXN1840|Change From Baseline QRS Interval (ΔQRS) For ALXN1840|Placebo-corrected Change From Baseline Heart Rate (ΔΔHR) For ALXN1840|Placebo-corrected Change From Baseline PR Interval (ΔΔPR) For ALXN1840|Placebo-corrected Change From Baseline QRS Interval (ΔΔQRS) For ALXN1840|Treatment-emergent T-wave Morphology Abnormalities And U-waves|Area Under The Concentration Versus Time Curve From Time 0 To The Last Quantifiable Concentration (AUC0-t) Of Total Molybdenum And Plasma Ultrafiltrate Molybdenum|Maximum Observed Concentration (Cmax) Of Total Molybdenum And Plasma Ultrafiltrate Molybdenum|Time To Maximum Observed Concentration (Tmax) Of Total Molybdenum And Plasma Ultrafiltrate Molybdenum|Incidence Of Treatment-emergent Adverse Events","Alexion Pharmaceuticals|PPD|ERT: Clinical Trial Technology Solutions","All","18 Years to 50 Years   (Adult)","Phase 1","54","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","ALXN1840-HV-107","July 24, 2020","March 2021","March 2021","September 23, 2020",,"February 15, 2021","Clinical Research Site, Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04560816"
94,"NCT04551599","A Study of the Effects of Food and Age on Danicopan",,"Completed","No Results Available","Healthy","Drug: Danicopan","Area Under The Concentration Versus Time Curve From Time 0 To The Last Measurable Concentration (AUC0-t) Of Danicopan Under Both Fed And Fasted Conditions In Healthy Young Adults|Area Under The Concentration Versus Time Curve From Time 0 Extrapolated To Infinity (AUC0-inf) Of Danicopan Under Both Fed And Fasted Conditions In Healthy Young Adults|Maximum Observed Concentration (Cmax) Of Danicopan Under Both Fed And Fasted Conditions in Healthy Young Adults|Time To Maximum Observed Concentration (Tmax) Of Danicopan Under Both Fed And Fasted Conditions in Healthy Young Adults|AUC0-t Of Danicopan Under Fed Conditions In Healthy Elderly Males|AUC0-inf Of Danicopan Under Fed Conditions In Healthy Elderly Males|Cmax Of Danicopan Under Fed Conditions In Healthy Elderly Males|Tmax Of Danicopan Under Fed Conditions In Healthy Elderly Males|Number Of Healthy Young Adults And Healthy Elderly Males With Treatment-emergent Adverse Events","Alexion Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 1","27","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","ACH471-016","February 21, 2020","February 3, 2021","February 3, 2021","September 16, 2020",,"January 28, 2022","Clinical Trial Site, Tempe, Arizona, United States",,"https://ClinicalTrials.gov/show/NCT04551599"
95,"NCT04551586","A Study to Assess ACH-0145228 When Administered as Immediate Release Tablet Versus Powder-In-Capsule in Healthy Adult Participants",,"Completed","No Results Available","Healthy","Drug: ACH-0145228: Immediate Release|Drug: ACH-0145228: Powder-in-capsule","Relative Bioavailability Of ACH-0145228 Immediate Release Tablet And Powder-In-Capsule|Area Under The Concentration Versus Time Curve From Time 0 To The Last Measurable Concentration (AUC0-t) Of ACH-0145228 Immediate-release Tablet Under Both Fed And Fasted Conditions|AUC0-inf Of ACH-0145228 Immediate-release Tablet Under Both Fed And Fasted Conditions|Maximum Observed Concentration (Cmax) Of ACH-0145228 Immediate-release Tablet Under Both Fed And Fasted Conditions|Time To Maximum Observed Concentration (Tmax) Of ACH-0145228 Immediate-release Tablet Under Both Fed And Fasted Conditions|AUC0-t Of ACH-0145228 Powder-in-capsule Under Fasted Conditions|AUC0-inf Of ACH-0145228 Powder-in-capsule Under Fasted Conditions|Cmax Of ACH-0145228 Powder-in-capsule Under Fasted Conditions|Tmax Of ACH-0145228 Powder-in-capsule Under Fasted Conditions|Number Of Participants With Treatment-emergent Adverse Events","Alexion Pharmaceuticals","All","18 Years to 55 Years   (Adult)","Phase 1","28","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science","ACH228-004","June 26, 2020","October 19, 2020","October 19, 2020","September 16, 2020",,"December 28, 2021","Clinical Trial Site, Lincoln, Nebraska, United States",,"https://ClinicalTrials.gov/show/NCT04551586"
96,"NCT04526210","Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants",,"Completed","No Results Available","Wilson Disease","Drug: ALXN1840|Drug: Bupropion Hydrochloride","Maximum Observed Plasma Concentration (Cmax) Of Bupropion With And Without The Coadministration Of ALXN1840|Area Under The Plasma Concentration Versus Time Curve From Time 0 To The Last Quantifiable Concentration (AUCt) Of Bupropion With And Without The Coadministration Of ALXN1840|Area Under The Plasma Concentration Versus Time Curve From Time 0 To Infinity (AUCinf) Of Bupropion With And Without The Coadministration Of ALXN1840|Cmax Of Hydroxybupropion With And Without The Coadministration Of ALXN1840|AUCt Of Hydroxybupropion With And Without The Coadministration Of ALXN1840|AUCinf Of Hydroxybupropion With And Without The Coadministration Of ALXN1840|Cmax Of Molybdenum With Coadministration Of Bupropion|AUCt Of Molybdenum With Coadministration Of Bupropion|AUCinf Of Molybdenum With Coadministration Of Bupropion","Alexion Pharmaceuticals","All","18 Years to 50 Years   (Adult)","Phase 1","54","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ALXN1840-HV-103","October 21, 2020","May 19, 2021","May 19, 2021","August 25, 2020",,"July 22, 2021","Clinical Trial Site, Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04526210"
97,"NCT04526197","Phase 1 Study of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy Participants.",,"Completed","No Results Available","Wilson Disease","Drug: ALXN1840|Drug: Celecoxib","Maximum Observed Plasma Concentration (Cmax) Of Celecoxib With And Without The Coadministration Of ALXN1840|Area Under The Plasma Concentration Versus Time Curve From Time 0 To The Last Quantifiable Concentration (AUCt) Of Celecoxib With And Without The Coadministration Of ALXN1840|Area Under The Plasma Concentration Versus Time Curve From Time 0 To Infinity (AUCinf) Of Celecoxib With And Without The Coadministration Of ALXN1840|Cmax Of Molybdenum With Coadministration Of Celecoxib|AUCt Of Molybdenum With Coadministration Of Celecoxib|AUCinf Of Molybdenum With Coadministration Of Celecoxib","Alexion Pharmaceuticals","All","18 Years to 50 Years   (Adult)","Phase 1","36","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ALXN1840-HV-105","July 8, 2020","November 3, 2020","November 3, 2020","August 25, 2020",,"November 9, 2021","Clinical Trial Site, Austin, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04526197"
98,"NCT04451434","Study of Danicopan in Participants of Japanese Descent",,"Completed","No Results Available","Healthy","Drug: Danicopan","Number Of Participants With Treatment-Emergent Adverse Events|Area Under The Concentration Versus Time Curve (AUC) Of Danicopan In Both Fed And Fasted States|Maximum Observed Concentration (Cmax) Of Danicopan In Both Fed And Fasted States|Time To Maximum Observed Concentration (Tmax) Of Danicopan In Both Fed And Fasted States|Dose Proportionality Of Danicopan In Fed State Assessed by AUC|Dose Proportionality Of Danicopan In Fed State Assessed by Cmax|Activity Of Danicopan As Measured By Alternative Pathway Wieslab Assay|Complement Factor B Fraction b Levels","Alexion Pharmaceuticals","All","18 Years to 55 Years   (Adult)","Phase 1","9","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ALXN2040-HV-101","August 17, 2020","September 28, 2020","September 28, 2020","June 30, 2020",,"February 15, 2021","Clinical Study Site, Brisbane, Australia",,"https://ClinicalTrials.gov/show/NCT04451434"
99,"NCT04369469","Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia",,"Terminated","No Results Available","COVID-19 Severe Pneumonia|Acute Lung Injury|Acute Respiratory Distress Syndrome|Pneumonia, Viral","Biological: Ravulizumab|Other: Best Supportive Care","Survival (based on all-cause mortality) at Day 29|Number of days free of mechanical ventilation at Day 29|Duration of intensive care unit stay at Day 29|Change from baseline in Sequential Organ Failure Assessment at Day 29|Change from baseline in SpO2/FiO2 at Day 29|Duration of hospitalization at Day 29|Survival (based on all-cause mortality) at Day 60 and Day 90","Alexion Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","202","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ALXN1210-COV-305","May 11, 2020","February 8, 2021","April 8, 2021","April 30, 2020",,"September 22, 2021","Central Arkansas Veterans Healthcare System, Little Rock, Arkansas, United States|LAC/USC Health Center, Los Angeles, California, United States|UC Irvine Medical Center, Orange, California, United States|MedStar Georgetown University Hospital, Washington, District of Columbia, United States|University of Florida, Jacksonville, Florida, United States|Mayo Clinic Florida, Jacksonville, Florida, United States|Rush University Medical Center, Chicago, Illinois, United States|Norton Healthcare, Louisville, Kentucky, United States|Baltimore VA Medical Center, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Boston Medical Center, Boston, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Mayo Clinic Health System, Mankato, Minnesota, United States|Mayo Clinic, Rochester, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|NYU Langone Health Center, New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Westchester Medical Center, Valhalla, New York, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Baptist Memorial Hospital, Memphis, Tennessee, United States|Houston Methodist Hospital, Houston, Texas, United States|Mayo Clinic Health System in Eau Claire, Eau Claire, Wisconsin, United States|Mayo Clinic Health System, La Crosse, Wisconsin, United States|Hôpital Raymond Poincaré, Garches, Hauts De Seine, France|Hôpital Henri Mondor, Créteil, Val De Marne, France|Hôpital Bicêtre, Le Kremlin-Bicêtre cedex, Val De Marne, France|Medical Hospital, Tokyo Medical and Dental University, Bunkyō-Ku, Tokyo-To, Japan|Jikei University Hospital, Minato-Ku, Tokyo, Japan|Tokyo Medical University Hospital, Shinjuku-Ku, Tokyo, Japan|Hospital Universitari de Bellvitge, L'Hospitalet De Llobregat, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Clinic de Barcelona, Barcelona, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|King's College Hospital, London, Greater London, United Kingdom|Hammersmith Hospital, London, Greater London, United Kingdom|Royal Liverpool University Hospital, Liverpool, Merseyside, United Kingdom|Queen Elizabeth Hospital, Birmingham, West Midlands, United Kingdom|St James's University Hospital, Leeds, West Yorkshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04369469"
100,"NCT04355494","SOLIRIS® (Eculizumab) Treatment of Participants With COVID-19",,"No longer available","No Results Available","COVID-19|Pneumonia, Viral|Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)","Biological: eculizumab",,"Alexion Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)",,,"Industry","Expanded Access:Intermediate-size Population",,"ECU-COV-401",,,,"April 21, 2020",,"March 9, 2021","Cedars-Sinai Medical Center, Los Angeles, California, United States|Boston Medical Center, Boston, Massachusetts, United States|Newton-Wellesley Hospital, Newton, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Hôpital Henri Mondor, Creteil, France|Hôpital Garches Raymond Poincaré, Garches, France|Hôpital de Bicêtre, Le Kremlin Bicêtre, France|Hôpital Saint Louis, Paris, France|Hôpital Paul Brousse, Villejuif, France",,"https://ClinicalTrials.gov/show/NCT04355494"
101,"NCT04320602","Ravulizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Currently Treated With High-Dose Eculizumab",,"Active, not recruiting","No Results Available","Paroxysmal Nocturnal Hemoglobinuria","Biological: Eculizumab|Biological: Ravulizumab","Proportion Of Participants Who Experience Free Complement Component 5 (C5)-associated Breakthrough Hemolysis (BTH)|Proportion Of Participants Who Experience BTH|Hemolysis As Directly Measured By Lactate Dehydrogenase (LDH) Percent Change From Baseline To Day 351|Proportion Of Participants Who Receive A Transfusion|Proportion Of Participants With Stabilized Hemoglobin","Alexion Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 4","20","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ALXN1210-PNH-401|2019-003440-74","March 26, 2021","November 30, 2022","November 30, 2022","March 25, 2020",,"September 27, 2021","Clinical Study Site, Leeds, United Kingdom|Clinical Study Site, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04320602"
102,"NCT04248465","An Efficacy and Safety Study of Ravulizumab in ALS Participants",,"Terminated","No Results Available","Amyotrophic Lateral Sclerosis|ALS","Drug: Placebo|Biological: Ravulizumab","Change From Baseline In Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) Total Score|Time To Ventilator Assistance-free Survival|Change From Baseline In Slow Vital Capacity|Incidence Of Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events, And TEAEs Leading To Study Drug Discontinuation|Change From Baseline In Muscle Strength As Assessed By Handheld Dynamometry|Change From Baseline In Serum Neurofilament Light Chain","Alexion Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","382","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ALXN1210-ALS-308|2019-004619-30","March 30, 2020","October 17, 2021","October 17, 2021","January 30, 2020",,"November 30, 2021","Barrow Neurological Institute, Phoenix, Arizona, United States|Neuromuscular Research Center and Clinic, Phoenix, Arizona, United States|HonorHealth Research Institute, Scottsdale, Arizona, United States|Loma Linda University Medical Center, Loma Linda, California, United States|University of Southern California, Los Angeles, California, United States|University of California-Irvine, Orange, California, United States|Stanford University Medical Center, Palo Alto, California, United States|University of California San Diego Medical Center, San Diego, California, United States|Norris MDA/ALS Center, San Francisco, California, United States|University of California San Francisco Medical Center, San Francisco, California, United States|University of Colorado Anschutz Medical Campus School of Medicine, Aurora, Colorado, United States|University of Florida at Shands Jacksonville, Jacksonville, Florida, United States|University of South Florida, Tampa, Florida, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Indiana University Medical Center, Indianapolis, Indiana, United States|University of Kansas Medical Center Research Institute, Inc., Kansas City, Kansas, United States|University of Kentucky, Lexington, Kentucky, United States|Johns Hopkins University School Of Medicine, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Las Vegas Clinic, Las Vegas, Nevada, United States|Beth Israel Medical Center - PRIME, New York, New York, United States|Hospital for Special Surgery, New York, New York, United States|Atrium Health Neuroscience Institute, Charlotte, North Carolina, United States|The Cleveland Clinic Foundation, Cleveland, Ohio, United States|The Ohio State University, Columbus, Ohio, United States|Allegheny Neurological Associates, Pittsburgh, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Austin Neuromuscular Center, Austin, Texas, United States|Houston Methodist Neurological Institute-Movement Disorders Clinic, Houston, Texas, United States|Nerve & Muscle Center of Texas, Houston, Texas, United States|University of Vermont Medical Center, Burlington, Vermont, United States|Virginia Commonwealth University, Neurology Clinical and Translational Research Office, Richmond, Virginia, United States|Sentara Neurology Specialists, Virginia Beach, Virginia, United States|Swedish Neuroscience Institute, Seattle, Washington, United States|Brain and Mind Centre, Camperdown, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|Perron Institute for Neurological and Translational Science, Nedlands, Western Australia, Australia|UZ Leuven, Leuven, Belgium|Heritage Medical Research Centre (HMRC), Edmonton, Alberta, Canada|Stan Cassidy Center for Rehabilitation, Fredericton, New Brunswick, Canada|LHSC - University Hospital, London, Ontario, Canada|Toronto Sunnybrook Hospital, Toronto, Ontario, Canada|Montreal Neurological Institute and Hospital, Montreal, Quebec, Canada|University Hospital of Quebec-Universite Laval, Québec, Quebec, Canada|Royal University Hospital, Saskatoon, Saskatchewan, Canada|Ålborg Universitets Hospital, Aalborg, Denmark|Aarhus University Hospital Department of Neurology, Aarhus, Denmark|Bispebjerg Hospital, Copenhagen, Denmark|CHU de Nice Hôpital Pasteur 2, Nice Cedex 1, Alpes Maritimes, France|CHU de Limoges - Hôpital Dupuytren, Limoges cedex, Haute Vienne, France|Hopital Gui de Chauliac, Montpellier, Herault, France|CHU Tours - Hôpital Bretonneau, Tours Cedex 9, Indre Et Loire, France|Hopital Neurologique Pierre Wertheimer, Bron cedex, Rhone, France|Hopital Roger Salengro - CHU Lille, Lille, France|Hôpital de la Timone, Marseille, France|Groupe Hospitalier Pitie-Salpetriere, Paris cedex 13, France|Universitaetsklinikum Ulm, Ulm, Baden Wuerttemberg, Germany|Klinikum rechts der Isar der TU Muenchen, Muenchen, Bayern, Germany|Universitaetsmedizin Goettingen, Goettigen, Niedersachsen, Germany|Medizinische Hochschule Hannover, Hannover, Niedersachsen, Germany|Universitaetsklinikum Jena, Jena, Thueringen, Germany|Beaumont Hospital, Dublin, Ireland|Rambam Health Care Center, Haifa, Israel|Hadassah University Hospital - Ein Kerem, Jerusalem, Israel|Tel Aviv Sourasky Medical Center, Tel Aviv, Israel|Ospedale San Raffaele, Milano, Italy|ICS Maugeri IRCCS, Milano, Italy|Istituto Auxologico Italiano, Milano, Italy|Azienda Ospedaliero-Universitaria di Modena - Ospedale Civile di Baggiovara, Modena, Italy|Azienda Ospedaliero Universitaria Policlinico Paolo Giaccone, Palermo, Italy|Azienda Ospedaliero Universitaria Pisana, Pisa, Italy|University of Turin, Torino, Italy|Nagoya University Hospital, Nagoya-shi, Aichi-Ken, Japan|Chiba University Hospital, Chiba-shi, Chiba-Ken, Japan|Yoshino Neurology Clinic, Ichikawa-shi, Chiba-Ken, Japan|Tohoku University Hospital, Sendai-shi, Miyagi-Ken, Japan|Niigata University Medical & Dental Hospital, Niigata-shi, Niigata-Ken, Japan|Shiga University of Medical Science Hospital, Ōtsu, Shiga-Ken, Japan|Tokushima University Hospital, Tokushima-shi, Tokushima-Ken, Japan|Medical Hospital, Tokyo Medical and Dental University, Bunkyo-ku, Tokyo-To, Japan|Toho University Omori Medical Center, Ota-ku, Tokyo-To, Japan|Keio University Hospital, Shinjuku-Ku, Tokyo-To, Japan|University Medical Centre Utrecht, Utrecht, Netherlands|CityClinic, Warszawa, Poland|Hospital Universitari de Bellvitge, L'Hospitalet De Llobregat, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital San Rafael, Madrid, Spain|Hospital Universitari i Politecnic La Fe, Valencia, Spain|Karolinska Trial Alliance (KTA), Huddinge, Sweden|Norrlands universitetssjukhus, Umeå, Sweden|Kantonsspital St. Gallen, Saint Gallen, Switzerland|The National Hospital for Neurology & Neurosurgery, London, Greater London, United Kingdom|Royal Hallamshire Hospital, Sheffield, West Midlands, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04248465"
103,"NCT04233073","Trial of Andexanet in Patients Receiving an Oral FXa Inhibitor Who Require Urgent Surgery","Annexa-S","Terminated","No Results Available","Surgery","Drug: andexanet alfa","Proportion of patients with good or excellent intraoperative hemostatic efficacy as determined by the surgeon's assessment and confirmed by an independent adjudication committee|Percent change from baseline in anti-fXa activity","Alexion Pharmaceuticals","All","18 Years to 84 Years   (Adult, Older Adult)","Phase 2","10","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19-515","May 11, 2021","November 23, 2021","January 25, 2022","January 18, 2020",,"March 7, 2022","University of Arizona-Banner Health-Phoenix, Phoenix, Arizona, United States|University of Arizona-Banner Health-Tucson, Tucson, Arizona, United States|Long Beach Medical Center, Long Beach, California, United States|Riverside University Healthcare System, Moreno Valley, California, United States|George Washington University, Washington, District of Columbia, United States|Intercoastal Medical Group, Sarasota, Florida, United States|Tampa General Hospital, Tampa, Florida, United States|University of Iowa, Iowa City, Iowa, United States|Tufts University Medical Center, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Cooper University Hospital, Camden, New Jersey, United States|Northwell Health System, Staten Island, New York, United States|Carolinas Medical Center - Atrium Health, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Wexner Medical Center at The Ohio State University, Columbus, Ohio, United States|Ascension St. John Clinical Research Institute, Tulsa, Oklahoma, United States|Oregon Health Science Center, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Allegehny Health Network Allegheny General Hosptial, Pittsburgh, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|LKH-Universitätsklinikum Graz, Graz, Austria|Medizinische Universität Innsbruck, Innsbruck, Austria|Klinikum Klagenfurt am Wörthersee, Klagenfurt am Wörthersee, Austria|Medizinische Universität Wien - AKH, Wien, Austria|CHU de Clermont-Ferrand, Clermont-Ferrand, France|CHU Dijon-Bourgogne, Dijon, France|CHU de Lille, Lille, France|CHU Nantes, Hôtel Dieu, Nantes, France|Hôpital Saint-Antoine, Paris, France|Hôpital Cochin, Paris, France|Universitätsklinikum RWTH Aachen, Aachen, Germany|Universitätsklinikum Bonn, Bonn, Germany|Klinikum Dortmund gGmbH, Dortmund, Germany|Universitätsklinikum Freiburg, Freiburg, Germany|Universitätsklinikum Giessen, Gießen, Germany|Universitätsklinikum Heidelberg, Heidelberg, Germany|Klinikum Konstanz, Konstanz, Germany|Kliniken der Stadt Köln gGmbH, Köln, Germany|Katholisches Klinikum Mainz, Mainz, Germany|BG Unfallklinik Murnau, Murnau Am Staffelsee, Germany|Universitätsklinikum Würzburg, Würzburg, Germany|Barzilai Medical Center, Ashkelon, Israel|Rambam Medical Center, Haifa, Israel|Shaare Zedek Medical Center, Jerusalem, Israel|Hadassah Medical Center, Jerusalem, Israel|Rabin Medical Center, Petah Tikva, Israel|Shonan Kamakura General Hospital, Kamakura, Japan|Fukuoka Tokushukai Hospital, Kasuga, Japan|St. Marianna University School of Medicine Hospital, Kawasaki, Japan|National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan|Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan|St.Mary's Hospital, Kurume, Japan|Japanese Red Cross Nagoya Daini Hospital, Nagoya, Japan|Sakai City Medical Center, Sakai, Japan|Tohoku University Hospital, Sendai, Japan|Nippon Medical School Hospital, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT04233073"
104,"NCT04201262","An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD",,"Active, not recruiting","No Results Available","Neuromyelitis Optica|Neuromyelitis Optica Spectrum Disorder","Biological: Ravulizumab","Time To First Adjudicated On-Trial Relapse|Incidence Of Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events, And TEAEs Leading To Study Drug Discontinuation|Adjudicated On-Trial Annualized Relapse Rate|Clinically Important Worsening In Expanded Disability Status Scale","Alexion Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","58","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ALXN1210-NMO-307|CHAMPION-NMO-307","December 13, 2019","April 30, 2022","July 31, 2024","December 17, 2019",,"February 21, 2022","Clinical Study Site, Birmingham, Alabama, United States|Clinical Study Site, Mobile, Alabama, United States|Clinical Study Site, Carlsbad, California, United States|Clinical Study Site, Aurora, Colorado, United States|Clinical Study Site, Fort Collins, Colorado, United States|Clinical Study Site, Washington, District of Columbia, United States|Clinical Study Site, Miami, Florida, United States|Clinical Study Site, Atlanta, Georgia, United States|Clinical Study Site, Rolling Meadows, Illinois, United States|Clinical Study Site, Kansas City, Kansas, United States|Clinical Study Site, Lexington, Kentucky, United States|Clinical Study Site, Boston, Massachusetts, United States|Clinical Study Site, Rochester, Minnesota, United States|Clinical Study Site, Jackson, Mississippi, United States|Clinical Study Site, Saint Louis, Missouri, United States|Clinical Study Site, Chapel Hill, North Carolina, United States|Clinical Study Site, Winston-Salem, North Carolina, United States|Clinical Study Site, Cincinnati, Ohio, United States|Clinical Study Site, Dallas, Texas, United States|Clinical Study Site, Houston, Texas, United States|Clinical Study Site, Round Rock, Texas, United States|Clinical Study Site, Camperdown, New South Wales, Australia|Clinical Study Site, New Lambton Heights, New South Wales, Australia|Clinical Study Site, Parkville, Victoria, Australia|Clinical Study Site, Fitzroy, Australia|Clinical Study Site, Wien, Austria|Clinical Study Site, Burnaby, British Columbia, Canada|Clinical Study Site, Edmonton, Canada|Clinical Study Site, Aarhus, Denmark|Clinical Study Site, Bron Cedex, France|Clinical Study Site, Montpellier, France|Clinical Study Site, Nîmes, France|Clinical Study Site, Strasbourg, France|Clinical Study Site, Berlin, Germany|Clinical Study Site, Dresden, Germany|Clinical Study Site, Leipzig, Germany|Clinical Study Site, Muenchen, Germany|Clinical Study Site, Cefalu, Italy|Clinical Study Site, Gallarate, Italy|Clinical Study Site, Napoli, Italy|Clinical Study Site, Orbassano, Italy|Clinical Study Site, Roma, Italy|Clinical Study Site, Roma, Italy|Clinical Study Site, Chiba, Japan|Clinical Study Site, Fukuoka-shi, Japan|Clinical Study Site, Kawagoe-shi, Japan|Clinical Study Site, Niigata-shi, Japan|Clinical Study Site, Sendai-shi, Japan|Clinical Study Site, Sendai, Japan|Clinical Study Site, Goyang-si, Korea, Republic of|Clinical Study Site, Seoul, Korea, Republic of|Clinical Study Site, Seoul, Korea, Republic of|Clinical Study Site, Seoul, Korea, Republic of|Clinical Study Site, Seoul, Korea, Republic of|Clinical Study Site, Seoul, Korea, Republic of|Clinical Study Site, Seoul, Korea, Republic of|Clinical Study Site, Katowice, Poland|Clinical Study Site, Katowice, Poland|Clinical Study Site, Lodz, Poland|Clinical Study Site, Barakaldo, Spain|Clinical Study Site, Barcelona, Spain|Clinical Study Site, Barcelona, Spain|Clinical Study Site, Madrid, Spain|Clinical Study Site, Madrid, Spain|Clinical Study Site, Malaga, Spain|Clinical Study Site, Valencia, Spain|Clinical Study Site, Liverpool, United Kingdom|Clinical Study Site, Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04201262"
105,"NCT04195763","Patient Reported Outcomes in Adults With Pediatric-onset Hypophosphatasia Treated With Strensiq® (Asfotase Alfa)",,"Unknown status","No Results Available","Hypophosphatasia","Drug: asfotase alfa","Change From Baseline In Patient Reported Outcomes (PROs) Questionnaire Scores","Alexion Pharmaceuticals|Xcenda, LLC","All","18 Years and older   (Adult, Older Adult)",,"100","Industry|Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","ALX-HPP-503","November 6, 2019","December 2021","December 2021","December 12, 2019",,"December 12, 2019","Xcenda, LLC, Palm Harbor, Florida, United States",,"https://ClinicalTrials.gov/show/NCT04195763"
106,"NCT04189315","Relieving Burden of Hypophosphatasia in Adults With Functional Impairment Due to Chronic Disease","REBUILD","Withdrawn","No Results Available","Hypophosphatasia","Drug: asfotase alfa","Change From Baseline To Week 36 In Plasma Concentrations Of Inorganic Pyrophosphate (PPi) In Group 1|Change From Baseline To Week 36 In Plasma Concentrations Of PPi In Group 2|Change From Baseline To Week 36 In The 36-item Short-Form Survey (SF-36) Physical Component Summary (PCS) Score In Groups 1 And 2|Change From Baseline To Week 36 In The Repeated Chair Stand Test (A Component Of The Short Physical Performance Battery [SPPB]) In Groups 1 And 2","Alexion Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 4","0","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AA-HPP-406","April 2020","August 2022","August 2022","December 6, 2019",,"June 4, 2020",,,"https://ClinicalTrials.gov/show/NCT04189315"
107,"NCT03920293","Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis",,"Active, not recruiting","No Results Available","Generalized Myasthenia Gravis","Biological: Ravulizumab|Drug: Placebo","Change From Baseline In Myasthenia Gravis-Activities Of Daily Living (MG-ADL) Total Score At Week 26|Change From Baseline In The Quantitative Myasthenia Gravis (QMG) Total Score At Week 26|Change From Baseline In the Revised 15 Component Myasthenia Gravis Quality of Life (MG-QOL15r) At Week 26|Change From Baseline In The Myasthenia Gravis Activities of Daily Living (MG-ADL) Total Score of at least 3 points At Week 26|Change From Baseline In the The Quantitative Myasthenia Gravis (QMG) total score by at least 5 points At Week 26","Alexion Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","175","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","ALXN1210-MG-306|2018-003243-39","March 26, 2019","May 11, 2021","December 31, 2023","April 18, 2019",,"September 20, 2021","Clinical Trial Site, Phoenix, Arizona, United States|Clinical Trial Site, Phoenix, Arizona, United States|Clinical Trial Site, Phoenix, Arizona, United States|Clinical Trial Site, Loma Linda, California, United States|Clinical Trial Site, Los Angeles, California, United States|Clinical Trial Site, Orange, California, United States|Clinical Trial Site, Palo Alto, California, United States|Clinical Trial Site, San Francisco, California, United States|Clinical Trial Site, Sylmar, California, United States|Clinical Trial Site, Aurora, Colorado, United States|Clinical Trial Site, Colorado Springs, Colorado, United States|Clinical Trial Site, Fort Collins, Colorado, United States|Clinical Trial Site, New Haven, Connecticut, United States|Clinical Trial Site, Washington, District of Columbia, United States|Clinical Trial Site, Clearwater, Florida, United States|Clinical Trial Site, Jacksonville, Florida, United States|Clinical Trial Site, Tampa, Florida, United States|Clinical Trial Site, Atlanta, Georgia, United States|Clinical Trial Site, Augusta, Georgia, United States|Clinical Trial Site, Chicago, Illinois, United States|Clinical Trial Site, Chicago, Illinois, United States|Clinical Trial Site, Rolling Meadows, Illinois, United States|Clinical Trial Site, Indianapolis, Indiana, United States|Clinical Trial Site, Fairway, Kansas, United States|Clinical Trial Site, Lexington, Kentucky, United States|Clinical Trial Site, Lexington, Kentucky, United States|Clinical Trial Site, Baltimore, Maryland, United States|Clinical Trial Site, Boston, Massachusetts, United States|Clinical Trial Site, Burlington, Massachusetts, United States|Clinical Trial Site, East Lansing, Michigan, United States|Clinical Trial Site, Grand Rapids, Michigan, United States|Clinical Trial Site, Detroit Lakes, Minnesota, United States|Clinical Trial Site, Columbia, Missouri, United States|Clinical Trial Site, Saint Louis, Missouri, United States|Clinical Trial Site, Las Vegas, Nevada, United States|Clinical Trial Site, Las Vegas, Nevada, United States|Clinical Trial Site, East Setauket, New York, United States|Clinical Trial Site, Great Neck, New York, United States|Clinical Trial Site, New York, New York, United States|Clinical Trial Site, New York, New York, United States|Clinical Trial Site, Chapel Hill, North Carolina, United States|Clinical Trial Site, Charlotte, North Carolina, United States|Clinical Trial Site, Durham, North Carolina, United States|Clinical Trial Site, Cincinnati, Ohio, United States|Clinical Trial Site, Cleveland, Ohio, United States|Clinical Trial Site, Cleveland, Ohio, United States|Clinical Trial Site, Columbus, Ohio, United States|Clinical Trial Site, Columbus, Ohio, United States|Clinical Trial Site, Springfield, Oregon, United States|Clinical Trial Site, Hershey, Pennsylvania, United States|Clinical Trial Site, Philadelphia, Pennsylvania, United States|Clinical Trial Site, Philadelphia, Pennsylvania, United States|Clinical Trial Site, Charleston, South Carolina, United States|Clinical Trial Site, Charleston, South Carolina, United States|Clinical Trial Site, Cordova, Tennessee, United States|Clinical Trial Site, Nashville, Tennessee, United States|Clinical Trial Site, Austin, Texas, United States|Clinical Trial Site, Dallas, Texas, United States|Clinical Trial Site, Houston, Texas, United States|Clinical Trial Site, Round Rock, Texas, United States|Clinical Trial Site, San Antonio, Texas, United States|Clinical Trial Site, Burlington, Vermont, United States|Clinical Trial Site, Richmond, Virginia, United States|Clinical Trial Site, Seattle, Washington, United States|Clinical Trial Site, Morgantown, West Virginia, United States|Clinical Trial Site, Milwaukee, Wisconsin, United States|Clinical Trial Site, Wien, Austria|Clinical Trial Site, Calgary, Alberta, Canada|Clinical Trial Site, Edmonton, Alberta, Canada|Clinical Trial Site, London, Ontario, Canada|Clinical Trial Site, Toronto, Ontario, Canada|Clinical Trial Site, Montreal, Canada|Clinical Trial Site, Prague, Czech Republic, Czechia|Clinical Trial Site, Ostrava, Moravian-Silesian, Czechia|Clinical Trial Site, Brno, Czechia|Clinical Trial Site, Prague, Czechia|Clinical Trial Site, Copenhagen, Hovedstaden, Denmark|Clinical Trial Site, Aarhus N, Jutland, Denmark|Clinical Trial Site, Aalborg, North Jutland Region, Denmark|Clinical Trial Site, Lille, Cedex, France|Clinical Trial Site, Marseille, Provence-Alpes-Cote d'Azur, France|Clinical Trial Site, Nice, Provence-Alpes-Cote d'Azur, France|Clinical Trial Site, Garches, France|Clinical Trial Site, Würzburg, Bavaria, Germany|Clinical Trial Site, Essen, Nordrhein-Westfalen, Germany|Clinical Trial Site, Münster, Nordrhein-Westfalen, Germany|Clinical Trial Site, Halle, Sachsen-Anhalt, Germany|Clinical Trial Site, Leipzig, Saxony, Germany|Clinical Trial Site, Berlin, Germany|Clinical Trial Site, Hamburg, Germany|Clinical Trial Site, Hannover, Germany|Clinical Trial Site, Haifa, Hefa, Israel|Clinical Trial Site, Tel Aviv-Yafo, Tel-Aviv, Israel|Clinical Trial Site, Bologna, Emilia-Romagna, Italy|Clinical Trial Site, Genova, Genoa, Italy|Clinical Trial Site, Milan, Lombardia, Italy|Clinical Trial Site, Bergamo, Roma, Italy|Clinical Trial Site, Rome, Roma, Italy|Clinical Trial Site, Rome, Roma, Italy|Clinical Trial Site, Messina, Sicilia, Italy|Clinical Trial Site, Nagoya-shi, Aichi, Japan|Clinical Trial Site, Chuo Ku, Chiba, Japan|Clinical Trial Site, Fukuoka-shi, Fukuoka, Japan|Clinical Trial Site, Sapporo-shi, Hokkaido, Japan|Clinical Trial Site, Kanazawa-shi, Ishikawa, Japan|Clinical Trial Site, Sendai-shi, Miyagi, Japan|Clinical Trial Site, Nagasaki-shi, Nagasaki, Japan|Clinical Trial Site, Niigata-shi, Niigata, Japan|Clinical Trial Site, Izumi-Shi, Osaka, Japan|Clinical Trial Site, Moriguchi-shi, Osaka, Japan|Clinical Trial Site, Osaka Sayama-shi, Osaka, Japan|Clinical Trial Site, Suita-shi, Osaka, Japan|Clinical Trial Site, Toyonaka-shi, Osaka, Japan|Clinical Trial Site, Kawagoe-shi, Saitama, Japan|Clinical Trial Site, Sapporo-shi, Sapporo, Japan|Clinical Trial Site, Bunkyō-Ku, Tokyo, Japan|Clinical Trial Site, Bunkyō-Ku, Tokyo, Japan|Clinical Trial Site, Shinjuku-Ku, Tokyo, Japan|Clinical Trial Site, Ube-shi, Yamaguchi, Japan|Clinical Trial Site, Hanamaki-shi, Japan|Clinical Trial Site, Tokyo, Japan|Clinical Trial Site, Yangsan, Gyeongsangnam-do, Korea, Republic of|Clinical Trial Site, Daegu, Korea, Republic of|Clinical Trial Site, Seoul, Korea, Republic of|Clinical Trial Site, Seoul, Korea, Republic of|Clinical Trial Site, Seoul, Korea, Republic of|Clinical Trial Site, Seoul, Korea, Republic of|Clinical Trial Site, Seoul, Korea, Republic of|Clinical Trial Site, Seoul, Korea, Republic of|Clinical Trial Site, Amsterdam, Noord-Holland, Netherlands|Clinical Trial Site, Leiden, Noord-Holland, Netherlands|Clinical Trial Site, Porto, Portugal|Clinical Trial Site, Barakaldo, Bizkaia, Spain|Clinical Trial Site, Barcelona, Spain|Clinical Trial Site, Barcelona, Spain|Clinical Trial Site, Barcelona, Spain|Clinical Trial Site, Barcelona, Spain|Clinical Trial Site, Madrid, Spain|Clinical Trial Site, Madrid, Spain|Clinical Trial Site, Madrid, Spain|Clinical Trial Site, Murcia, Spain|Clinical Trial Site, Valencia, Spain|Clinical Trial Site, Zürich, Switzerland",,"https://ClinicalTrials.gov/show/NCT03920293"
108,"NCT03759366","A Phase 3 Open-Label Study of Eculizumab in Pediatric Participants With Refractory Generalized Myasthenia Gravis (gMG)",,"Active, not recruiting","No Results Available","Myasthenia Gravis|Myasthenia Gravis, Juvenile Form|Myasthenia Gravis, Generalized","Drug: Eculizumab","Change From Baseline In The QMG Total Score Over Time Regardless Of Rescue Treatment|Change From Baseline In The Myasthenia Gravis-Activities Of Daily Living (MG-ADL) Score Over Time Regardless Of Rescue Treatment|Change From Baseline In The MG Composite (MGC) Score Over Time Regardless Of Rescue Treatment|Change From Baseline In European Quality Of Life 5-Dimension Youth (EQ-5D-Y) Score Over Time Regardless Of Rescue Treatment|Change From Baseline In Neurological Quality Of Life (Neuro-QoL) Pediatric Fatigue Score Over Time Regardless Of Rescue Treatment|Myasthenia Gravis Foundation Of America (MGFA) Post-Interventional Status Over Time Regardless Of Rescue Treatment|Number Of Participants With Clinical Deteriorations, Myasthenic Crises, And Rescue Therapy Use Over Time|Pharmacokinetics: Plasma Concentration Of Eculizumab Over Time|Free Complement Component 5 (C5) Concentrations Over Time|Percentage Of Hemolysis (In Vitro Assay) Over Time","Alexion Pharmaceuticals","All","6 Years to 17 Years   (Child)","Phase 3","11","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ECU-MG-303","December 21, 2018","January 22, 2022","July 31, 2025","November 30, 2018",,"October 29, 2021","Clinical Trial Site, Los Angeles, California, United States|Clinical Trial Site, Tampa, Florida, United States|Clinical Trial Site, Chicago, Illinois, United States|Clinical Trial Site, Columbia, Missouri, United States|Clinical Trial Site, Saint Louis, Missouri, United States|Clinical Trial Site, Chapel Hill, North Carolina, United States|Clinical Trial Site, Akron, Ohio, United States|Clinical Trial Site, Philadelphia, Pennsylvania, United States|Clinical Trial Site, Charleston, South Carolina, United States|Clinical Trial Site, Chiba-shi, Chiba-Ken, Japan|Clinical Trial Site, Saitama, Iruma-gun, Japan|Clinical Trial Site, Tokyo, Itabasha-ku, Japan|Clinical Trial Site, Tokyo, Shinjuku-ku, Japan|Clinical Trial Site, Mibu, Tochigi, Japan|Clinical Trial Site, Amsterdam, Netherlands|Clinical Trial Site, Leiden, Netherlands",,"https://ClinicalTrials.gov/show/NCT03759366"
109,"NCT03661528","Trial of Andexanet Alfa in ICH Patients Receiving an Oral FXa Inhibitor",,"Recruiting","No Results Available","Acute Intracranial Hemorrhage","Drug: andexanet alfa|Drug: Usual Care","Proportion of patients with good or excellent hemostatic efficacy as rated by an independent adjudication committee|Change from baseline in anti-fXa activity","Alexion Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 4","1200","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","18-513","June 6, 2019","May 31, 2024","July 30, 2024","September 7, 2018",,"January 26, 2022","Dignity Health/Barrow Neurological Institute, Phoenix, Arizona, United States|University of Arizona, Tucson, Arizona, United States|University of California Irvine, Orange, California, United States|Holy Cross Hospital, Fort Lauderdale, Florida, United States|Sacred Heart Hospital, Pensacola, Florida, United States|Tampa General Hospital, Tampa, Florida, United States|Loyola University Medical Center, Maywood, Illinois, United States|University of Iowa, Iowa City, Iowa, United States|Anne Arundel Medical Center, Annapolis, Maryland, United States|Wayne State University, Detroit, Michigan, United States|Ascension St. John Hospital, Detroit, Michigan, United States|Beaumont Hospital - Royal Oak, Royal Oak, Michigan, United States|Beaumont Health, Troy, Michigan, United States|University of Missouri, Columbia, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Albany Medical Center Hospital, Albany, New York, United States|Harrington Heart & Vascular Institute, Cleveland, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Ascension St. John Clinical Research Institute, Tulsa, Oklahoma, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania, United States|Allegheny Health Network, Pittsburgh, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Seton Medical Center - Austin, Austin, Texas, United States|Dell Seton Medical Center, Austin, Texas, United States|Marshall Health, Huntington, West Virginia, United States|Medizinische Universität Innsbruck, Innsbruck, Austria|Klinikum Klagenfurt, Abteilung für Neurologie, Klagenfurt, Austria|Kepler Universitätsklinikum, Neuromed Campus, Linz, Austria|Kepler Universitätsklinikum, Med. Campus II., Linz, Austria|Christian-Doppler Klinik, Landeskliniken Salzburg, Universitätsklinik für Neurologie, Salzburg, Austria|Universitätsklinikum St. Pölten, Neurologie, St. Polten, Austria|Krankenhaus der Barmherzige Brüder KH Wien, Neurologie, Wien, Austria|Medizinische Universität Wien, Neurologie, Wien, Austria|UZ Gent, Neurologie, Brugge, Belgium|Cliniques Universitaires, Brussels, Belgium|Ziekenhuis Oost-Limburg campus St-Jan, Neurologie, Genk, Belgium|AZ Groeninge, Kortrijk, Belgium|UZ Leuven campus Gasthuisberg, Leuven, Belgium|Clinique Saint-Pierre, Ottignies, Belgium|University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada|University of Alberta Hospital, Edmonton, Alberta, Canada|Royal Columbian Hospital, New Westminster, British Columbia, Canada|University of British Columbia, Vancouver, British Columbia, Canada|Hamilton General Hospital, Hamilton, Ontario, Canada|London Health Sciences Centre, London, Ontario, Canada|Montreal Neurological Institute and Hospital, Montreal, Quebec, Canada|CHU de Quebec-Universite Laval, Hôpital de l'Enfant Jésus, QC, Quebec, Canada|FNusA, Brno, Czechia|Nemocnice Jihlava, Jihlava, Czechia|FN Olomouc, Olomouc, Czechia|Vitkovicka nemocnice a.s.-Neurologicke oddeleni, Ostrava, Czechia|FN Motol, Prague, Czechia|ÚVN, Prague, Czechia|Aarhus University Hospital, Aarhus, Denmark|Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark|West-Tallinn Central Hospital, Tallinn, Estonia|Tartu University Hospital, Tartu, Estonia|Helsinki University Hospital, Helsinki, Finland|Turku University Hospital, Turku, Finland|CHU d'Angers, Angers, France|CHU Bordeaux, Groupe Hospitalier Pellegrin, Bordeaux, France|Centre Hospitalier Fleyriat Service de Neurologie, Bourg-en-Bresse, France|CHU Gabriel Montpied, CHU de Clermont-Ferrand, Clermont-Ferrand, France|CHU Edouard Herriot, Anaesthesia-resuscitation, Lyon, France|Hôpital Central, Neurologie, Nancy, France|Hôpital Lariboisière, Neurologie, Paris, France|Hopital Sainte Anne, GHU Paris Psychiatrie et Neurosciences, Paris, France|Hopital Bichat, Paris, France|Fondation Ophtalmologique Rothschild - Hôpital, Neurovascular unit, Paris, France|Foch Hospital, Suresnes, France|Hôpital d'Instruction des Armées Sainte Anne, Toulon, France|CHU Purpan-Pierre Paul de Riquet, Toulouse, Intensive care-resuscitation, Toulouse, France|Klinikum Altenburger Land, Neurologie, Altenburg, Germany|Universitätsklinikum Augsburg, Augsburg, Germany|RHÖN-KLINIKUM Campus Bad Neustadt, Bad Neustadt An Der Saale, Germany|Charité Universitätsmedizin Berlin und Centrum für Schlaganfallforschung Berlin Neurologie, Berlin, Germany|Universitätsklinikum Knappschaftskrankenhaus Bochum GmbH, Bochum, Germany|Universitätsklinikum Bonn, Bonn, Germany|Klinikum Bremen-Nord, Stroke Unit, Bremen, Germany|Allgemeines Krankenhaus Celle, Celle, Germany|Klinikum Chemnitz gGmbH, Chemnitz, Germany|Klinikum Dortmund, Neurologische Klinik, Dortmund, Germany|Krankenhaus Dresden Friedrichstadt, II. Medizinische Klinik, Innere Medizin, Angiologie und Hämostaseologie, Dresden, Germany|Universitätsklinikum Carl Gustav Carus, Dresden, Germany|Universitätsklinik Erlangen, Neurologische Klinik, Erlangen, Germany|Alfried-Krupp Krankenhaus Essen, Neuologie, Essen, Germany|Universitätsklinikum Frankfurt -Zentrum der Neurologie und Neurochirurgie, Frankfurt am main, Germany|Klinikum Frankfurt - Klinik für Neurologie, Frankfurt, Germany|Universitätsmedizin Greifswald, Abteilung Transfusionsmedizin am Institut für Immunologie, Greifswald, Germany|UMG-Universitätsmedizin Göttingen, Göttingen, Germany|Asklepios Klinik Barmbek, Abteilung Neurologie, Hamburg, Germany|Universitätsklinikum Hamburg-Eppendorf Klinik und Poliklinik für Neurologie Kopf- und Neurozentrum, Hamburg, Germany|Medizinische Hochschule Hannover Klinik für Neurologie OE 7210, Hanover, Germany|Universitätsklinik Heidelberg , Neurologische Klinik, Heidelberg, Germany|Klinikum Konstanz, Konstanz, Germany|""UKSH - Klinik für Neurologie des Universitätsklinikums Schleswig-Holstein Campus Lübeck, Lubeck, Germany|Katholisches Klinikum Lünen, Lünen, Germany|Universitätsklinikum Mannheim, Neuroligische Klinik, Mannheim, Germany|Johannes Wesling Klinikum Minden, Minden, Germany|Klinikum der Universität München, Munich, Germany|Universitatsklinikum Munster, Klinik Fur Neurologie, Münster, Germany|Klinikum Osnabrück, Osnabrück, Germany|Universitätsklinikum Regensburg, Neurologie, Regensburg, Germany|Nordwest-Krankenhaus Sanderbusch gGmbH, Neurologie, Sanderbusch, Germany|Klinikum Stuttgart, Stuttgart, Germany|Universitätsklinikum Tübingen, Tübingen, Germany|RKU - Universitäts- und Rehabilitationskliniken Ulm gGmbH, Abteilung für Neurologie, Ulm, Germany|University General Hospital of Alexandroupolis, Alexandroupoli, Greece|University General Hospital of Athens ""Attikon"", Athens, Greece|University Hospital of Heraklion, Heraklion, Greece|University General Hospital of Thessaloniki ""AHEPA"", Thessaloniki, Greece|Assuta Ashdod Medical Center, Ashdod, Israel|Soroka Medical Center, Be'er Sheva, Israel|Rambam Medical Center, Haifa, Israel|Shaare Zedek Medical Center, Jerusalem, Israel|Hadassah Medical Center, Jerusalem, Israel|Rabin Medical Center, Petah tikva, Israel|The Chaim Sheba Medical Center, Ramat Gan, Israel|Sourasky Medical Center, Tel Aviv-Yafo, Israel|Azienda Unità Sanitaria Locale (AUSL) Bologna Ospedale Maggiore, Bologna, Italy|Ospedale Policlinico ""San Martino"" Clinica Neurologica Centro Ictus, Genova, Italy|U.O. Neurologia - Stroke Unit Ospedale San Raffaele Milan, Milano, Italy|Azienda Socio-Sanitaria Territoriale (ASST) Grande Ospedale Metropolitano ""Niguarda"" Dipartimento di Neuroscienze Struttura Complessa di Neurologia e Stroke Unit, Milano, Italy|Azienda Socio Sanitaria Territoriale (ASST) di Monza, Monza, Italy|Azienda Ospedaliera di Perugia Ospedale ""Santa Maria della Misericordia"" Medicina Interna Cardiovascolare e d'Urgenza Stroke Unit, Perugia, Italy|Fondazione Policlinico ""Tor Vergata"" Dipartimento di Neurologia, Roma, Italy|Azienda Ospedaliera ""San Camillo-Forlanini"" Padiglione ""Lancisi"", Roma, Italy|Policlinico ""Umberto I"" Università degli Studi di Roma ""La Sapienza"" Dipartimento di Neurologia e Psichiatria, Roma, Italy|Policlinico ""Gemelli"" Area Neuroscienze Neurologia, Roma, Italy|Azienda Ospedaliera Univresitaria Senese, Siena, Italy|Pauls Stradins Clinical University Hospital, Riga, Latvia|Riga East University Hospital, Riga, Latvia|Republican Vilnius University hospital, Vilnius, Lithuania|University Hospital Santaros klinikos, Vilnius, Lithuania|Neuroloog OLVG West, Amsterdam, Amsterdam, Netherlands|Foundation VUmc, Amsterdam, Netherlands|Academic Medical Center, Amsterdam, Netherlands|Isala Hospital, Zwolle, Netherlands|St. Olavs Hospital, Trondheim, Norway|Copernicus PL,M.Kopernik Hospital, Gdańsk, Poland|Szpital Specjalistyczny im. Sw. Lukasza, Gmina Końskie, Poland|Samodzielny Publiczny Specjalistyczny Szpital Zachodni, Grodzisk Mazowiecki, Poland|WSzS Oddzial Neurologii i Udarowy, Lublin, Poland|Samodzielny Publiczny Szpital Kliniczny Nr 4, Lublin, Poland|Holy Spirit Specialist Hospital in Sandomierz, Sandomierz, Poland|Institute of Psychiatry and Neurology, Warsaw, Poland|Masovian Brodno Hospital, Warsaw, Poland|Hospital São Sebastião, Feira, Portugal|Hospital da Senhora da Oliveira - Guimarães, Guimarães, Portugal|Hospital Egas Moniz, Lisbon, Portugal|Hospital Pedro Hispano, Senhora da Hora, Portugal|Centro Hospitalar de Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal|Hospital Universitario de Albacete, Albacete, Spain|Hospital Universitario de Cruces, Barakaldo, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Hospital Universitario de Bellvitge, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Complejo Asistencial Universitario de León, León, Spain|Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain|Hospital Ramon y Cajal, Madrid, Spain|Hospital 12 Octubre, Madrid, Spain|Complejo Hospitalario Universitario de Santiago (CHUS), Santiago de Compostela, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Hospital Universitario y Politécnico de La Fe, Valencia, Spain|University Hospital Basel, Basel, Switzerland|Universitätsklinik für Neurologie und Stroke Zentrum Inselspital, Bern, Switzerland|Kantonsspital St. Gallen, St. Gallen, Switzerland|Universitätsspital Zürich, Zurich, Switzerland|Fairfield General Hospital, Bury, United Kingdom|Addenbrooke's Hospital, Cambridge, United Kingdom|Queen Elizabeth University Hospital, Glasgow, United Kingdom|Northwick Park Hospital, Harrow, United Kingdom|Leeds General Infirmary, Leeds, United Kingdom|Leicester Royal Infirmary, Leicester, United Kingdom|St.George's Hospital, London, United Kingdom|University College London Hospitals, London, United Kingdom|The Royal Victoria Infirmary, Newcastle Upon Tyne, United Kingdom|Nottingham City Hospital, Nottingham, United Kingdom|Salford Royal Hospital, Salford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT03661528"
110,"NCT03459443","A Proof of Concept Study for a 12 Month Treatment in Patients With C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN)",,"Completed","No Results Available","C3 Glomerulonephritis|C3 Glomerulopathy|Immune Complex Membranoproliferative Glomerulonephritis|IC-MPGN|Dense Deposit Disease","Drug: Danicopan","Change From Baseline In Composite Biopsy Score At End Of Initial 12-Month Treatment Period|Participants With Reduction In Proteinuria At The End Of Initial 12-Month Treatment Period|Change From Baseline In Proteinuria At End Of Initial 12-Month Treatment Period|Percent Change From Baseline In Proteinuria At End Of Initial 12-Month Treatment Period|Slope Of Estimated Glomerular Filtration Rate (eGFR) From Baseline To End Of Initial 12-Month Treatment Period|Change From Baseline In eGFR At End Of Initial 12-Month Treatment Period|Participants With Significant Improvement In eGFR Relative To Baseline At End Of Initial 12-Month Treatment Period|Change From Baseline In eGFR Over 12 Months Of Treatment For Participants Meeting eGFR Inclusion Criteria At Study Entry|Change From Baseline In Measured GFR At The End Of The Initial 12-Month Treatment Period","Alexion Pharmaceuticals","All","12 Years to 65 Years   (Child, Adult, Older Adult)","Phase 2","22","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACH471-205","June 20, 2018","March 29, 2021","March 29, 2021","March 9, 2018",,"October 21, 2021","Clinical Study Site, Birmingham, Alabama, United States|Clinical Study Site, Stanford, California, United States|Clinical Study Site, New Haven, Connecticut, United States|Clinical Study Site, Cincinnati, Ohio, United States|Clinical Study Site, Columbus, Ohio, United States|Clinical Study Site, Philadelphia, Pennsylvania, United States|Clinical Study Site, Sydney, New South Wales, Australia|Clinical Study Site, Brisbane, Queensland, Australia|Clinical Study Site, Melbourne, Victoria, Australia|Clinical Study Site, Antwerpen, Belgium|Clinical Study Site, Ranica, Italy|Clinical Study Site, Leiden, Netherlands|Clinical Study Site, Nijmegen, Netherlands",,"https://ClinicalTrials.gov/show/NCT03459443"
111,"NCT03369236","A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G)",,"Completed","Has Results","C3 Glomerulopathy|C3 Glomerulonephritis|Dense Deposit Disease","Drug: Danicopan|Drug: Placebo","Change From Baseline In Composite Biopsy Score At Week 28|Participants With Reduction In Proteinuria At Week 28|Change From Baseline In Proteinuria At Week 28|Percent Change From Baseline In Proteinuria At Week 28|Slope Of Estimated Glomerular Filtration Rate (eGFR) From Baseline To 6 Months|Slope Of Estimated Glomerular Filtration Rate (eGFR) After Open-label Danicopan Treatment|Change From Baseline In eGFR At Week 28|Participants With Significant Improvement In eGFR Relative To Baseline At Week 28|Participants With Significant Improvement In eGFR Relative To Baseline At Week 52","Alexion Pharmaceuticals","All","17 Years to 65 Years   (Child, Adult, Older Adult)","Phase 2","13","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ACH471-204|2017-000663-33","June 12, 2018","December 11, 2019","December 18, 2020","December 11, 2017","November 4, 2021","November 4, 2021","Clinical Study Site, Aurora, Colorado, United States|Clinical Study Site, Lawrenceville, Georgia, United States|Clinical Study Site, Iowa City, Iowa, United States|Clinical Study Site, Baltimore, Maryland, United States|Clinical Study Site, New York, New York, United States|Clinical Study Site, New York, New York, United States|Clinical Study Site, London, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/36/NCT03369236/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/36/NCT03369236/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03369236"
112,"NCT03131219","Study of Ravulizumab in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS)",,"Active, not recruiting","Has Results","Atypical Hemolytic Uremic Syndrome (aHUS)","Biological: Ravulizumab","Proportion Of Complement Inhibitor Treatment-naïve Participants With Complete Thrombotic Microangiopathy (TMA) Response|Time To Complete TMA Response In Complement Inhibitor Treatment-naïve Participants|Participants Who Do Not Require Dialysis|Proportion Of Complement Inhibitor Treatment-naïve Participants With Complete TMA Response Through All Available Follow-Up|Observed Value And Change From Baseline In eGFR At Week 26|Participants With Change From Baseline In CKD Stage At Week 26|Change From Baseline In Platelet Count At Week 26|Change From Baseline In LDH At Week 26|Change From Baseline In Hemoglobin At Week 26|Proportion Of Complement Inhibitor Treatment-naïve Participants With An Increase From Baseline In Hemoglobin ≥20 g/L Through Week 26|Change From Baseline In Quality Of Life As Measured By The Functional Assessment Of Chronic Illness Therapy (FACIT)-Fatigue Version 4 Questionnaire (Participants ≥5 Years Of Age) At Week 26","Alexion Pharmaceuticals","All","up to 17 Years   (Child)","Phase 3","31","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ALXN1210-aHUS-312|2016-002499-29","August 31, 2017","December 3, 2019","January 2024","April 27, 2017","September 16, 2020","September 16, 2020","Clinical Trial Site, Aurora, Colorado, United States|Clinical Trial Site, Hollywood, Florida, United States|Clinical Trial Site, Atlanta, Georgia, United States|Clinical Trial Site, Detroit, Michigan, United States|Clinical Trial Site, Omaha, Nebraska, United States|Clinical Trial Site, Charlotte, North Carolina, United States|Clinical Trial Site, Bruxelles, Belgium|Clinical Trial Site, Heidelberg, Germany|Clinical Trial Site, Milan, Italy|Clinical Trial Site, Fuchū, Japan|Clinical Trial Site, Ōbu, Japan|Clinical Trial Site, Jeju, Korea, Republic of|Clinical Trial Site, Seoul, Korea, Republic of|Clinical Trial Site, Yangsan, Korea, Republic of|Clinical Trial Site, Barcelona, Spain|Clinical Trial Site, Coruña, Spain|Clinical Trial Site, Esplugues De Llobregat, Spain|Clinical Trial Site, Valencia, Spain|Clinical Trial Site, Glasgow, United Kingdom|Clinical Trial Site, London, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/19/NCT03131219/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/19/NCT03131219/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT03131219"
113,"NCT03056040","ALXN1210 Versus Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab",,"Active, not recruiting","Has Results","Paroxysmal Nocturnal Hemoglobinuria (PNH)","Biological: Ravulizumab|Biological: Eculizumab","Percent Change In Lactate Dehydrogenase Levels From Baseline To Day 183|Percentage Of Participants With Breakthrough Hemolysis|Change From Baseline To Day 183 In Functional Assessment Of Chronic Illness Therapy (FACIT)-Fatigue Scores|Percentage Of Participants Who Achieved Transfusion Avoidance|Percentage Of Participants With Stabilized Hemoglobin Levels","Alexion Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","195","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ALXN1210-PNH-302|2016-002026-36","June 5, 2017","March 8, 2018","March 2021","February 16, 2017","March 21, 2019","August 12, 2020","Clinical Trial Site, Duarte, California, United States|Clinical Trial Site, Los Angeles, California, United States|Clinical Trial Site, Baltimore, Maryland, United States|Clinical Trial Site, Detroit, Michigan, United States|Clinical Trial Site, Bronx, New York, United States|Clinical Trial Site, Canberra, Australian Capital Territory, Australia|Clinical Trial Site, Kogarah, New South Wales, Australia|Clinical Trial Site, Liverpool, New South Wales, Australia|Clinical Trial Site, Woolloongabba, Queensland, Australia|Clinical Trial Site, Parkville, Victoria, Australia|Clinical Trial Site, Toronto, Ontario, Canada|Clinical Trial Site, Toronto, Ontario, Canada|Clinical Trial Site, Montréal, Quebec, Canada|Clinical Trial Site, Amiens, France|Clinical Trial Site, Marseille, France|Clinical Trial Site, Paris, France|Clinical Trial Site, Pierre-Bénite, France|Clinical Trial Site, Saint-Priest-en-Jarez, France|Clinical Trial Site, Strasbourg, France|Clinical Trial Site, Ulm, Baden Wuerttemberg, Germany|Clinical Trial Site, Aachen, Nordrhein Westfalen, Germany|Clinical Trial Site, Essen, Nordrhein Westfalen, Germany|Clinical Trial Site, Firenze, Italy|Clinical Trial Site, Milano, Italy|Clinical Trial Site, Napoli, Italy|Clinical Trial Site, Torino, Italy|Clinical Trial Site, Vicenza, Italy|Clinical Trial Site, Kanazawa-shi, Ishikawa, Japan|Clinical Trial Site, Suwa, Nagano, Japan|Clinical Trial Site, Suita-shi, Osaka, Japan|Clinical Trial Site, Shinagawa-Ku, Tokyo, Japan|Clinical Trial Site, Fukushima, Japan|Clinical Trial Site, Daegu, Korea, Republic of|Clinical Trial Site, Daejeon, Korea, Republic of|Clinical Trial Site, Gyeonggi-do, Korea, Republic of|Clinical Trial Site, Gyeonggi-do, Korea, Republic of|Clinical Trial Site, Incheon, Korea, Republic of|Clinical Trial Site, Seoul, Korea, Republic of|Clinical Trial Site, Seoul, Korea, Republic of|Clinical Trial Site, Seoul, Korea, Republic of|Clinical Trial Site, Seoul, Korea, Republic of|Clinical Trial Site, Maastricht, Netherlands|Clinical Trial Site, Nijmegen, Netherlands|Clinical Trial Site, Barcelona, Spain|Clinical Trial Site, Madrid, Spain|Clinical Trial Site, Majadahonda, Spain|Clinical Trial Site, Airdrie, United Kingdom|Clinical Trial Site, Leeds, United Kingdom|Clinical Trial Site, London, United Kingdom","""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/40/NCT03056040/SAP_001.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/40/NCT03056040/Prot_002.pdf","https://ClinicalTrials.gov/show/NCT03056040"
114,"NCT02987504","Study of Samalizumab in Patients With Advanced Cancer",,"Terminated","No Results Available","Advanced Solid Tumors","Drug: Samalizumab","Number Of Participants Experiencing DLT Graded According To CTCAE Version 4.03, Observed In The Cycle 1 In Order To Meet The Objective Of Assessment Of The MTD|Maximum Plasma Concentration After Administration Of Samalizumab|Area Under The Plasma Drug Concentration-time Curve After Administration Of Samalizumab|Objective Response Rate Using Response Evaluation Criteria In Solid Tumors (RECIST) 1.1|Disease Control Rate Using RECIST 1.1|Duration Of Response|Progression Free Survival|Overall Survival","Alexion Pharmaceuticals|Quintiles, Inc.","All","18 Years and older   (Adult, Older Adult)","Phase 1","10","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ALXN6000-ONC-102","November 17, 2016","September 12, 2017","September 27, 2017","December 9, 2016",,"July 18, 2018","New Haven, Connecticut, United States|Grand Rapids, Michigan, United States|San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02987504"
115,"NCT02949128","Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)",,"Active, not recruiting","Has Results","Atypical Hemolytic Uremic Syndrome (aHUS)","Biological: Ravulizumab","Proportion Of Participants With Complete Thrombotic Microangiopathy (TMA) Response|Time To Complete TMA Response|Proportion Of Participants With Complete TMA Response At Week 26|Observed Value And Change From Baseline In Estimated Glomerular Filtration Rate (eGFR) At Week 26|Proportion Of Participants With Change From Baseline In Chronic Kidney Disease (CKD) Stage At Week 26|Change From Baseline In Platelet Count At Week 26|Change From Baseline In LDH At Week 26|Change From Baseline In Hemoglobin At Week 26|Proportion Of Participants With An Increase From Baseline In Hemoglobin ≥ 20 g/L Through Week 26|Change From Baseline In Quality Of Life As Measured By The EuroQol 5-Dimension 3-Level (EQ-5D-3L) At Week 26|Change From Baseline In Quality Of Life As Measured By The Functional Assessment Of Chronic Illness Therapy (FACIT)-Fatigue Version 4 Questionnaire At Week 26","Alexion Pharmaceuticals","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","58","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ALXN1210-aHUS-311|2016-002027-29","March 18, 2017","November 16, 2018","July 2023","October 31, 2016","February 10, 2020","May 5, 2020","Clinical Trial Site, Fort Wayne, Indiana, United States|Clinical Trial Site, Fort Wayne, Indiana, United States|Clinical Trial Site, Durham, North Carolina, United States|Clinical Trial Site, Winston-Salem, North Carolina, United States|Clinical Trial Site, Columbus, Ohio, United States|Clinical Trial Site, Clayton, Australia|Clinical Trial Site, Geelong, Australia|Clinical Trial Site, Parkville, Australia|Clinical Trial Site, Vienna, Austria|Clinical Trial Site, Brussels, Belgium|Clinical Trial Site, London, Canada|Clinical Trial Site, Bordeaux, France|Clinical Trial Site, Clermont-Ferrand, France|Clinical Trial Site, Lille, France|Clinical Trial Site, Montpellier, France|Clinical Trial Site, Nice, France|Clinical Trial Site, Paris, France|Clinical Trial Site, Aachen, Germany|Clinical Trial Site, Essen, Germany|Clinical Trial Site, Hanover, Germany|Clinical Trial Site, Muenchen, Germany|Clinical Trial Site, Tuebingen, Germany|Clinical Trial Site, Bologna, Italy|Clinical Trial Site, Firenze, Italy|Clinical Trial Site, Saitama, Japan|Clinical Trial Site, Tokyo, Japan|Clinical Trial Site, Gyeonggi-do, Korea, Republic of|Clinical Trial Site, Seoul, Korea, Republic of|Clinical Trial Site, Moscow, Russian Federation|Clinical Trial Site, Saint Petersburg, Russian Federation|Clinical Trial Site, Barcelona, Spain|Clinical Trial Site, Madrid, Spain|Clinical Trial Site, Valencia, Spain|Clinical Trial Site, Taichung, Taiwan|Clinical Trial Site, Taipei City, Taiwan|Clinical Trial Site, Taipei, Taiwan|Clinical Trial Site, Cardiff, United Kingdom|Clinical Trial Site, London, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT02949128/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/28/NCT02949128/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02949128"
116,"NCT02946463","ALXN1210 (Ravulizumab) Versus Eculizumab in Complement Inhibitor Treatment-Naïve Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)",,"Active, not recruiting","Has Results","Paroxysmal Nocturnal Hemoglobinuria (PNH)","Biological: Ravulizumab|Biological: Eculizumab","Proportion Of Participants With Normalization Of Lactate Dehydrogenase (LDH) Levels|Percentage Of Participants Who Achieved Transfusion Avoidance (TA)|Percentage Of Participants With Breakthrough Hemolysis (BTH)|Percent Change From Baseline In Lactate Dehydrogenase (LDH) Levels|Change From Baseline In Quality Of Life As Assessed By The Functional Assessment Of Chronic Illness Therapy (FACIT)-Fatigue|Percentage Of Participants With Stabilized Hemoglobin Levels","Alexion Pharmaceuticals","All","12 Years and older   (Child, Adult, Older Adult)","Phase 3","249","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ALXN1210-PNH-301|2016-002025-11","December 20, 2016","January 25, 2018","January 31, 2023","October 27, 2016","February 12, 2019","November 24, 2021","Clinical Trial Site, Los Angeles, California, United States|Clinical Trial Site, Los Angeles, California, United States|Clinical Trial Site, Fort Worth, Texas, United States|Clinical Trial Site, Buenos Aires, Argentina|Clinical Trial Site, Buenos Aires, Argentina|Clinical Trial Site, Córdoba, Argentina|Clinical Trial Site, Perth, Australia|Clinical Trial Site, Linz, Austria|Clinical Trial Site, Vienna, Austria|Clinical Trial Site, Hasselt, Belgium|Clinical Trial Site, Leuven, Belgium|Clinical Trial Site, Belém, Brazil|Clinical Trial Site, Rio de Janeiro, Brazil|Clinical Trial Site, Salvador, Brazil|Clinical Trial Site, São Paulo, Brazil|Clinical Trial Site, São Paulo, Brazil|Clinical Trial Site, Edmonton, Canada|Clinical Trial Site, Toronto, Canada|Clinical Trial Site, Plzen, Czechia|Clinical Trial Site, Praha, Czechia|Clinical Trial Site, Tallinn, Estonia|Clinical Trial Site, Poitiers, Vienne, France|Clinical Trial Site, Limoges, France|Clinical Trial Site, Montpellier, France|Clinical Trial Site, Paris, France|Clinical Trial Site, Pierre-Bénite, France|Clinical Trial Site, Rennes, France|Clinical Trial Site, Essen, Germany|Clinical Trial Site, Ulm, Germany|Clinical Trial Site, Ascoli Piceno, Italy|Clinical Trial Site, Firenze, Italy|Clinical Trial Site, Milano, Italy|Clinical Trial Site, Napoli, Italy|Clinical Trial Site, Vicenza, Italy|Clinical Trial Site, Bunkyō-Ku, Japan|Clinical Trial Site, Bunkyō-Ku, Japan|Clinical Trial Site, Fukuoka, Japan|Clinical Trial Site, Fukushima, Japan|Clinical Trial Site, Hamamatsu-shi, Japan|Clinical Trial Site, Kanazawa-shi, Japan|Clinical Trial Site, Koshigaya-shi, Japan|Clinical Trial Site, Kumamoto, Japan|Clinical Trial Site, Nishinomiya-shi, Japan|Clinical Trial Site, Ogaki-shi, Japan|Clinical Trial Site, Okayama-city, Japan|Clinical Trial Site, Okayama-shi, Japan|Clinical Trial Site, Osakasayama-shi, Japan|Clinical Trial Site, Sapporo, Japan|Clinical Trial Site, Shimotsuke-shi, Japan|Clinical Trial Site, Shinagawa-Ku, Japan|Clinical Trial Site, Shinjuku-Ku, Japan|Clinical Trial Site, Shinjuku-Ku, Japan|Clinical Trial Site, Suita-shi, Japan|Clinical Trial Site, Tokorozawa-shi, Japan|Clinical Trial Site, Toyoake-shi, Japan|Clinical Trial Site, Tsukuba, Japan|Clinical Trial Site, Wakayama-shi, Japan|Clinical Trial Site, Yokohama-City, Japan|Clinical Trial Site, Yokohama-City, Japan|Clinical Trial Site, Anyang-si, Korea, Republic of|Clinical Trial Site, Busan, Korea, Republic of|Clinical Trial Site, Daegu, Korea, Republic of|Clinical Trial Site, Incheon, Korea, Republic of|Clinical Trial Site, Jeonju, Korea, Republic of|Clinical Trial Site, Jinju-si, Korea, Republic of|Clinical Trial Site, Seoul, Korea, Republic of|Clinical Trial Site, Seoul, Korea, Republic of|Clinical Trial Site, Seoul, Korea, Republic of|Clinical Trial Site, Seoul, Korea, Republic of|Clinical Trial Site, Seoul, Korea, Republic of|Clinical Trial Site, Seoul, Korea, Republic of|Clinical Trial Site, Seoul, Korea, Republic of|Clinical Trial Site, Seoul, Korea, Republic of|Clinical Trial Site, Seoul, Korea, Republic of|Clinical Trial Site, Suwon-si, Korea, Republic of|Clinical Trial Site, Suwon-si, Korea, Republic of|Clinical Trial Site, Ulsan, Korea, Republic of|Clinical Trial Site, Kota Bharu, Kelantan, Malaysia|Clinical Trial Site, Miri, Sarawak, Malaysia|Clinical Trial Site, Sibu, Sarawak, Malaysia|Clinical Trial Site, Ampang, Malaysia|Clinical Trial Site, Johor Bahru, Malaysia|Clinical Trial Site, Kota Bahru, Malaysia|Clinical Trial Site, Kota Bharu, Malaysia|Clinical Trial Site, Kota Kinabalu, Malaysia|Clinical Trial Site, Kubang Kerian, Malaysia|Clinical Trial Site, Kuching, Malaysia|Clinical Trial Site, Pulau Pinang, Malaysia|Clinical Trial Site, Monterrey, Mexico|Clinical Trial Site, Gdańsk, Poland|Clinical Trial Site, Warsaw, Poland|Clinical Trial Site, Arkhangel'sk, Russian Federation|Clinical Trial Site, Barnaul, Russian Federation|Clinical Trial Site, Bryansk, Russian Federation|Clinical Trial Site, Irkutsk, Russian Federation|Clinical Trial Site, Kaluga, Russian Federation|Clinical Trial Site, Kirov, Russian Federation|Clinical Trial Site, Krasnoyarsk, Russian Federation|Clinical Trial Site, Krasnoyarsk, Russian Federation|Clinical Trial Site, Moscow, Russian Federation|Clinical Trial Site, Moscow, Russian Federation|Clinical Trial Site, Murmansk, Russian Federation|Clinical Trial Site, Nizhny Novgorod, Russian Federation|Clinical Trial Site, Novosibirsk, Russian Federation|Clinical Trial Site, Petrozavodsk, Russian Federation|Clinical Trial Site, Rostov-na-Donu, Russian Federation|Clinical Trial Site, Saint Petersburg, Russian Federation|Clinical Trial Site, Saratov, Russian Federation|Clinical Trial Site, Ufa, Russian Federation|Clinical Trial Site, Singapore, Singapore|Clinical Trial Site, Barcelona, Spain|Clinical Trial Site, Madrid, Spain|Clinical Trial Site, Majadahonda, Spain|Clinical Trial Site, Uppsala, Sweden|Clinical Trial Site, Chang-hua, Taiwan|Clinical Trial Site, Hualien City, Taiwan|Clinical Trial Site, Kaohsiung, Taiwan|Clinical Trial Site, Taichung, Taiwan|Clinical Trial Site, Tainan, Taiwan|Clinical Trial Site, Taipei, Taiwan|Clinical Trial Site, Bangkok, Thailand|Clinical Trial Site, Hat Yai, Thailand|Clinical Trial Site, Pathum Wan, Thailand|Clinical Trial Site, Eskişehir, Turkey|Clinical Trial Site, Leeds, United Kingdom|Clinical Trial Site, London, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/63/NCT02946463/Prot_002.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/63/NCT02946463/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02946463"
117,"NCT02926872","Screening for Lysosomal Acid Lipase Deficiency",,"Terminated","No Results Available","Lysosomal Acid Lipase Deficiency","Other: There is no intervention in the study","Eligibility Criteria for LAL-D diagnosed patients|LIPA gene mutations for LAL-D diagnosed patients","Alexion Pharmaceuticals","All","2 Years to 16 Years   (Child)",,"22","Industry","Observational","Observational Model: Other|Time Perspective: Other","ALX-LAL-502","November 2016","June 5, 2017","June 5, 2017","October 6, 2016",,"June 16, 2017","Children's Healthcare of Atlanta, Atlanta, Georgia, United States|Texas Children's Hospital, Baylor College of Medicine, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02926872"
118,"NCT02797821","Pharmacokinetic and Dose Response Study of Asfotase Alfa in Adult Patients With Pediatric-Onset Hypophosphatasia (HPP)",,"Completed","Has Results","Hypophosphatasia","Drug: Asfotase alfa","Change In Plasma PPi From Baseline To Pre-3rd Dose At Week 9|Change In Plasma PLP From Baseline To Pre-3rd Dose At Week 9","Alexion Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","27","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AA-HPP-208","June 6, 2016","June 21, 2017","June 21, 2017","June 14, 2016","July 10, 2018","September 17, 2019","Shriners Hospitals for Children, Saint Louis, Missouri, United States|Duke University Medical Center, Durham, North Carolina, United States|Vanderbilt Medical Center Endocrinology, Nashville, Tennessee, United States|University of Würzburg, Würzburg, Germany","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/21/NCT02797821/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/21/NCT02797821/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02797821"
119,"NCT02618512","A Open Label Study in Previously Studied, SBC-103 Treatment Naïve MPS IIIB Subjects to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 Administered Intravenously","CL01-T","Terminated","Has Results","Mucopolysaccharidosis III, Type B (MPS IIIB)|Sanfilippo B","Drug: SBC-103","Safety and Tolerability of SBC-103","Alexion Pharmaceuticals","All","5 Years and older   (Child, Adult, Older Adult)","Phase 1|Phase 2","3","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NGLU-CL01-T|2015-001983-20","October 15, 2015","August 18, 2017","August 18, 2017","December 1, 2015","April 17, 2018","April 17, 2018","Birmingham, United Kingdom","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/12/NCT02618512/ICF_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/12/NCT02618512/Prot_001.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/12/NCT02618512/SAP_002.pdf","https://ClinicalTrials.gov/show/NCT02618512"
120,"NCT02614898","Evaluation of Potential Predictors of Disease Progression in Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Including Genetics, Biomarkers, and Treatment","EVIDENCE","Terminated","Has Results","Atypical Hemolytic Uremic Syndrome","Other: Eculizumab","Rate Of Thrombotic Microangiopathy (TMA) Manifestations During Eculizumab Treatment Compared To Off-Treatment|Change From Baseline To 24 Months In Estimated Glomerular Filtration Rate (eGFR)|Incidence Of Plasma Exchange And Plasma Infusion (PE/PI)","Alexion Pharmaceuticals","All","Child, Adult, Older Adult",,"67","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","ECU-aHUS-403|2015-003135-35","November 4, 2015","October 5, 2017","October 5, 2017","November 25, 2015","January 2, 2020","January 2, 2020","Clinical Trial Site, Washington, District of Columbia, United States|Clinical Trial Site, Atlanta, Georgia, United States|Clinical Trial Site, Chicago, Illinois, United States|Clinical Trial Site, Boston, Massachusetts, United States|Clinical Trial Site, Hackensack, New Jersey, United States|Clinical Trial Site, Charlotte, North Carolina, United States|Clinical Trial Site, Columbus, Ohio, United States|Clinical Trial Site, Houston, Texas, United States|Clinical Trial Site, Adelaide, Australia|Clinical Trial Site, Clayton, Australia|Clinical Trial Site, Heidelberg, Australia|Clinical Trial Site, Kingswood, Australia|Clinical Trial Site, Liverpool, Australia|Clinical Trial Site, Nedlands, Australia|Clinical Trial Site, Parkville, Australia|Clinical Trial Site, Parkville, Australia|Clinical Trial Site, Perth, Australia|Clinical Trial Site, Westmead, Australia|Clinical Trial Site, Woolloongabba, Australia|Clinical Trial Site, Hannover, Germany|Clinical Trial Site, Hannöver, Germany|Clinical Trial Site, Kiel, Germany|Clinical Trial Site, Luebeck, Germany|Clinical Trial Site, London, United Kingdom","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/98/NCT02614898/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02614898"
121,"NCT02605993","Open-label, Multiple Ascending Dose Study of Ravulizumab (ALXN1210) in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)",,"Active, not recruiting","Has Results","Paroxysmal Nocturnal Hemoglobinuria|PNH","Biological: Ravulizumab","Percent Change In LDH Levels From Baseline To Day 253 And Day 281|Percent Change In Free Hemoglobin Levels From Baseline To Day 253 And Day 281|Percent Change In Haptoglobin Levels From Baseline To Day 253 And Day 281|Percent Change In Reticulocyte/Erythrocyte Count From Baseline To Day 253 And Day 281|Percent Change In PNH RBC Types II And III Clone Size From Baseline To Day 253|Percent Change In D-dimer From Baseline To Day 253 And Day 281|Change In Clinical Manifestations Of PNH From Baseline To Day 253 And Day 281","Alexion Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","26","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ALXN1210-PNH-201|2015-002674-20","January 4, 2016","February 23, 2017","March 2022","November 17, 2015","February 18, 2019","August 7, 2020","Clinical Trial Site, Toronto, Ontario, Canada|Clinical Trial Site, Lyon, Pierre-Bénite, France|Clinical Trial Site, Lille, France|Clinical Trial Site, Paris, France|Clinical Trial Site, Ulm, Baden Wuerttemberg, Germany|Clinical Trial Site, Aachen, Nordrhein Westfalen, Germany|Clinical Trial Site, Essen, Nordrhein Westfalen, Germany|Clinical Trial Site, Seoul, Korea, Republic of|Clinical Trial Site, Seoul, Korea, Republic of|Clinical Trial Site, Badalona, Barcelona, Spain|Clinical Trial Site, Majadahonda, Madrid, Spain|Clinical Trial Site, Barcelona, Spain|Clinical Trial Site, Madrid, Spain|Clinical Trial Site, Taipei City, Taiwan|Clinical Trial Site, Leeds, West Yorkshire, United Kingdom|Clinical Trial Site, London, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/93/NCT02605993/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/93/NCT02605993/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02605993"
122,"NCT02531867","Post-approval Clinical Study of Asfotase Alfa Treatment for Patients With Hypophosphatasia (HPP) in Japan",,"Completed","Has Results","Hypophosphatasia","Biological: Asfotase Alfa","Number of Participants With Adverse Events (AEs) Including Injection Site Reactions (ISRs) and Injection Associated Reactions (IARs)","Alexion Pharmaceuticals","All","Child, Adult, Older Adult","Phase 4","13","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AA-HPP-409","June 2015","November 2015","November 2015","August 25, 2015","May 8, 2017","May 8, 2017",,,"https://ClinicalTrials.gov/show/NCT02531867"
123,"NCT02376751","An Expanded Access Protocol for Sebelipase Alfa for Patients With Lysosomal Acid Lipase Deficiency",,"No longer available","No Results Available","Lysosomal Acid Lipase Deficiency","Drug: sebelipase alfa",,"Alexion Pharmaceuticals","All","8 Months and older   (Child, Adult, Older Adult)",,,"Industry","Expanded Access",,"LAL-EA01",,,,"March 3, 2015",,"June 8, 2016",,,"https://ClinicalTrials.gov/show/NCT02376751"
124,"NCT02345421","A Study to Identify and Characterize LAL-D Patients in High-risk Populations",,"Terminated","No Results Available","Lysosomal Acid Lipase Deficiency",,"LAL D frequency based on LAL enzyme assay.","Alexion Pharmaceuticals","All","2 Years and older   (Child, Adult, Older Adult)",,"640","Industry","Observational","Observational Model: Case-Only","LAL-CSS01","December 2014","September 2015","October 2015","January 26, 2015",,"May 24, 2016","Birmingham, Alabama, United States|Phoenix, Arizona, United States|Los Angeles, California, United States|San Francisco, California, United States|Gainesville, Florida, United States|Jacksonville, Florida, United States|Miami, Florida, United States|New Orleans, Louisiana, United States|Minneapolis, Minnesota, United States|Bronx, New York, United States|Durham, North Carolina, United States|Oklahoma City, Oklahoma, United States|Portland, Oregon, United States|Houston, Texas, United States|San Antonio, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02345421"
125,"NCT02324049","Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 in Mucopolysaccharidosis III, Type B (MPS IIIB)",,"Completed","Has Results","Mucopolysaccharidosis IIIB","Drug: SBC-103","Number Of Participants Who Experienced Severe Treatment-emergent Adverse Events (TEAEs)","Alexion Pharmaceuticals","All","2 Years to 12 Years   (Child)","Phase 1|Phase 2","11","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NGLU-CL02","January 22, 2015","October 16, 2017","October 16, 2017","December 24, 2014","July 12, 2018","August 21, 2018","Minneapolis, Minnesota, United States|Pittsburgh, Pennsylvania, United States|Barcelona, Spain|Birmingham, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/49/NCT02324049/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/49/NCT02324049/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02324049"
126,"NCT02306720","An Observational, Longitudinal, Prospective, Long-Term Registry Of Patients With Hypophosphatasia (HPP)",,"Enrolling by invitation","No Results Available","Hypophosphatasia (HPP)",,"Patient-reported Outcomes","Alexion Pharmaceuticals","All","Child, Adult, Older Adult",,"500","Industry","Observational","Observational Model: Case-Control|Time Perspective: Prospective","ALX-HPP-501","December 2014","December 2024","December 2024","December 3, 2014",,"January 12, 2021","Little Rock, Arkansas, United States|Centennial, Colorado, United States|Lakewood, Colorado, United States|Hartford, Connecticut, United States|Tampa, Florida, United States|Decatur, Georgia, United States|Chicago, Illinois, United States|Boston, Massachusetts, United States|Rochester, Minnesota, United States|Rochester, New York, United States|Syracuse, New York, United States|Durham, North Carolina, United States|Cincinnati, Ohio, United States|Columbus, Ohio, United States|Pittsburgh, Pennsylvania, United States|Providence, Rhode Island, United States|Nashville, Tennessee, United States|Salt Lake City, Utah, United States|Westmead, New South Wales, Australia|Parkville, Victoria, Australia|Winnipeg, Manitoba, Canada|Toulouse, Haute Garonne, France|Paris cedex 14, Paris, France|Le Kremlin-Bicêtre, Île-de-France, France|Würzburg, Bayern, Germany|Essen, Nordrhein-Westfalen, Germany|Dresden, Sachsen, Germany|Dublin, Ireland|Firenze, Italy|Genova, Italy|Milano, Italy|Pisa, Italy|Rome, Italy|San Giovanni Rotondo, Italy|Verona, Italy|Lisboa, Portugal|Kurgan, Russian Federation|Moscow, Russian Federation|Saint Petersburg, Russian Federation|Riyadh, Saudi Arabia|Granollers, Barcelona, Spain|Barcelona, Spain|Madrid, Spain|Móstoles, Spain|Palma, Spain|Pamplona, Spain|Bristol, Avon, United Kingdom|Birmingham, United Kingdom|Leicester, United Kingdom|London, United Kingdom|Manchester, United Kingdom|Newcastle upon Tyne, United Kingdom|Norwich, United Kingdom|Sheffield, United Kingdom|Stanmore, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02306720"
127,"NCT02293408","Natural History Study to Characterise the Course of Disease Progression in Participants With Mucopolysaccharidosis Type IIIB",,"Terminated","No Results Available","MPS IIIB (Sanfilippo B Syndrome)",,"Collection And Analysis Of Clinical Characteristics Of MPS IIIB|Longitudinal Analysis Of The Course Of Disease Progression In Participants With MPS IIIB","Alexion Pharmaceuticals","All","1 Year and older   (Child, Adult, Older Adult)",,"30","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","NGLU-NH02","September 14, 2014","July 11, 2017","July 11, 2017","November 18, 2014",,"September 13, 2018","Minneapolis, Minnesota, United States|Pittsburgh, Pennsylvania, United States|Porto Alegre, Brazil|Monza, Italy|Coimbra, Portugal|Barcelona, Spain|Birmingham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02293408"
128,"NCT02293382","A Retrospective Chart Review of Deceased Patients With Mucopolysaccharidosis Type IIIB",,"Completed","No Results Available","MPS IIIB (Sanfilippo Syndrome)",,"Evaluation of disease presentation and the course of disease progression including the end stage of the disease in patients with MPS IIIB, assessed from medical history data obtained by retrospective chart review of deceased patients.","Alexion Pharmaceuticals","All","Child, Adult, Older Adult",,"30","Industry","Observational","Observational Model: Case-Only|Time Perspective: Retrospective","NGLU-NH01","July 2013","January 2015","January 2015","November 18, 2014",,"February 3, 2017","Pittsburg, Pennsylvania, United States|Porte Alegre, Brazil|Amsterdam, Netherlands|Barcelona, Spain|Birmingham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02293382"
129,"NCT02245412","A Phase 2A Study of ALXN1007 in Participants With Newly Diagnosed Acute Lower Gastrointestinal Graft-Versus-Host Disease","GIGVHD","Terminated","Has Results","Acute Graft-Versus-Host Disease|GIGVHD","Biological: ALXN1007 10 mg/kg once weekly|Biological: ALXN1007 20 mg/kg once weekly|Biological: ALXN1007 20 mg/kg twice weekly","Overall Acute Graft-Versus-Host Disease (GVHD) Response Rate At Day 28|Pharmacokinetics (PK): Time To Maximum Observed Concentration In Plasma (Tmax) Of IV ALXN1007|PK: Maximum Observed Concentration In Plasma (Cmax) Of IV ALXN1007|PK: Area Under The Plasma (Or Serum) Concentration Versus Time Curve (AUC) Of IV ALXN1007","Alexion Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","25","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ALXN1007-GIGVHD-201","November 14, 2014","February 27, 2017","February 27, 2017","September 19, 2014","October 6, 2017","January 3, 2019","City of Hope, Duarte, California, United States|Emory University Hospital, Atlanta, Georgia, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|University of Minnesota Medicine - Hematology, Oncology and Transplantation Office, Minneapolis, Minnesota, United States|Washington University in St. Louis, Saint Louis, Missouri, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Abramson Cancer Perelman Center for Advanced Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|CHU de Grenoble - Hôpital Nord, Grenoble, Isere, France|Groupe Hospitalier Sud - Hôpital Haut-Lévêque - Centre François, Gironde, France|Hôpital Saint-Louis, Paris, France","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/12/NCT02245412/Prot_002.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/12/NCT02245412/SAP_003.pdf","https://ClinicalTrials.gov/show/NCT02245412"
130,"NCT02235493","Non-interventional Substudy of ALX-HPP-502 to Assess Natural History of Patients With Juvenile-onset HPP Who Served as Historical Controls in ENB-006-09",,"Completed","Has Results","Hypophosphatasia|Bone Disease","Biological: Retrospective Case Only","Modified Performance-Oriented Mobility Assessment-Gait Subtest (MPOMA-G) - Change From Baseline to Last Overall|Performance-Oriented Mobility Assessment-Gait Subtest (POMA-G) - Change From Baseline to Last Overall","Alexion Pharmaceuticals","All","5 Years and older   (Child, Adult, Older Adult)",,"6","Industry","Observational","Observational Model: Other|Time Perspective: Retrospective","ALX-HPP-502s","August 2014","September 2014","September 2014","September 10, 2014","September 28, 2015","March 13, 2019","Saint Louis, Missouri, United States",,"https://ClinicalTrials.gov/show/NCT02235493"
131,"NCT02193867","Clinical Study In Infants With Rapidly Progressive Lysosomal Acid Lipase Deficiency",,"Terminated","Has Results","Lysosomal Acid Lipase Deficiency","Drug: Sebelipase Alfa","Participants Experiencing Severe Treatment-emergent Adverse Events (TEAEs)|Percentage Of Participants Surviving To 12, 18, 24, And 36 Months Of Age|Median Age At Death|Change From Baseline In Percentiles For Weight For Age (WFA) At 12, 24, And 36 Months|Number Of Participants With Stunting, Wasting, Or Underweight At Baseline, 12, 24, And 36 Months|Change From Baseline In Serum Transaminases (ALT And AST) At Month 12, 24, And 36|Change From Baseline In Serum Ferritin At Month 12, 24, And 36|Number Of Participants Achieving And Maintaining Transfusion-free Hemoglobin Normalization (TFHN)","Alexion Pharmaceuticals","All","up to 8 Months   (Child)","Phase 2","10","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LAL-CL08","June 6, 2014","October 30, 2018","October 30, 2018","July 18, 2014","November 18, 2019","November 18, 2019","Phoenix, Arizona, United States|Kuopio, Finland|Naples, Italy|Birmingham, United Kingdom|Manchester, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/67/NCT02193867/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/67/NCT02193867/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02193867"
132,"NCT02145182","Prevention of Delayed Graft Function Using Eculizumab Therapy (PROTECT Study)",,"Completed","Has Results","Delayed Graft Function","Drug: Eculizumab|Drug: Placebo","Percentage Of Participants With Delayed Graft Function (DGF) In The First Seven Days Post-transplant|Percentage Of Participants With DGF, Functional DGF, And Immediate Graft Function|Percentage Of Participants Who Required Dialysis Post Transplantation|Estimated Glomerular Filtration Rate (eGFR)|Percentage Of Participants With Rejection-free Graft Survival","Alexion Pharmaceuticals|CTI Clinical Trial and Consulting Services","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","288","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","ECU-DGF-201|2013-004650-25","August 21, 2014","November 22, 2016","November 22, 2016","May 22, 2014","December 17, 2018","December 17, 2018","Birmingham, Alabama, United States|Phoenix, Arizona, United States|Los Angeles, California, United States|Palo Alto, California, United States|San Francisco, California, United States|San Francisco, California, United States|Aurora, Colorado, United States|New Haven, Connecticut, United States|Washington, District of Columbia, United States|Tampa, Florida, United States|Augusta, Georgia, United States|Chicago, Illinois, United States|Lexington, Kentucky, United States|New Orleans, Louisiana, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|Ann Arbor, Michigan, United States|Detroit, Michigan, United States|Minneapolis, Minnesota, United States|Saint Louis, Missouri, United States|Livingston, New Jersey, United States|Bronx, New York, United States|New York, New York, United States|New York, New York, United States|Chapel Hill, North Carolina, United States|Winston-Salem, North Carolina, United States|Charleston, South Carolina, United States|Fort Worth, Texas, United States|Houston, Texas, United States|Charlottesville, Virginia, United States|Richmond, Virginia, United States|Seattle, Washington, United States|Camperdown, New South Wales, Australia|Westmead, New South Wales, Australia|Adelaide, South Australia, Australia|Clayton, Victoria, Australia|Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil|Vancouver, British Columbia, Canada|Halifax, Nova Scotia, Canada|Toronto, Ontario, Canada|Montreal, Quebec, Canada|Prague, Czechia|Bordeaux, France|Créteil, France|Le Kremlin-Bicêtre, France|Lyon, France|Nantes, France|Paris, France|Paris, France|Strasbourg, France|Suresnes, France|Toulouse, France|Tours, France|Berlin, Germany|Dresden, Germany|Erlangen, Germany|Essen, Germany|Hamburg, Germany|Hannoversch Münden, Germany|Hannover, Germany|Kiel, Germany|Bari, Italy|Brescia, Italy|Milano, Italy|Padova, Italy|Torino, Italy|Verona, Italy|Badalona, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Madrid, Spain|Santander, Spain|Sevilla, Spain|Valencia, Spain|Valencia, Spain|Zaragoza, Spain",,"https://ClinicalTrials.gov/show/NCT02145182"
133,"NCT02112994","Safety and Efficacy Study of Sebelipase Alfa in Participants With Lysosomal Acid Lipase Deficiency",,"Completed","Has Results","Lysosomal Acid Lipase Deficiency","Drug: Sebelipase Alfa","Participants Experiencing Severe Treatment-emergent Adverse Events (TEAEs)|Percent Change In Serum Lipids From Baseline To Week 144|Participants Testing Positive For Anti-drug Antibodies (ADAs)|Percent Change In Body Mass Index (BMI)-For-Age Percentile From Baseline To Week 144 In Pediatric Participants|Shift In Child-Pugh Status From Baseline To Week 144","Alexion Pharmaceuticals","All","8 Months and older   (Child, Adult, Older Adult)","Phase 2","31","Industry","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LAL-CL06|2011-004287-30","June 24, 2014","December 28, 2017","December 28, 2017","April 14, 2014","January 15, 2019","December 4, 2019","Chicago, Illinois, United States|Shreveport, Louisiana, United States|Cincinnati, Ohio, United States|Westmead, Australia|Brussels, Belgium|Sao Paulo, Brazil|Halifax, Nova Scotia, Canada|Zagreb, Croatia|Copenhagen, Denmark|Freiburg, Germany|Padova, Italy|Mexico City, Mexico|Amsterdam, Netherlands|Moscow, Russian Federation|A Coruna, Spain|Barcelona, Spain|Madrid, Spain|Balcali, Turkey|Birmingham, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT02112994/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/94/NCT02112994/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02112994"
134,"NCT02104219","Retrospective, Non-interventional Natural History of Patients With Juvenile-onset Hypophosphatasia (HPP)",,"Completed","Has Results","Hypophosphatasia (HPP)",,"Radiographic Global Impression of Change - RGI-C|Change in Height Z-score From Baseline to Last Assessment|Change in Weight Z-score From Baseline to Last Assessment","Alexion Pharmaceuticals","All","5 Years and older   (Child, Adult, Older Adult)",,"32","Industry","Observational","Observational Model: Other|Time Perspective: Retrospective","ALX-HPP-502","March 2014","September 2014","September 2014","April 4, 2014","December 18, 2015","April 1, 2019","Atlanta, Georgia, United States|Indianapolis, Indiana, United States|Boston, Massachusetts, United States|Saint Louis, Missouri, United States|Springfield, Missouri, United States|Durham, North Carolina, United States|Cincinnati, Ohio, United States|Houston, Texas, United States|Seattle, Washington, United States|Sydney, Australia|Winnipeg, Manitoba, Canada|Le Kremlin-Bicêtre, France|Paris, France|Toulouse, France|Rotterdam, Netherlands|Moscow, Russian Federation|Istanbul, Turkey|Manchester, United Kingdom|Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02104219"
135,"NCT02090179","Evaluation of Blood Brain Barrier Integrity and Structural Abnormalities in MPS IIIB Patients Using Multimodal Magnetic Resonance Imaging",,"Completed","No Results Available","MPS IIIB (Sanfilippo B Syndrome)",,"Blood Brain Barrier integrity in MPS IIIB subjects|Blood Brain Barrier transfer coefficient|Structural brain abnormalities in MPS IIIB","Alexion Pharmaceuticals","All","5 Years and older   (Child, Adult, Older Adult)",,"5","Industry","Observational","Observational Model: Case-Only|Time Perspective: Prospective","NGLU-CL01|2013-001938-18","December 2013","May 2014","May 2014","March 18, 2014",,"June 27, 2016","Birmingham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02090179"
136,"NCT02003144","An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients",,"Active, not recruiting","No Results Available","Neuromyelitis Optica|Neuromyelitis Optica Spectrum Disorder","Biological: eculizumab","Evaluate the long-term safety of eculizumab in patients with relapsing NMO.|Evaluate the long-term efficacy of eculizumab in patients with relapsing NMO","Alexion Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","119","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ECU-NMO-302|2013-001151-12","January 2015","June 2021","June 2021","December 6, 2013",,"February 17, 2021","Mayo Clinic Arizona, Scottsdale, Arizona, United States|The Research Center of Southern California, Oceanside, California, United States|Georgetown University Hospital, Washington, District of Columbia, United States|University of Miami McKnight Brain Institute, Miami, Florida, United States|Neurological Services of Orlando, Orlando, Florida, United States|Allied Physicians Inc. of Fort Wayne, Fort Wayne, Indiana, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Baptist Health Lexington, Nicholasville, Kentucky, United States|Johns Hopkins University Medical Center, Baltimore, Maryland, United States|Mayo Clinic - Rochester, Rochester, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Multiple Sclerosis Comprehensive Care Center NYU Langone Medical Center, New York, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|Ohio Health Reserach Institute, Columbus, Ohio, United States|University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Multiple Sclerosis Treatment Center of Dallas, Dallas, Texas, United States|The University of Texas Health Science, San Antonio, Texas, United States|University of Utah, Salt Lake City, Utah, United States|Hospital Universitario Austral, Pilar, Buenos Aires, Argentina|Fundacion Rosarina de Neuro Rehabilitacion, Rosario, Santa Fe, Argentina|Hospital General de Agudos Dr. J. M. Ramos Mejia, Ciudad Autonoma, Buenos Aires,, Argentina|Hospital General de Agudos Juan Antonio Fernandez, Ciudad Autonoma, Buenos Aires, Argentina|Brain and Mind Research Institute, Camperdown, New South Wales, Australia|St. Vincent's Hospital, Fitzroy, Victoria, Australia|The Ottawa Hospital, Ottawa, Ontario, Canada|Fundacion Cardiovascular de Colombia, Floridablanca, Santander, Colombia|Clinical Hospital Centre Zagreb, Zagreb, Croatia|VFN v Praze, Praha, Czechia|Krajska zdravotni, a.s. - Nemocnice, Teplice, Czechia|Århus Universitetshospital, Arhus, Denmark|University Hospital Heidelberg, Heidelberg, Baden Wuerttemberg, Germany|Neurologische Klinik und Poliklinik, Munich, Bayern, Germany|University Hospital Heinrich Heine University, Dusseldorf, Nordrhein Westfalen, Germany|Universitaetsmedizin Rostock, Rostock, Germany|Prince of Wales Hospital, Shatin, Hong Kong|Policlinico di Catania, Catania, Italy|Azienda Ospedaliera Universitaria, Napoli, Italy|Azienda Ospedaliera di Padova, Padova, Italy|Azienda Ospedaliera Sant'Andrea-Università di Roma La Sapienza, Rome, Italy|Chiba University Hospital, Chiba-shi, Chiba-Ken, Japan|Hyogo College of Medicine Hospital, Nishinomiya-shi, HyogoKen, Japan|Kyoto Min-iren Chuo Hospital, Kyoto-shi, Kyoto-Fu, Japan|Tohoku University Hospital, Sendai-shi, Miyagi-Ken, Japan|Yamaguchi University Hospital, Ube-shi, Yamaguchi-Ken, Japan|Kyushu University Hospital, Fukuoka, Japan|National Center Hospital, NCNP, Tokio, Japan|National Cancer Center, Goyang-si, Gyeonggi-do, Korea, Republic of|Seoul University National Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University, Seoul, Korea, Republic of|Hospital Umum Sarawak, Kuching, Sarawak, Malaysia|Hospital Kuala Lumpur, Kuala Lumpur, Malaysia|Republican Clinical Hospital for Rehabilitation of Healthcare Ministry of Republic of Tatarstan, Kazan, Russian Federation|SBEI ""Krasnoyarsk SMU n.a. Prof. V.F. Voyno-Yasenetsky"", Krasnoyarsk, Russian Federation|Federal State Budget Institution of Healthcare - Siberian District Medical Center of FMBA of Russia, Novosibirsk, Russian Federation|SEIHPE ""Rostov SMU of MoH of RF"", Rostov-on Don, Russian Federation|Hospital de Cruces, Barakaldo, Bizkaia, Spain|Hospital Universitario Reina Sofia, Cordoba, Spain|Hospital Universitario Clinico San Carlos, Madrid, Spain|Cheng Hsin General Hospital, Taipei, Taiwan|Thammasat University Hospital, Pathum Thani, Thailand|Hacettepe University Medical Faculty, Ankara, Turkey|Trakya University Medical Faculty, Edirne, Turkey|Dokuz Eylul University Medicine Faculty, Izmir, Turkey|Kocaeli University Medical Faculty, Kocaeli, Turkey|Ondokuz Mayis Univ. Med. Fac., Samsun, Turkey|The Walton Centre, Liverpool, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02003144"
137,"NCT01997229","Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study)",,"Completed","Has Results","Refractory Generalized Myasthenia Gravis","Biological: Eculizumab|Drug: Placebo","Myasthenia Gravis Activities of Daily Living Profile (MG-ADL): Change From Baseline in MG-ADL Total Score at Week 26 by Worst-Rank Analysis of Covariance (ANCOVA)","Alexion Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","125","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ECU-MG-301|2013-003589-15","December 2013","February 2016","June 2016","November 28, 2013","February 7, 2018","July 16, 2019","University of Alabama, Birmingham, Alabama, United States|University of California San Francisco-Fresno, Fresno, California, United States|University of Southern California, Los Angeles, California, United States|University of California-Irvine, Orange, California, United States|University of California Davis Health System, Sacramento, California, United States|California Pacific Medical Center, San Francisco, California, United States|Stanford University School of Medicine, Stanford, California, United States|Yale New Haven Hospital, New Haven, Connecticut, United States|University of Florida Health Science Center, Jacksonville, Florida, United States|University of Miami School of Medicine, Miami, Florida, United States|University of South Florida, Tampa, Florida, United States|Georgia Regents University, Augusta, Georgia, United States|Medical Associates of North Georgia, Canton, Georgia, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|University of Iowa College of Medicine, Iowa City, Iowa, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|Johns Hopkins University School Of Medicine, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Lahey Clinic Inc., Burlington, Massachusetts, United States|Wayne State University School of Medicine, Detroit, Michigan, United States|Las Vegas Clinic, Las Vegas, Nevada, United States|Buffalo General Hospital, Buffalo, New York, United States|Hospital For Special Surgery/New York Presbyterian Hospital Cornell Campus, New York, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Carolinas Healthcare System, Charlotte, North Carolina, United States|Duke University Health System, Durham, North Carolina, United States|Ohio State University Medical Center, Columbus, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Wesley Neurology Clinic, Cordova, Tennessee, United States|Vanderbilt Medical Center, Nashville, Tennessee, United States|UT Southwestern, Dallas, Texas, United States|Methodist Neurological Institute, Houston, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|University of Vermont Medical Center, Burlington, Vermont, United States|University of Washington, Seattle, Washington, United States|Hospital Italiano, Ciudad Autonoma, Buenos Aires, Argentina|Instituto de Investigaciones Neurologicas Raul Carrea, FLENI, Ciudad Autonoma, Buenos Aires, Argentina|St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|UZ Antwerpen, Edegem, Belgium|AZ Sint-Lucas - Campus Sint-Lucas, Gent, Belgium|UZ Leuven, Leuven, Belgium|Hospital Mãe de Deus, Porto Alegre, Rio Grande Do Sul, Brazil|Faculdade de Medicina do ABC, Santo André, Sao Paulo, Brazil|Fundação Faculdade Regional de Medicina de São José do Rio Preto, São José do Rio Preto, Sao Paulo, Brazil|HUCFF-UFRJ - Hospital Universitário Clementino Fraga Filho - Universidade Federal do Rio de Janeiro, Rio De Janeiro, Brazil|UNIFESP - Universidade Federal de São Paulo, São Paulo, Brazil|University of Alberta Hospital, Edmonton, Alberta, Canada|Toronto General Hospital, Toronto, Ontario, Canada|Montreal Neurological Institute, Montreal, Quebec, Canada|Vseobecna fakultni nemocnice v Praze, Praha, Prague, Czechia|Fakultni nemocnice Brno, Brno, Czechia|Fakultni nemocnice Ostrava, Ostrava - Poruba, Czechia|Århus Universitetshospital, Aarhus C, Denmark|Rigshospitalet, København Ø, Denmark|Helsingin yliopistollinen keskussairaala, Helsinki, Finland|Neuro NEO Oy, Turku, Finland|CHU de Nice Hôpital Pasteur 2, Nice Cedex 3, Alpes Maritimes, France|Groupe Hospitalier Pellegrin - Hôpital Pellegrin, Bordeaux Cedex, Gironde, France|Hopital Roger Salengro - CHU Lille, Lille Cedex, Nord, France|Hopital Neurologique Pierre Wertheimer, Bron cedex, Rhone, France|LMU-Campus Innenstadt, Muenchen, Bayern, Germany|Medizinische Hochschule Hannover, Hannover, Niedersachsen, Germany|Navy Hospital of Athens, Athens, Greece|General Hospital of Thessaloniki ""G. Papanikolaou"", Thessaloniki, Greece|Jahn Ferenc Del-Pesti Korhaz, Budapest, Hungary|Szegedi Tud.Egyetem Szent-Gyorgyi Albert Klin. Közp., Szeged, Hungary|Policlinico di Catania, Catania, Italy|Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy|Azienda Ospedaliera Universitaria ""Federico II"", Napoli, Italy|Ospedale San Camillo IRCCS, Padova, Italy|Azienda Ospedaliero Universitaria Pisana, Pisa, Italy|Umberto I Pol. di Roma-Università di Roma La Sapienza, Roma, Italy|Policlinico Universitario Agostino Gemelli, Roma, Italy|Azienda Ospedaliera Sant'Andrea - Università di Roma La Sapienza, Roma, Italy|Ospedale Santa Chiara, Trento, Italy|Chiba University Hospital, Chiba-shi, Chiba-Ken, Japan|Kyushu University Hospital, Fukuoka-shi, Fukuoka-Ken, Japan|Sapporo Medical University Hospital, Sapporo-shi, Hokkaido, Japan|Hanamaki General Hospitals, Hanamaki-shi, Iwate-Ken, Japan|NHO Sendai Medical Center, Sendai-shi, Miyagi-Ken, Japan|NHO Nagasaki Kawatana Medical Center, Kawatana, Nagasaki-Ken, Japan|Nagasaki University Hospital, Nagasaki-shi, Nagasaki-Ken, Japan|Kinki University Hospital, Osakasayama-shi, Osaka-Fu, Japan|Osaka University Hospital, Suita-shi, Osaka-Fu, Japan|Toho University Ohashi Medical Center, Meguro-ku, Tokyo-To, Japan|Yamaguchi University Hospital, Ube-shi, Yamaguchi-Ken, Japan|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Seoul Metropolitan Government Seoul National University, Seoul, Korea, Republic of|Academisch Medisch Centrum, Amsterdam, Netherlands|Leiden Universitair Medisch Centrum, Leiden, Netherlands|Maastricht University Medical Center, Maastricht, Netherlands|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital Universitari de Bellvitge, Barcelona, Spain|Hospital Universitario La Paz, Madrid, Spain|Sahlgrenska Sjukhuset, Göteborg, Sweden|Karolinska Universitetssjukhuset - Solna, Stockholm, Sweden|Hacettepe University Medical Faculty, Ankara, Turkey|Karadeniz Tecnical Uni. Med. Fac., Istanbul, Turkey|Dokuz Eylul University Medicine Faculty, Izmir, Turkey|Kocaeli University Medical Faculty, Kocaeli, Turkey|Ondokuz Mayıs University of Medicine, Samsun, Turkey|The Walton Centre, Liverpool, Merseyside, United Kingdom|Queen Elizabeth Hospital, Birmingham, West Midlands, United Kingdom|King's College Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01997229"
138,"NCT01892345","A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study)",,"Terminated","Has Results","Neuromyelitis Optica|Neuromyelitis Optica Spectrum Disorder","Drug: Eculizumab|Drug: Placebo","Participants With An Adjudicated On-trial Relapse|Adjudicated On-trial Annualized Relapse Rate (ARR)|Change From Baseline In EDSS At End Of Study|Change From Baseline In Modified Rankin Scale (mRS) Score At End Of Study|Change From Baseline In Hauser Ambulation Index (HAI) Score At End of Study|Change From Baseline In European Quality Of Life (EuroQoL) Health 5-Dimension Questionnaire (EQ-5D) Visual Analogue Scale At End Of Study|Change From Baseline In EuroQoL EQ-5D Index Score At End Of Study","Alexion Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","143","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ECU-NMO-301","April 11, 2014","July 17, 2018","July 17, 2018","July 4, 2013","June 26, 2019","June 26, 2019","Mayo Clinic Arizona, Scottsdale, Arizona, United States|The Research Center of Southern California, Carlsbad, California, United States|Georgetown University Hospital, Washington, District of Columbia, United States|University of Miami McKnight Brain Institute, Miami, Florida, United States|Neurological Services of Orlando, Orlando, Florida, United States|Fort Wayne Neurological Center, Fort Wayne, Indiana, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Baptist Health Lexington, Lexington, Kentucky, United States|University of Maryland Medical Center, Baltimore, Maryland, United States|John Hopkins University School of Medicine, Baltimore, Maryland, United States|Mayo Clinic - Rochester, Rochester, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Multiple Sclerosis Comprehensive Care Center, NYU Langone Medical Center, New York, New York, United States|The Ohio State University, Wexner Medical Center, CarePoint at Gahanna, Gahanna, Ohio, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Multiple Sclerosis Treatment Center of Dallas, Dallas, Texas, United States|University of Utah Health Care, Salt Lake City, Utah, United States|Swedish Neuroscience Institute, Seattle, Washington, United States|Hospital General de Agudos Juan Antonio Fernandez, Ciudad Autonoma, Buenos Aires, Buenos Aires, Argentina|Hospital J. M. Ramos Mejia, Ciudad Autonoma, Buenos Aires, Buenos Aires, Argentina|Hospital Universitario Austral, Pilar, Buenos Aires, Argentina|Fundacion Rosarina de Neuro Rehabilitacion, Rosario, Santa Fe, Argentina|University of Sydney, Brain and Mind Center, Camperdown, New South Wales, Australia|St. Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia|Clinical Hospital Centre Zagreb, Zagreb, Croatia|Vseobecna fakultni nemocnice Neurologicka klinika, Praha, Czechia|Århus Universitetshospital, Århus, Denmark|Universitaetsklinikum Heidelberg, Abteilung Neuroonkologie, Heidelberg, Baden Wuerttemberg, Germany|Klinikum rechts der Isar der TU Muenchen, Neurologische Klinik und Poliklinik, Munich, Bayern, Germany|Universitaetsmedizin Rostock, Klinik für Neurologie, Rostock, Germany|Prince of Wales Hospital, Shatin, Hong Kong|Universitaria Policlinico di Catania, Catania, Italy|Azienda Ospedaliera Universitaria Federico II, Napoli, Italy|Azienda Ospedaliera San Camillo Forlanini, Rome, Italy|Neurological Centre of Latium Dipartimento di Neuroscienze, Rome, Italy|Chiba University Hospital, Chiba-shi, Chiba, Japan|Hyogo College of Medicine Hospital, Nishinomiya-shi, Hyogo, Japan|Kyoto Min-iren Chuo Hospital, Kyoto-shi, Kyoto, Japan|Tohoku University Hospital, Sendai-shi, Miyagi, Japan|Tokyo Medical and Dental University, Bunkyo-ku, Tokyo, Japan|Yamaguchi University Hospital, Ube-shi, Yamaguchi, Japan|Kyushu University Hospital, Fukuoka, Japan|National Center Hospital, NCNP, Tokio, Japan|National Cancer Center, Goyang-si, Gyeonggi-do, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Seoul University National Hospital, Seoul, Korea, Republic of|Severance Hospital, Yonsei University, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Hospital Kuala Lumpur, Kuala Lumpur, Malaysia|Republican Clinical Hospital for Rehabilitation of Healthcare Ministry of Republic of Tatarstan, Kazan, Russian Federation|FSBHI 'Siberian Clinical Center of FMBA', Krasnoyarsk, Russian Federation|Federal State Budget Institution of Healthcare - Siberian District Medical Center of FMBA of Russia, Novosibirsk, Russian Federation|SBEIHPE ""Rostov SMU of MoH of RF"", Rostov-on Don, Russian Federation|First Pavlov State Medical University of St.Petersburg, St. Petersburg, Russian Federation|Hospital de Cruces, Barakaldo, Bizkaia, Spain|Hospital Universitario Reina Sofia, Cordoba, Spain|Hospital Universitario Clinico San Carlos, Madrid, Spain|Cheng Hsin General Hospital, Taipei, Taiwan|Navamindradhiraj University, Vajira Hospital, Dusit, Thailand|Thammasat University Hospital, Pathumthani, Thailand|Sunprasitthiprasong Hospital, Ubon Ratchathani, Thailand|Hacettepe University Medical Faculty, Ankara, Turkey|Istanbul University Cerrahpasa Medical Faculty, Istanbul, Turkey|Istanbul Bilim Universty Medical Fac., Istanbul, Turkey|Dokuz Eylul University Medicine Faculty, Izmir, Turkey|Kocaeli University Medical Faculty, Kocaeli, Turkey|Ondokuz Mayis Univ. Med. Fac., Samsun, Turkey|The Walton Centre, Liverpool, United Kingdom|John Radcliffe Hospital, Oxford, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT01892345/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/45/NCT01892345/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01892345"
139,"NCT01883544","Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALXN1007 in Healthy Male and Female Subjects",,"Completed","No Results Available","Healthy Subjects","Drug: ALXN1007","To evaluate the safety and tolerability of multiple, IV doses of ALXN1007 in healthy male and female subjects as assessed by physical exam, vital signs, electrocardiogram (ECG), immunogenicity, laboratory analysis, and assessment of adverse events (AEs","Alexion Pharmaceuticals","All","25 Years to 55 Years   (Adult)","Phase 1","16","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ALXN1007-US-HV-102","June 2013","December 2013","January 2014","June 21, 2013",,"March 31, 2014","PAREXEL Baltimore EPCU, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01883544"
140,"NCT01849562","Safety, Tolerability and Efficacy of 12-weeks of Sovaprevir, ACH-3102 and Ribavirin in Treatment-naive GT-1 HCV Subjects",,"Completed","Has Results","Hepatitis C, Chronic","Drug: Sovaprevir|Drug: ACH-3102|Drug: RBV|Drug: Placebo","Incidence of Sustained Virologic Response 4 Weeks (SVR4) After the Completion of Treatment.|Safety and Tolerability of 12 Weeks of Sovaprevir and 3102 in Combination With Ribavirin in Subjects With Chronic Hepatitis C Genotype 1 Viral Infection.","Alexion Pharmaceuticals","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","ACH102-007","April 2013","November 2013","April 2014","May 8, 2013","February 4, 2015","September 17, 2015","Franco Felizarta, Bakersfield, California, United States|eStudy Site, La Mesa, California, United States|Gastrointestinal Specialists of Georgia, Marietta, Georgia, United States|Nashville Gastrointestinal Specialists, Nashville, Tennessee, United States|Liver Associates of Texas PA, Houston, Texas, United States|American Research Corporation, San Antonio, Texas, United States|Medical Associates of Central Virginia, Lynchburg, Virginia, United States|Toronto Liver Centre, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT01849562"
141,"NCT01757431","The Safety and Efficacy of Eculizumab in Japanese Patients With Atypical Hemolytic Uremic Syndrome (aHUS)",,"Completed","No Results Available","Atypical Hemolytic Uremic Syndrome (aHUS)","Drug: Eculizumab","Adverse events and serious adverse events and their severity and relationship to the drug","Alexion Pharmaceuticals","All","Child, Adult, Older Adult","Phase 2","2","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","C11-005J","May 16, 2012","September 24, 2013","September 25, 2013","December 31, 2012",,"March 10, 2017","Nagano Red Cross Hospital, Nagano, Japan|Tokyo Medical and Dental University Hospital, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT01757431"
142,"NCT01755429","To Characterize the Safety and Tolerability of Eculizumab in Two Japanese aHUS Patients",,"Completed","No Results Available","ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS)",,"Change in platelet count from baseline","Alexion Pharmaceuticals","All","Child, Adult, Older Adult",,"2","Industry","Observational","Time Perspective: Retrospective","C11-004J","May 2012","May 2012","July 2012","December 24, 2012",,"December 24, 2012","Shinshu University School of Medicine, Matsumoto, Japan|Tokyo Medical and Dental University, Tokyo, Japan",,"https://ClinicalTrials.gov/show/NCT01755429"
143,"NCT01700179","Evaluation of Safety Tolerability and Antiviral Activity of ACH-0143102 Plus RBV Treatment Naive HCV GT1b Subjects",,"Completed","Has Results","Chronic Hepatitis C Infection","Drug: ACH-0143102|Drug: Ribavirin","SVR12","Alexion Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 1","8","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACH102-005","September 2012","September 2013","September 2013","October 4, 2012","October 3, 2014","October 10, 2014","Dr. Aasim Sheikh, Marietta, Georgia, United States|Dr. Robert Herring Jr, Nashville, Tennessee, United States|Victor Ankoma-Sey, Houston, Texas, United States|Vinod Rustgi, MD, Fairfax, Virginia, United States|Robert Brennan, Lynchburg, Virginia, United States|Michael Ryan, MD, Norfolk, Virginia, United States",,"https://ClinicalTrials.gov/show/NCT01700179"
144,"NCT01567085","Safety & Efficacy Of Eculizumab In The Prevention Of AMR In Sensitized Recipients Of A Kidney Transplant From A Deceased Donor",,"Completed","Has Results","Stage V Chronic Kidney Disease","Drug: Eculizumab","Post-transplantation Treatment Failure In The First 9 Weeks Post Transplantation","Alexion Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","80","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","C10-002|2010-019631-35","August 29, 2012","June 11, 2015","May 24, 2017","March 30, 2012","May 3, 2019","May 3, 2019","Adelaide, Australia|Camperdown, Australia|Parkville, Australia|Bordeaux, France|Paris, France|Paris, France|Toulouse, France|Tours, France|Brescia, Italy|Padova, Italy|Barcelona, Spain|Gothenburg, Sweden|Uppsala, Sweden|Cambridge, United Kingdom|London, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/85/NCT01567085/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/85/NCT01567085/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01567085"
145,"NCT01528917","An Observational Study of Patients With Lysosomal Acid Lipase Deficiency/Cholesteryl Ester Storage Disease Phenotype",,"Completed","No Results Available","Cholesterol Ester Storage Disease(CESD)|Lysosomal Acid Lipase Deficiency",,"Clinical History Summary","Alexion Pharmaceuticals","All","5 Years and older   (Child, Adult, Older Adult)",,"49","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","LAL-2-NH01","June 2011","January 2013","May 2013","February 8, 2012",,"July 20, 2016","Stanford University, Stanford, California, United States|Children's Memorial Hospital, Chicago, Illinois, United States|University of Minnesota, Minneapolis, Minnesota, United States|Morgan Stanley Children's Hospital of New York-Presbyterian, New York, New York, United States|Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States|Seattle Children's, Seattle, Washington, United States|Hospital for Sick Kids, Toronto, Canada|1st Faculty of Medicine Charles University, Prague, Czech Republic|Hôpital Necker-Enfants Malades, Paris, France|Gaslini Institute, Genoa, Italy|Regina Margherita Hospital, Turin, Italy|Children's Memorial Health Institute, Warsaw, Poland|Hopitaux Universitares De Geneve, Geneve, Switzerland|Birmingham Children's Hospital, Birmingham, United Kingdom|Addenbrooke's Hospital, Cambridge, United Kingdom|Salford Royal, Salford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01528917"
146,"NCT01522170","aHUS Observational Long Term Follow-Up","LTFU","Terminated","No Results Available","Atypical Hemolytic Uremic Syndrome",,"TMA complication-free survival|Duration of response, change over time of value for platelets, LDH, eGFR, Hgb, TMA intervention","Alexion Pharmaceuticals","All","Child, Adult, Older Adult",,"94","Industry","Observational","Observational Model: Case-Only|Time Perspective: Other","C11-003","March 2012","January 2017","January 2017","January 31, 2012",,"February 24, 2017","Emory Healthcare - Children's Center, Atlanta, Georgia, United States|Dunwoody Pediatrics & Children's Healthcare of Atlanta, Dunwoody, Georgia, United States|Fort Wayne Medical Oncology and Hematology, Fort Wayne, Indiana, United States|Fort Wayne, Indiana, United States|Boston Children's Hospital, Boston, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Children's Hospital at Montefiore, Bronx, New York, United States|Hudson Valley Oncology Hematology, Hawthorne, New York, United States|Weill Cornell Medical College, New York, New York, United States|Cincinnati Children's Hospital, Cincinnati, Ohio, United States|Arthur James Cancer Hospital, Columbus, Ohio, United States|Driscoll Children's Hospital, Corpus Christi, Texas, United States|The Methodist Hospital Research Institute, Houston, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States|Providence Sacred Heart Medical Center & Children's Hospital, Spokane, Washington, United States|Fox Valley Hematology, Osh Kosh, Wisconsin, United States|Royal Adelaide Hospital, North Tce. Adelaide, Australia|Universitatsklinik fur Innere Medizin Medizinische Universitat Graz, Graz, Austria|Medizinische Universitaet Innsbruck, Innsbruck, Austria|UZ Gent Dienst nefrologie, Gent, Belgium|Chu Sart Tilman, Liège, Belgium|Centre Hospitalier Universitaire (CHU) Sainte-Justine, Montreal, Canada|The Hospital for Sick Children, Toronto, Canada|Centre Hospitalier Universitaire Pellegrin, Service de Nephrologie Transplantation Dialyse, Bordeaux Cedex, France|CHRU de Caen, Caen, France|Le Kremlin Bicetre Hospital, Nephrology Unit, Le Kremlin Bicetre, France|CHRU de Lille-Hopital A.Calmette, Lille, France|Hôpital Edouard Herriot, Lyon, France|Hopital de la Timone Enfants, Unité de Néphrologie, Marseille, France|CHU Hotel Dieu, Nantes, France|Le Centre Hospitalier Universitaire de Nice, Nice, France|Centre Hospitalier Regional de la Source, Service de nephrologie/hemodialyse, Orleans, France|Hopital Robert-Debré, Service de Néphrologie Pédiatrique, Paris, France|Hopital Tenon, Paris, France|Centre Hospitalier Inter-Communal de Cornouaille, Quimper, France|Hôpital de Bois Guillaume CHU de Rouen, Rouen Cedex, France|CHU-CH Charles Nicolle Pavillon de Pédiatrie, Rouen, France|CHU de Saint-Etienne, Saint Priest En Jarez, France|Nouvel Hopital Civil, Strasbourg, France|CHRU de Tours, Tours, France|Universitaetsklinikum Aachen Klinik fuer Nieren- und Hochdruckkrankheiten, Aachen, Germany|Hannover University Clinic, Hannover, Germany|Universitaet Heidelberg, Heidelberg, Germany|A.O. Papa Giovanni XXIII, Bergamo, Italy|Azienda Ospedaliero-Universitaria Careggi, Firenze, Italy|Istituto Giannina Gaslini, Genova, Italy|Fondazione IRCCS Ca Granda, Ospedale Maggiore Policlinico Maggiore Policlinico, Milano, Italy|Ospedale dei Bambini G. di Cristina, Palermo, Italy|AMC Medical Research B.V., Amsterdam, Netherlands|Radboud University Nijmegen Medical Centre Nijmegen, Nijmegen, Netherlands|Nephrology Clinic, Karolinska University Hospital, Stockholm, Sweden|INSELSPITAL Universitaetsklinik fuer Kinderheilkunde Kindernephrologie, Bern, Switzerland|Royal Devon & Exeter NHS Foundation Trust, Exeter, United Kingdom|Gartnavel General Hospital, Glasgow, United Kingdom|The Newcastle upon Tyne Hospitals NHS, Newcastle upon Tyne, United Kingdom|City Hospital, Nottingham University Hospitals, NHS Trust, Nottingham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01522170"
147,"NCT01488097","Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of SBC-102 (Sebelipase Alfa) in Adult Subjects With Lysosomal Acid Lipase Deficiency",,"Completed","Has Results","Cholesterol Ester Storage Disease (CESD)|Lysosomal Acid Lipase Deficiency|LAL-Deficiency","Drug: sebelipase alfa","Number Of Participants Reporting TEAEs And IARs|Changes From Baseline In ALT And AST|Changes From Baseline In Liver Volume|Changes From Baseline In Liver Fat Content|Changes From Baseline In GGT And ALP|Changes From Baseline In Serum Lipids|Changes From Baseline In Serum Ferritin|Changes From Baseline In Hs-CRP","Alexion Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","8","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LAL-CL04","December 12, 2011","June 21, 2017","June 21, 2017","December 8, 2011","May 9, 2016","July 20, 2018","Eureka, California, United States|Sacramento, California, United States|San Francisco, California, United States|Minneapolis, Minnesota, United States|New York, New York, United States|Sudbury, Ontario, Canada|Prague, Czechia|Paris, France|Leeds, United Kingdom|Salford, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/97/NCT01488097/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/97/NCT01488097/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01488097"
148,"NCT01454986","Study to Evaluate Safety, Tolerability, PK and PD of ALXN1007 in Healthy Subjects",,"Completed","No Results Available","Healthy","Drug: ALXN1007|Other: Placebo","Safety and tolerability of a single dose of ALXN1007.|PK parameters of ALXN1007|PD parameters of ALXN1007","Alexion Pharmaceuticals","All","25 Years to 55 Years   (Adult)","Phase 1","64","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","C11-002","November 2011","August 2013","October 2013","October 19, 2011",,"February 3, 2017","PAREXEL Baltimore EPCU, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01454986"
149,"NCT01419028","A Retrospective Study of the Natural History of Patients With Severe Perinatal and Infantile Hypophosphatasia (HPP)",,"Completed","Has Results","Hypophosphatasia (HPP)",,"Survival|Invasive Ventilator-free Survival Time","Alexion Pharmaceuticals","All","Child, Adult, Older Adult",,"48","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","ENB-011-10","August 2012","June 2013","February 2014","August 17, 2011","July 21, 2014","April 1, 2019","Cedars-Sinai Medical Center, Los Angeles, California, United States|Indiana University school of medicine, Indianapolis, Indiana, United States|Shriners Hospital for Children, Saint Louis, Missouri, United States|Oregon Health & Science University, Portland, Oregon, United States|Cook Children's Health Care System, Fort Worth, Texas, United States|Royal Children's Hospital, Parkville, Australia|University of Manitoba Health Sciences Centre, Winnipeg, Canada|Universitatsmedizin Mainz, Villa, Mainz, Germany|Universitätsklinikum Würzburg Kinderklinik, Pädiatrische Infektiologie und Immunologie, Würzburg, Germany|Hospital Infantil Universitario Nino Jesus Universidad autonoma de Madrid, Madrid, Spain|National Taiwan University Hospital, Taipei, Taiwan|Birmingham Childrens Hospital, Birmingham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01419028"
150,"NCT01410916","Safety and Efficacy Study of Eculizumab in Shiga-Toxin Producing Escherichia Coli Hemolytic-Uremic Syndrome (STEC-HUS)","STEC-HUS","Completed","No Results Available","Shiga-like Toxin-producing Escherichia Coli","Drug: Eculizumab (Soliris®)","Improvement in Systemic TMA & Vital Organ Involvement at 8 weeks of treatment defined as either complete or partial responder based on hematologic normalization/improvement & clinically important improvement in Vital Organs: Brain, Kidney, and Thrombosis","Alexion Pharmaceuticals","All","2 Months and older   (Child, Adult, Older Adult)","Phase 2|Phase 3","198","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","C11-001|2011-002691-17","July 2011","January 2012","June 2012","August 5, 2011",,"April 5, 2013","Bielefeld, Germany|Bielefeld, Germany|Bonn, Germany|Bremen, Germany|Bremerhaven, Germany|Essen, Germany|Flensburg, Germany|Göttingen, Germany|Hamburg, Germany|Hamburg, Germany|Hamburg, Germany|Hannover, Germany|Karlsruhe, Germany|Köln, Germany|Lubeck, Germany|Magdeburg, Germany|Munchen, Germany|Munich, Germany|Munster, Germany|Oldenburg, Germany|Ulm, Germany|Wildeshausen, Germany",,"https://ClinicalTrials.gov/show/NCT01410916"
151,"NCT01371825","Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Sebelipase Alfa in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency",,"Completed","Has Results","Lysosomal Acid Lipase Deficiency|Wolman Disease","Drug: Sebelipase alfa (SBC-102)","Percentage Of Participants In The Primary Efficacy Analysis Set (PES) Surviving To 12 Months Of Age|Percentage Of Participants Surviving Beyond 12 Months Of Age|Median Age At Death|Change From Baseline To Months 12, 24, 36, 48, And 60 In Weight For Age (WFA) Percentiles|Number Of Participants With Stunting, Wasting, Or Underweight|Change From Baseline To Months 12, 24, 36, 48, And 60 In Serum Transaminases (ALT And AST)|Change From Baseline To Months 12, 24, 36, 48, And 60 In Serum Ferritin|Number Of Participants Achieving And Maintaining Transfusion-free Hemoglobin Normalization [TFHN]","Alexion Pharmaceuticals","All","up to 24 Months   (Child)","Phase 2|Phase 3","9","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LAL-CL03","May 4, 2011","January 3, 2018","January 3, 2018","June 13, 2011","April 18, 2016","January 30, 2019","Irvine, California, United States|Cairo, Egypt|Grenoble, France|Paris, France|Dublin, Ireland|London, United Kingdom|Manchester, United Kingdom","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/25/NCT01371825/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/25/NCT01371825/SAP_001.pdf","https://ClinicalTrials.gov/show/NCT01371825"
152,"NCT01358370","A Retrospective Natural History Study of Patients With Lysosomal Acid Lipase Deficiency/Wolman Phenotype",,"Completed","No Results Available","Lysosomal Acid Lipase Deficiency|Wolman Disease",,"Time to Death","Alexion Pharmaceuticals","All","Child, Adult, Older Adult",,"40","Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","LAL-1-NH01","November 2010","January 2013","March 2013","May 23, 2011",,"June 27, 2016","Cedars-Siani Medical Center, Los Angeles, California, United States|Stanford University, Palo Alto, California, United States|University of Minnesota, Minneapolis, Minnesota, United States|Columbia University, New York, New York, United States|Ney York Presbyterian Hosptial, New York, New York, United States|North Shore Long Island Jewish Medical Center, New York, New York, United States|Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States|The Hospital for Sick Children, Toronto, Ontario, Canada|Hospital Necker- Enfants Malades, Paris, France|Instituto Giannina Gaslini- Ospedale Pediatrico IRCCS, Genova, Italy|University of Turin, Turin, Italy|Birmingham Children's Hospital NHS Foundation Trust, Birmingham, United Kingdom|Kings College London, London, United Kingdom|Manchester Children's Hospital, Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01358370"
153,"NCT01307098","Safety, Tolerability and Pharmacokinetics of SBC-102 (Sebelipase Alfa) in Adult Participants With Lysosomal Acid Lipase Deficiency",,"Completed","Has Results","Cholesterol Ester Storage Disease(CESD)|Lysosomal Acid Lipase Deficiency|LAL-Deficiency","Drug: Sebelipase alfa 0.35 mg/kg|Drug: Sebelipase alfa 1 mg/kg|Drug: Sebelipase alfa 3 mg/kg","Number Of Participants Reporting TEAEs And Infusion-Related Reactions (IRRs)","Alexion Pharmaceuticals","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","9","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LAL-CL01","April 25, 2011","January 6, 2012","January 6, 2012","March 2, 2011","December 11, 2018","December 11, 2018","Stanford, California, United States|New York, New York, United States|Pittsburgh, Pennsylvania, United States|Prague, Czechia|Paris, France|Cambridge, United Kingdom|Manchester, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01307098"
154,"NCT01205152","Extension Study of Protocol ENB-002-08 - Study of Asfotase Alfa in Infants and Young Children With Hypophosphatasia (HPP)",,"Completed","Has Results","Hypophosphatasia","Biological: asfotase alfa","Long-term Tolerability of Subcutaneous (SC) Asfotase Alfa|Long-term Efficacy of Asfotase Alfa in Treating Rickets in Infants and Young Children With Hypophosphatasia (HPP).|Long-term Pharmacodynamics (PD) of SC Asfotase Alfa: Plasma Inorganic Pyrophosphate (PPi) Levels|Long-term Pharmacodynamics (PD) of SC Asfotase Alfa: Pyridoxal-5-phosphate (PLP) Levels|Effect of SC Asfotase Alfa on Growth: Weight Z-scores|Effect of SC Asfotase Alfa on Growth: Height/Length Z-scores|Effect of SC Asfotase Alfa on Respiratory Function","Alexion Pharmaceuticals","All","24 Weeks to 42 Months   (Child)","Phase 2","10","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ENB-003-08|FD-R-003745-03","April 2009","August 2016","August 2016","September 20, 2010","November 17, 2017","March 13, 2019","Alfred I. DuPont Hospital for Children, Wilmington, Delaware, United States|St. John's Medical Research Institute, Springfield, Missouri, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|St. Vincent Hospital, Green Bay, Wisconsin, United States|Tawam Hospital, Al Ain, Abu-Dhabi, United Arab Emirates|Royal Maternity Hospital, Royal Belfast Hospital for Sick Children, Belfast, Northern Ireland, United Kingdom|Sheffield Children's Hospital, Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01205152"
155,"NCT01203826","Extension Study of Protocol ENB-006-09 - Study of Asfotase Alfa in Children With Hypophosphatasia (HPP)",,"Completed","Has Results","Hypophosphatasia (HPP)","Biological: Asfotase Alfa","Skeletal Radiograph Evaluation Using a Qualitative Radiographic Global Impression of Change (RGI-C) Scale Compared to Baseline (Pre-treatment) in Study ENB-006-09.","Alexion Pharmaceuticals","All","5 Years to 12 Years   (Child)","Phase 2","12","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ENB-008-10","April 2010","June 2016","June 2016","September 16, 2010","July 26, 2017","March 13, 2019","Shriners Hospital for Children, Saint Louis, Missouri, United States|Children's Hospital Health Sciences Centre, Winnipeg, Manitoba, Canada",,"https://ClinicalTrials.gov/show/NCT01203826"
156,"NCT01194973","An Open-label, Multi-center Clinical Trial of Eculizumab in Adult Patients With Atypical Hemolytic-uremic Syndrome",,"Completed","Has Results","Atypical Hemolytic-Uremic Syndrome","Drug: Eculizumab","Percentage of Patients With Complete TMA Response|Percentage of Patients With Modified Complete TMA Response|Percentage of Patients With Complete Hematologic Response|Percentage of Patients With Platelet Count Normalization|Percentage of Patients With Estimated Glomerular Filtration Rate (eGFR) Improvement|Platelet Count Change From Baseline to 26 Weeks|Platelet Count Change From Baseline to 52 Weeks","Alexion Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","44","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","C10-004","July 2010","October 2013","February 2014","September 3, 2010","April 24, 2015","May 30, 2017","Burlington, Massachusetts, United States|Hackensack, New Jersey, United States|New York, New York, United States|Columbus, Ohio, United States|Houston, Texas, United States|Liège, Belgium|Caen, France|Lille, France|Nantes, France|Nice, France|Paris, France|Paris, France|Toulouse, France|Tours, France|Essen, Germany|Hannover, Germany|Bergamo, Italy|Firenze, Italy|Barcelona, Spain|Cordoba, Spain|Exeter, United Kingdom|London, United Kingdom|Newcastle, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01194973"
157,"NCT01194804","E07-001: Safety and Efficacy Extension Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients",,"Completed","Has Results","Paroxysmal Nocturnal Hemoglobinuria","Drug: Eculizumab","Change From Baseline in Lactate Dehydrogenase|Change From Baseline in FACIT-Fatigue Scale Total Score|Change From Baseline in PNH Red Blood Cell (RBC) Count|Change From Baseline in Number of Units of Packed RBCs Transfused|Change From Baseline in Plasma Free Hemoglobin","Alexion Pharmaceuticals|CMIC Co, Ltd. Japan","All","12 Years and older   (Child, Adult, Older Adult)","Phase 2","27","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","E07-001","April 2008","September 2010","March 2011","September 3, 2010","July 12, 2019","September 17, 2019",,,"https://ClinicalTrials.gov/show/NCT01194804"
158,"NCT01193348","An Open-Label, Multi-Center Clinical Trial of Eculizumab in Pediatric Patients With Atypical Hemolytic-Uremic Syndrome","aHUS","Completed","Has Results","Atypical Hemolytic-Uremic Syndrome","Drug: Eculizumab","Proportion of Patients With Complete TMA Response|Proportion of Patients With Complete Hematologic Response|Proportion of Patients With Platelet Count Normalization|Proportion of Patients With Estimated Glomerular Filtration Rate (eGFR) Improvement|Platelet Count Change From Baseline to 26 Weeks|Platelet Count Change From Baseline to 52 Weeks|Pharmacokinetics (PK) and Pharmacodynamics (PD); Minimum and Maximum Blood Concentration (Body Weight Cohort 5 - <10kg) N=3|Pharmacokinetics (PK) and Pharmacodynamics (PD); Minimum and Maximum Blood Concentration (Body Weight Cohort 10 - <20kg) N=7|Pharmacokinetics (PK) and Pharmacodynamics (PD); Minimum and Maximum Blood Concentration (Body Weight Cohort 20 - <30kg)|Pharmacokinetics (PK) and Pharmacodynamics (PD); Minimum and Maximum Blood Concentration (Body Weight Cohort 30 - <40kg) N=1|Pharmacokinetics (PK) and Pharmacodynamics (PD); Minimum and Maximum Blood Concentration (Body Weight Cohort ≥40kg) N=5","Alexion Pharmaceuticals","All","1 Month to 18 Years   (Child, Adult)","Phase 2","22","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","C10-003","September 2010","January 2014","April 2014","September 1, 2010","April 29, 2015","April 29, 2015","Atlanta, Georgia, United States|Hackensack, New Jersey, United States|Corpus Christi, Texas, United States|Spokane, Washington, United States|North Adelaide, South Australia, Australia|Gent, Belgium|Toronto, Ontario, Canada|Lille, France|Marseille, France|Paris, France|Rouen, France|Hannover, Germany|Milano, Italy|Palermo, Italy|Nijmegen, Netherlands|London, United Kingdom|Nottingham, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01193348"
159,"NCT01176266","Open-Label Study of Asfotase Alfa in Infants and Children ≤ 5 Years of Age With Hypophosphatasia (HPP)",,"Completed","Has Results","Hypophosphatasia","Drug: asfotase alfa","Effect of Asfotase Alfa Treatment on Skeletal Manifestations of Hypophosphatasia (HPP)|Safety and Tolerability of Repeated Subcutaneous (SC) Injections of Asfotase Alfa|Effect of Asfotase Alfa Treatment on Ventilator-free Survival (Week 312)|Effect of Asfotase Alfa Treatment on Respiratory Function|Effect of Asfotase Alfa Treatment on Physical Growth - Length/Height Z-scores Change From Baseline to Last Obtained Value|Effect of Asfotase Alfa Treatment on Physical Growth - Weight Z-scores Change From Baseline to Last Obtained Value|Effect of Asfotase Alfa on Biomarkers - Plasma Inorganic Pyrophosphate (PPi) Change From Baseline to Last Obtained Value|Effect of Asfotase Alfa on Biomarkers - Plasma Pyridoxal-5' Phosphate (PLP) Change From Baseline to Last Obtained Value|Effect of Asfotase Alfa on Serum Parathyroid Hormone (PTH) - Change From Baseline to Last Obtained Value|Effect of Asfotase Alfa Treatment on Tooth Loss|Pharmacokinetic (PK) Properties of Asfotase Alfa (Tlast)|Pharmacokinetic (PK) Properties of Asfotase Alfa (Tmax)|Pharmacokinetic (PK) Properties of Asfotase Alfa (Cmax)|Pharmacokinetic (PK) Properties of Asfotase Alfa (AUCt)","Alexion Pharmaceuticals","All","up to 5 Years   (Child)","Phase 2|Phase 3","69","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ENB-010-10","July 2010","September 2016","September 2016","August 5, 2010","February 26, 2018","March 13, 2019","Children's Hospital & Research Center Oakland, Oakland, California, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|Lady Cilento Children's Hospital, South Brisbane, Queensland, Australia|Royal Children'S Hospital Melbourne, Parkville, Victoria, Australia|Health Sciences Centre Winnipeg, University of Manitoba, Winnipeg, Manitoba, Canada|Necker Hospital, Paris, France|Chu de Toulouse, Toulouse, France|Universitätskinderklinikum Würzburg, Würzburg, Germany|Istituto Giannina Gaslini, Genova, Italy|Ospedale Pediatrico Bambino Gesù, Roma, Italy|Fukuoka Higashi Medical Hospital, Koga, Fukuoka, Japan|Ishikawa Prefectural Hospital, Kanazawa, Ishikawa, Japan|St. Marianna University School of Medicine, Yokohayama City Seibu Hospital, Yokohama, Kanagawa, Japan|Tokyo Medical University Hospital, Shinjuku, Tokyo, Japan|Saitama Municipal Hospital, Saitama, Japan|Federal State Budgetary Institution, Moscow, Russian Federation|King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia|Hospital Infantil Universitario Nino Jesus, Madrid, Spain|Uludag University, Bursa, Turkey|Birmingham Children's Hospital, Birmingham, United Kingdom|Royal Manchester Children'S Hospital, Manchester, United Kingdom|Sheffield Children'S Hospital, Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01176266"
160,"NCT01163149","Safety and Efficacy Study of Asfotase Alfa in Adolescents and Adults With Hypophosphatasia (HPP)",,"Completed","Has Results","Hypophosphatasia","Drug: asfotase alfa","Change From Baseline to Week 24 for Plasma Pyridoxal-5' Phosphate (PLP)|Change From Baseline to Week 24 for Plasma Inorganic Pyrophosphate (PPi)|Safety and Tolerability of Asfotase Alfa|Change From Baseline in Bone Mineral Content (BMC) as Measured by Dual-energy X-ray Absorptiometry (DXA)|Change From Baseline in Bone Mineral Density (BMD) as Measured by Dual-energy X-ray Absorptiometry (DXA)|Change in Walking Ability as Measured by the Six-Minute Walk Test (6MWT)|Change From Baseline in HPP-related Osteomalacia as Measured by Trans-iliac Crest Bone Biopsy: Osteoid Volume/Bone Volume|Change From Baseline in HPP-related Osteomalacia as Measured by Trans-iliac Crest Bone Biopsy: Osteoid Thickness|Change From Baseline in HPP-related Osteomalacia as Measured by Trans-iliac Crest Bone Biopsy: Mineralization Lag Time","Alexion Pharmaceuticals","All","13 Years to 65 Years   (Child, Adult, Older Adult)","Phase 2","19","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ENB-009-10","June 2010","June 2016","June 2016","July 15, 2010","September 18, 2017","March 13, 2019","Shriner's Hospital for Children, Saint Louis, Missouri, United States|Duke University Medical Center, Durham, North Carolina, United States|Health Sciences Centre Winnipeg, University of Manitoba, Winnipeg, Manitoba, Canada",,"https://ClinicalTrials.gov/show/NCT01163149"
161,"NCT00952484","Safety and Efficacy of Asfotase Alfa in Juvenile Patients With Hypophosphatasia (HPP)",,"Completed","Has Results","Hypophosphatasia (HPP)","Biological: asfotase alfa","Change in Rickets Severity on Skeletal Radiographs From Baseline to Week 24 as Measured by the Radiographic Global Impression of Change (RGI-C) Scale|Change in Osteomalacia - Osteoid Thickness (as Measured by Trans-iliac Crest Bone Biopsy)|Change in Osteomalacia - Osteoid Volume/Bone Volume (as Measured by Trans-iliac Crest Bone Biopsy)|Change in Osteomalacia - Mineralization Lag Time (as Measured by Trans-iliac Crest Bone Biopsy)|Change in Height (Z-scores)|Change in Biomarkers of Asfotase Alfa Activity as Measured by Plasma Inorganic Pyrophosphate (PPi)|Change in Biomarkers of Asfotase Alfa Activity as Measured by Pyridoxal-5'-Phosphate (PLP)|Maximum Serum Concentration of Asfotase Alfa (Cmax).|Time at Maximum Serum Concentration of Asfotase Alfa (Tmax)|Area Under Serum Concentration-time Curve to Last Measurable Concentration of Asfotase Alfa (AUCt)|Time at Maximum Serum Concentration of Asfotase Alfa (Tmax).","Alexion Pharmaceuticals","All","5 Years to 12 Years   (Child)","Phase 2","13","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ENB-006-09","September 2009","July 2010","July 2010","August 6, 2009","July 26, 2011","April 1, 2019","Shriners Hospital for Children, Saint Louis, Missouri, United States|The University of Manitoba Health Services Centre, Winnipeg, Manitoba, Canada",,"https://ClinicalTrials.gov/show/NCT00952484"
162,"NCT00894075","Safety and Efficacy Study of ENB-0040 in Juvenile Patients With Hypophosphatasia (HPP)",,"Withdrawn","No Results Available","Hypophosphatasia","Biological: ENB-0040","Skeletal radiographs using a qualitative Clinical Global Impression of Change (CGI-C) scoring system|PK using serum peak and trough levels and PD of plasma inorganic pyrophosphate (PPi) and plasma pyridoxal-5' phosphate (PLP) as biomarkers for HPP.","Alexion Pharmaceuticals","All","5 Years to 12 Years   (Child)","Phase 2","0","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ENB-004-09","July 2009","December 2014","December 2014","May 6, 2009",,"January 25, 2013",,,"https://ClinicalTrials.gov/show/NCT00894075"
163,"NCT00844844","Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Resistant aHUS","aHUS","Completed","Has Results","Atypical Hemolytic Uremic Syndrome","Drug: Eculizumab","Platelet Count Change From Baseline to 26 Weeks|Percentage of Patients With Platelet Count Normalization|Percentage of Patients With Hematologic Normalization|Percentage of Patients With Complete TMA Response|TMA Intervention Rate|Platelet Count Change From Baseline to 156 Weeks|Pharmacokinetics (PK) and Pharmacodynamics (PD); Minimum and Maximum Blood Concentration","Alexion Pharmaceuticals","All","12 Years to 17 Years   (Child)","Phase 2","1","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","C08-002B|BB-IND-11075|EudraCT Number 2008-006953-41","May 2009","September 2010","July 2013","February 16, 2009","December 3, 2014","July 23, 2015","Atlanta, Georgia, United States|Fort Wayne, Indiana, United States|New York, New York, United States|New York, New York, United States|Grapevine, Texas, United States|Houston, Texas, United States|Innsbruck, Austria|Bordeaux, France|Lyon, France|Nantes, France|Paris, France|Quimper, France|Saint Priest en Jarez, France|Tours, France|Aachen, Germany|Essen, Germany|Newcastle, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00844844"
164,"NCT00844545","Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-Resistant aHUS","aHUS","Completed","Has Results","Atypical Hemolytic Uremic Syndrome","Drug: Eculizumab","Platelet Count Change From Baseline to 26 Weeks|Percentage of Patients With Platelet Count Normalization|Percentage of Patients With Hematologic Normalization|Percentage of Patients With Complete TMA Response|TMA Intervention Rate|Platelet Count Change From Baseline to 156 Weeks|Pharmacokinetics (PK) and Pharmacodynamics (PD); Minimum and Maximum Blood Concentration","Alexion Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","16","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","C08-002A|BB-IND-11075|EudraCT Number 2008-006952-23","May 2009","September 2010","July 2013","February 16, 2009","December 1, 2014","July 23, 2015","Atlanta, Georgia, United States|Fort Wayne, Indiana, United States|New York, New York, United States|New York, New York, United States|Grapevine, Texas, United States|Houston, Texas, United States|Innsbruck, Austria|Bordeaux, France|Lyon, France|Nantes, France|Paris, France|Quimper, France|Saint Priest en Jarez, France|Tours, France|Aachen, Germany|Essen, Germany|Newcastle, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00844545"
165,"NCT00844428","Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Sensitive aHUS","aHUS","Completed","Has Results","Atypical Hemolytic Uremic Syndrome","Drug: eculizumab","Percentage of Patients With TMA Event-free Status|Percentage of Patients With Hematologic Normalization|Percentage of Patients With Complete TMA Response|TMA Intervention Rate|Platelet Count Change From Baseline to 26 Weeks|Percentage of Patients With Platelet Count Normalization|Platelet Count Change From Baseline to 156 Weeks|Pharmacokinetics (PK) and Pharmacodynamics (PD); Minimum and Maximum Blood Concentration","Alexion Pharmaceuticals","All","12 Years to 17 Years   (Child)","Phase 2","5","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","C08-003B|BB-IND 11075|EudraCT Number 2008-006955-28","July 2009","October 2010","December 2013","February 16, 2009","January 26, 2015","July 23, 2015","Toronto, Canada|Bois-Guillaume, France|Bordeaux, France|Lyon, France|Nantes, France|Paris, France|Starsbourg, France|Hannover, Germany|Genova, Italy|Nijmegen, Netherlands|Stockholm, Sweden|Exeter, United Kingdom|Glasgow, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00844428"
166,"NCT00838513","Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-sensitive Atypical Hemolytic Uremic Syndrome (aHUS)","aHUS","Completed","Has Results","Atypical Hemolytic Uremic Syndrome","Drug: eculizumab","Percentage of Patients With TMA Event-free Status|Percentage of Patients With Hematologic Normalization|Percentage of Patients With Complete TMA Response|TMA Intervention Rate|Platelet Count Change From Baseline to 26 Weeks|Percentage of Patients With Platelet Count Normalization|Platelet Count Change From Baseline to 156 Weeks|Pharmacokinetics (PK) and Pharmacodynamics (PD); Minimum and Maximum Blood Concentration","Alexion Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","15","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","C08-003A|BB-IND 11075|EudraCT Number 2008-006954-17","July 2009","October 2010","December 2013","February 6, 2009","January 26, 2015","July 23, 2015","Toronto, Canada|Bois-Guillaume, France|Bordeaux, France|Lyon, France|Nantes, France|Paris, France|Strasbourg, France|Hannover, Germany|Genova, Italy|Nijmegen, Netherlands|Stockholm, Sweden|Exeter, United Kingdom|Glasgow, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00838513"
167,"NCT00744042","Safety and Efficacy Study of Asfotase Alfa in Severely Affected Infants With Hypophosphatasia (HPP)",,"Completed","Has Results","Hypophosphatasia (HPP)","Biological: asfotase alfa","Change in Rickets Severity From Baseline to Week 24, Based on Assessment of Skeletal Radiographs Using Radiologic Global Impression of Change (RGI-C)|Maximum Serum Concentration of Asfotase Alfa (Cmax)|Time at Maximum Serum Concentration of Asfotase Alfa (Tmax)|Area Under Serum Concentration-time Curve to Last Measurable Concentration of Asfotase Alfa (AUCt)","Alexion Pharmaceuticals","All","up to 36 Months   (Child)","Phase 1|Phase 2","11","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ENB-002-08","September 2008","May 2010","May 2010","August 29, 2008","September 30, 2011","April 1, 2019","Arkansas Children's Hospital, Little Rock, Arkansas, United States|Alfred I. duPont Hospital for Children, Wilmington, Delaware, United States|St. John's Hospital, Springfield, Missouri, United States|University of Nebraska Medical Center, Munroe-Meyer Institute, Omaha, Nebraska, United States|Vanderbilt Children's Hospital, Nashville, Tennessee, United States|St. Vincent Hospital, Green Bay, Wisconsin, United States|The University of Manitoba Health Sciences Centre, Winnipeg, Manitoba, Canada|Tawam-John Hopkins Hospital, Al Ain, Abu-Dhabi, United Arab Emirates|Sheffield Children's Hospital, Sheffield, England, United Kingdom|Royal Belfast Hospital for Sick Children, Belfast, Northern Ireland, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00744042"
168,"NCT00739505","Safety Study of Human Recombinant Tissue Non-Specific Alkaline Phosphatase Fusion Protein Asfotase Alfa in Adults With Hypophosphatasia (HPP)",,"Completed","No Results Available","Hypophosphatasia (HPP)","Biological: Asfotase Alfa","To determine the safety and tolerability of Asfotase Alfa given intravenously and given subcutaneously.|To assess the pharmacokinetics (PK) of Asfotase Alfa given intravenously and subcutaneously|To assess the bioavailability of the subcutaneous Asfotase Alfa","Alexion Pharmaceuticals","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","6","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ENB-001-08","August 2008","January 2009","February 2009","August 21, 2008",,"March 29, 2019","Barnes Jewish Hospital- Washington University School of Medicine, Saint Louis, Missouri, United States|Duke University Medical Center, Durham, North Carolina, United States|Department of Pediatrics & Child Health, Health Sciences Centre Winnipeg, University of Manitoba, Winnipeg, Manitoba, Canada",,"https://ClinicalTrials.gov/show/NCT00739505"
169,"NCT00727194","Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis",,"Terminated","Has Results","Myasthenia Gravis","Drug: eculizumab|Drug: Placebo","Quantitative Myasthenia Gravis (QMG): The Primary Efficacy Endpoint in This Study Was the Percentage of Patients With a 3-point Reduction From Baseline in the QMG Total Score for Disease Severity.|Mean Change From Baseline in QMG Total Score|Change From Baseline in the MGFA Post-Intervention Status (PIS)|Change From Baseline in the MG-Activity of Daily Living Profile (MG-ADL)|Change From Baseline in the QoL Instrument, SF-36.|Change From Baseline in Respiratory Function Tests to Characterize the Degree of Involvement of Respiratory Muscles.|Change From Baseline to the End of Treatment (16 Weeks) in the Two Most Affected QMG Items for Disease Severity (Individual Test Item: Double Vision)|Change From Baseline to the End of Treatment (16 Weeks) in the Two Most Affected QMG Items for Disease Severity (Individual Test Item: Ptosis)","Alexion Pharmaceuticals","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","14","Industry","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","C08-001","October 2008","March 2011","July 2011","August 1, 2008","December 12, 2016","September 24, 2019","University of Alabama at Birmingham, Birmingham, Alabama, United States|University of California, Irvine, Orange, California, United States|University of California - Davis, Sacramento, California, United States|University of Florida & Shands Neuroscience Institute, Jacksonville, Florida, United States|Emory University, Atlanta, Georgia, United States|Wishard Hospital, Indianapolis, Indiana, United States|University of Kansas Medical Center, Kansas City, Kansas, United States|Johns Hopkins University School of Medicine, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Caritas St. Elizabeths' Medical Center, Boston, Massachusetts, United States|Wayne State University, Detroit, Michigan, United States|Mount Sinai School of Medicine, New York, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|University Hospitals - Case Medical Center, Cleveland, Ohio, United States|The Ohio State University, Columbus, Ohio, United States|The Warren Alpert Medical School of Brown University, Providence, Rhode Island, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University of Texas Southwestern Medical School, Dallas, Texas, United States|The University of Vermont College of Medicine, Burlington, Vermont, United States|University of Virginia, Charlottesville, Virginia, United States|The Northern Alberta Clinical trials and Research Centre, Edmonton, Alberta, Canada|Institute of Neurological Sciences, Department of Neurology, Southern General Hospital,, Glasgow, United Kingdom|Institute of Neurology, London, United Kingdom|Department of Clinical Neurology, West Wing, John Radcliffe Hospital, Oxford, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00727194"
170,"NCT00648739","Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM",,"Terminated","Has Results","B-cell Chronic Lymphocytic Leukemia|Multiple Myeloma","Drug: Samalizumab","Maximum Tolerated Dose (MTD) Of Samalizumab|Number Of Participants With Treatment-Emergent Adverse Events (TEAEs)|Percent Of Bound Samalizumab On B-Cell Chronic Lymphocytic Leukemia (B-CLL) Cells In Participants With B-CLL At Baseline (Predose) And Day 1 (Postdose)|Density Of B-CLL Cells Bound At Baseline (Predose) And Day 1 (Postdose)|Clinical Response Of Participants With B-CLL Following Samalizumab Dosing Using Modified NCI Working Group Response Criteria For ORR Rate|Clinical Response Of Participants With Multiple Myeloma (MM) Following Dosing With Samalizumab","Alexion Pharmaceuticals","All","Child, Adult, Older Adult","Phase 1|Phase 2","26","Industry","Interventional","Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","C07-003","June 19, 2008","December 14, 2010","December 14, 2010","April 1, 2008","March 5, 2019","March 5, 2019","Tucson, Arizona, United States|Atlanta, Georgia, United States|Morristown, New Jersey, United States|Durham, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT00648739"
171,"NCT00380159","Open-Label, 48 Week Extension Study of Elvucitabine in Combination With Background ART For Subjects Who Have Completed Study ACH443-014A",,"Completed","No Results Available","HIV-1 Infection","Drug: elvucitabine|Drug: Lamivudine|Drug: Emtricitabine","To assess the safety of 48weeks of 10mg/QD of elvucitabine in combination with ART|To describe the anti-viral activity of elvucitabine in combination with ART as measured by plasma HIV-1 RNA over 24 weeks","Alexion Pharmaceuticals","All","18 Years to 60 Years   (Adult)","Phase 2","4","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACH443-018","September 2006","December 2008","January 2009","September 25, 2006",,"March 17, 2014","ARCA, Atlanta, Georgia, United States|ACTU University of Cincinnati, Cincinnati, Ohio, United States|Dr. Salvador B Gautier Hospital, Santo Domindo, Dominican Republic|EPIMED, Berlin, Germany|immunologische Ambulanz, University Clinic, Bonn, Germany|Klinikum der Universitat zu Koln, Koln, Germany|Hospital La Paz, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT00380159"
172,"NCT00312039","Study of Once Daily Elvucitabine Versus Lamivudine in Subjects With a Documented M184V Mutation","Resistance","Completed","No Results Available","HIV Infections","Drug: elvucitabine|Drug: Lamivudine","Reduction in viral load|safety","Alexion Pharmaceuticals","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","20","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ACH443-014A","March 2006","October 2007","October 2007","April 7, 2006",,"January 22, 2014","UAB Birmingham, Birmingham, Alabama, United States|University of California at Davis, Sacramento, California, United States|University of Miami School of Medicine, Miami, Florida, United States|Orlando Immunology Center, Orlando, Florida, United States|Olayemi Osiyemi, West Palm Beach, Florida, United States|ACRA, Atlanta, Georgia, United States|Beth Israel Medical Center, New York, New York, United States|University of Cincinnati, Cincinnati, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00312039"
173,"NCT00122330","Study Using Eculizumab in Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients",,"Completed","No Results Available","Hemoglobinuria, Paroxysmal","Drug: eculizumab",,"Alexion Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","75","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Educational/Counseling/Training","TRIUMPH","October 2004",,"January 2006","July 22, 2005",,"December 4, 2006","City of Hope National Medical Center, Div. of Hematology & Bone Marrow Transplant, Duarte, California, United States|University of California at Los Angeles, Los Angeles, California, United States|Scripps Cancer Center, San Diego, California, United States|Stanford University Medical Center, Division of Hematology, Stanford, California, United States|Hartford Hospital, Cancer Clinical Research Office, Hartford, Connecticut, United States|Cleveland Clinic, Dept. of Clinical Research, Weston, Florida, United States|Indiana University Cancer Pavilion, Div. of Hematology-Oncology, Hematological Malignancy Program/Immunology, Indianapolis, Indiana, United States|Johns Hopkins University Medical Center, Baltimore, Maryland, United States|National Heart, Blood, and Lung Institute, National Institutes of Health, Bethesda, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Washington University School of Medicine, Dept. of Internal Medicine/Division of Hematology, St. Louis, Missouri, United States|NYU Clinical Cancer Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Duke University Health System, Division of Cell Therapy, Heme Malignancies Program, Durham, North Carolina, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Presbyterian Medical Center, PENN Comprehensive Hemophilia & Thrombosis Program, Philadelphia, Pennsylvania, United States|Princess Alexandra Hospital, Oncology Haematology Radiation Department, Woolloongabba, Queensland, Australia|Queen Elizabeth Hospital, Dept. of Haematology, Woodville South, South Australia, Australia|Royal Melbourne Hospital, Dept. of Clinical Haematology & Medical Oncology, Parkville, Victoria, Australia|The Royal Perth Hosptial, Department of Haematology/Level 2, Perth, Western Australia, Australia|Ucl St. Luc, Hematology Department, Brussels, Belgium|University of Alberta, Cross Cancer Institute, Edmonton, Alberta, Canada|Hospital De L'Hotel Dieu, Hematologie et Oncologie Medicale, Cedex, Paris, France|Hopital Saint-Louis, Centre G. Hayem-Secteur Bleu Porte 7, Laboratoire De Pathologie/Greffe de Moelle, Cedex, Paris, France|Universitatsklinikum Essen, Zentrum fur Innere Medizin, Essen, Germany|Universitatsklinik Greifswald, Innere Medizin C - Hamato-Onkologie, Greifswald, Germany|Medizinische Hochschule Hannover, Abt. Hamatologie/Onkologie, Zentrum fur Innere Medizin, Hannover, Germany|Saarland University Medical School, Internal Medicine 1, Homburg/Saar, Germany|Institut fur Klinische Transfusionmedizin und Immungenetik, Abtlg. Transfusionsmedizin des Universitatskinikums Ulm, Ulm, Germany|St. James Hospital, Haematology Department, Dublin, Ireland|Azienda Ospedaliera Universitaria Careggi, Dipartimento di area critica medico-chirurgica, Firenze, Italy|Ospedale San Martino, Dept. of Hematology, Genova, Italy|Ospedale Maggiore di Milano, Divisione di Ematologia, Milano, Italy|Universitar degli Studi di Napoli, Divisione di Ematologia, Azienda Universitar Policlinico, Napoli, Italy|Ospedale San Bortolo, Divisione di Ematologia, Vicenza, Italy|UMC St. Radboud, Dept. of Hematology, Nijmegen, GA, Netherlands|Lund University Hospital, Department of Internal Medicine, Section of Hematology, Lund, Sweden|Umea University Hospital, Dept. of Internal Medicine 3, Section for Hematology, Umea, Sweden|Universitatsklinik Basel, Division of Hematology, Basel, CH, Switzerland|Royal Cornwall Hospital, Haematology Dept., Truro, Cornwall, United Kingdom|Belfast City Hospital, Dept. of Haematology C Floor, Belfast, United Kingdom|Leeds General Infirmary, D Floor Brotherton Wing, Leeds, United Kingdom|St. George's Hospital, Department of Haematology, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00122330"
174,"NCT00122317","Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH)",,"Completed","Has Results","Paroxysmal Hemoglobinuria, Nocturnal","Drug: eculizumab","Incidence of Treatment-emergent Adverse Events|Hemolysis as Measured by Change From Baseline in LDH Area Under the Curve|Quality of Life as Measured by FACIT-Fatigue Scale Change From Baseline|Incidence of Thrombosis After Eculizumab Infusion","Alexion Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","187","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","E05-001","May 2005","September 2008","October 2008","July 22, 2005","June 5, 2017","March 13, 2018","Stanford University Medical Center, Division of Hematology, Stanford, California, United States|Hartford Hospital, Cancer Clinical Research Office, Hartford, Connecticut, United States|Cleveland Clinic Florida, Department of Clinical Research, Weston, Florida, United States|Indianapolis University Cancer Center, Indianapolis, Indiana, United States|Johns Hopkins University Medical Center, Baltimore, Maryland, United States|National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Mayo Clinic, Divison of Hematology, Rochester, Minnesota, United States|Washington University, Department of Internal Medicine/Division of Hematology, Saint Louis, Missouri, United States|NYU Clinical Cancer Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Duke University Medical Center, Division Cell Therapy, Heme Malignancies Program, Durham, North Carolina, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Presbyterian Medical Center, PENN Comprehensive Hemophilia & Thombosis Program, Philadelphia, Pennsylvania, United States|Royal North Shore Hospital, Haematology Department, Saint Leonards, New South Wales, Australia|Princess Alexandra Hospital, Oncology Haematology Radiation Department, Woolloongabba, Queensland, Australia|The Queen Elizabeth Hospital, Haematology/Oncology Department, Woodville South, South Australia, Australia|The Royal Perth Hospital, Department of Haematology/Level 2, Perth, Western Australia, Australia|Royal Melbourne Hospital, Department of Clinical Haematology & Medical Oncology, Parkville, Australia|Ucl St. Luc, Hematology Department, Brussels, Belgium|University of Alberta, Cross Cancer Institute, Edmonton, Alberta, Canada|London Regional Cancer Centre, Clinical Research Unit Room C3080, London, Ontario, Canada|Hopital Saint Louis, Centre d'investigation Clinique, Paris, Cedex, France|Universitatsklinikum Essen, Zentrum fur Innere Medizin, Essen, Germany|Medizinische Hochschule Hannover, Abt. Hamatologie/Onkologie, Zentrum fur Innere Medizin, Hannover, Germany|Universitatskliniken des Saarlandes, Innere Medizin 1, Homburg/Saar, Germany|Institut fur Klinische Transfusionmedizin und Immunogenetik, Abtlg. Transfusionmedizin des Univ. Ulm, Ulm, Germany|St. James's Hospital, Cancer Clinical Trial Office, Dublin, Ireland|Azienda Ospedaliera Universitaria Careggi, Dipartimento di area critica medico-chirurgica, Firenze, Italy|Ospedale San Martino, Department of Hematology, Genova, Italy|Ospedale Maggiore di Milano, Divisione di Ematologia, Milano, Italy|Universita degli Studi di Napoli, Divisione di Ematologia, Azienda Universitar Policlinico, Napoli, Italy|Ospedale San Bortolo, Divisione di Ematologia, Vicenza, Italy|UMC St. Radboud, Department of Hematology, Nijmegen, GA, Netherlands|Hospital Clinic i Provincial, Servicio de Hematologia, Barcelona, Spain|Hospital Universitario Germans Trias I Pujol, Servicio de Hematologia, Barcelona, Spain|Hospital De La Paz, Servicio de Hematologia, Madrid, Spain|Stockholm South Hospital, Division of Hematology, Stockholm, Sweden|Leeds General Infirmary, D Floor Brotherton Wing, Leeds, United Kingdom|St. George's Hospital, Department of Haematology, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00122317"
175,"NCT00122304","Study of Safety in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated With Eculizumab",,"Completed","No Results Available","Hemoglobinuria, Paroxysmal","Drug: eculizumab","Acceptable safety (adverse events [AEs], labs, electrocardiograms [ECGs], vital signs)|Primary surrogate of efficacy endpoint is hemolysis measured by LDH area under the curve.|Hemolysis measured by the change of LDH from baseline;|Quality of Life","Alexion Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","85","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SHEPHERD|C04-002","December 2004",,"November 2006","July 22, 2005",,"February 21, 2007","Norris Comprehensive Cancer Center, Los Angeles, California, United States|Stanford University Medical Center, Division of Hematology, Stanford, California, United States|Hartford Hospital, Cancer Clinical Research Office, Hartford, Connecticut, United States|Cleveland Clinic Florida, Dept. of Clinical Research, Weston, Florida, United States|Indiana University Cancer Pavilion, Indianapolis, Indiana, United States|Johns Hopkins University Medical Center, Baltimore, Maryland, United States|National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Mayo Clinic, Division of Hematology, Rochester, Minnesota, United States|Washington University Medical Center, Department of Internal Medicine/Division of Hematology, St. Louis, Missouri, United States|Cooper University Hospital, Cooper Cancer Institute, Voorhees, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|NYU Clinical Cancer Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Duke University Medical Center, Division Cell Therapy, Heme Malignancies Program, Durham, North Carolina, United States|The Cleveland Clinic Foundation, Cleveland, Ohio, United States|OHSU Center for Hematologic Malignancies, Portland, Oregon, United States|Presbyterian Medical Center, PENN Comprehensive Hemophilia & Thrombosis Program, Philadelphia, Pennsylvania, United States|University of Utah, Hematology-BMT Department, Salt Lake City, Utah, United States|Royal North Shore Hospital, Haematology Department, St. Leonard, New South Wales, Australia|Princess Alexandra Hospital, Oncology Haematology Radiation Department, Woolloongabba, Queensland, Australia|The Queen Elizabeth Hospital, Haematology/Oncology Department, Woodville South, South Australia, Australia|The Royal Perth Hospital, Dept. of Haematology/Level 2, Perth, Western Australia, Australia|Royal Melbourne Hospital, Dept. of Clinical Haematology & Medical Oncology, Parkville, Australia|Ucl St. Luc, Hematology Department, Brussels, Belgium|University of Alberta, Cross Cancer Institute, Edmonton, Alberta, Canada|London Regional Cancer Centre, Clinical Research Unit Room C3080, London, Ontario, Canada|Hopital Saint-Louis, Centre d'investigation Clinique, Paris, Cedex, France|Universitatsklinikum Essen, Zentrum fur Innere Medizin, Essen, Germany|Medizinische Hochschule Hannover, Abt. Hamatologie/Onkologie, Zentrum fur Innere Medizin, Hannover, Germany|Universitatskliniken des Saarlandes, Innere Medizin 1, Homburg/Saar, Germany|Institut fur Klinische Transfusionmedizin und Immungenetik, Abtlg. Transfusionmedizin des Univer. Ulm, Ulm, Germany|St. James Hospital, Haematology Dept., Cancer Clinical Trial Office, Dublin, Ireland|Azienda Ospedaliera Universitaria Careggi, Dipartimento di area critica medico-chirurgica, Firenze, Italy|Ospedale San Martino, Dept. of Hematology, Genova, Italy|Ospedale Maggiore di Milano, Divisione di Ematologia, Milano, Italy|Universita degli Studi di Napoli, Divisione di Ematologia, Azienda Universitar Policlinico, Napoli, Italy|Ospedale San Bortolo, Divisione di Ematologia, Vicenza, Italy|UMC St. Radboud, Department of Hematology, Nijmegen, Netherlands|Hospital Clinic i Provincial, Servicio de Hematologia, Barcelona, Spain|Hospital Universitario Germans Trias I Pujol, Servicio de Hematologia, Barcelona, Spain|Hospital De La Paz, Servicio de Hematologia, Madrid, Spain|Stockholm South Hospital, Division of Hematology, Stockholm, Sweden|University Hospital, Dept. of Haematology, Uppsala, Sweden|Kantonsspital Basel, Abteilung fuer Haematologie, Basel, Switzerland|Royal Cornwall Hospital, Truro, Cornwall, United Kingdom|Leeds General Infirmary, D Floor Brotherton Wing, Leeds, United Kingdom|St. Georges Hospital, Department of Haematology, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00122304"
176,"NCT00048308","Effect of Pexelizumab on All-Cause Mortality and Myocardial Infarction in Patients Undergoing Coronary Artery Bypass Graft Surgery With Cardio-Pulmonary Bypass",,"Completed","No Results Available","Cardio-pulmonary Bypass|Coronary Artery Bypass Graft","Drug: pexelizumab",,"Alexion Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 3","3000","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Prevention","2000099|PRIMO-CABG","January 2002","March 2003",,"October 31, 2002",,"February 23, 2017","Baptist Medical Center Cardiology, Birmingham, Alabama, United States|University of Alabama at Birmingham, Birmingham, Alabama, United States|IMC-Diagnostic and Medical Clinic, Mobile, Alabama, United States|Desert Samaritan - Lutheran Heart, Mesa, Arizona, United States|Good Samaritan Regional Medical Center, Phoenix, Arizona, United States|Saguaro Clinical Research, Tucson, Arizona, United States|Southern Arizona VAMC, Tucson, Arizona, United States|University of Arizona, Tucson, Arizona, United States|Sparks Regional Medical Center, Fort Smith, Arkansas, United States|University of Arkansas, Little Rock, Arkansas, United States|Brotman Medical Center, Beverly Hills, California, United States|Cardiovascular Associates of the Peninsula, Burlingame, California, United States|Seton Medical Center, Daly City, California, United States|St. Jude Medical Center, Fullerton, California, United States|Apex Cardiology, Inglewood, California, United States|Huntington Memorial Hospital, Los Angeles, California, United States|University of Southern California, Los Angeles, California, United States|St. Vincent's Hospital, Los Angeles, California, United States|University of California - Los Angeles, Los Angeles, California, United States|Crozer-Chester Medical Center, Oakland, California, United States|Tri-City Medical Center, Oceanside, California, United States|Mercy General Hospital, Sacramento, California, United States|San Diego Cardiac Center, San Diego, California, United States|Kaiser Foundation Hospital, San Francisco, California, United States|UCSF Moffitt-Long Hospital, San Francisco, California, United States|South Denver Cardiology Associates, Denver, Colorado, United States|Western Cardiology Associates, Denver, Colorado, United States|Heart and Vascular Clinic of Northern CO, Fort Collins, Colorado, United States|St. Vincent's Medical Center, Bridgeport, Connecticut, United States|Bridgeport Hospital, Bridgeport, Connecticut, United States|Christiana Care Health Services, Newark, Delaware, United States|Georgetown University Hospital, Washington, District of Columbia, United States|Cardiology Associates, Washington, District of Columbia, United States|Washington Hospital Center, Washington, District of Columbia, United States|VA Medical Center - Washington DC, Washington, District of Columbia, United States|Florida Cardiovascular Research, Atlantis, Florida, United States|Morton Plan Mease Health Care, Clearwater, Florida, United States|Heart Group Research, Fort Lauderdale, Florida, United States|Gulf Bay Cardiovascular and Thoracic Associates, Hudson, Florida, United States|Jacksonville Center for Clinical Research, Jacksonville, Florida, United States|MIMA Century Research Associates, Melbourne, Florida, United States|Brevard Cardiology Group, PA, Merritt Island, Florida, United States|Medical Research Unlimited, Miami, Florida, United States|Florida Heart Institute at Florida Hospital, Orlando, Florida, United States|Orlando Heart Center, Orlando, Florida, United States|Cardiology Consultants, Pensacola, Florida, United States|Ford Research Center, Pensacola, Florida, United States|Sarasota Memorial Hospital, Sarasota, Florida, United States|Northside Hospital ans Heart Institute, St. Petersburg, Florida, United States|Tallahassee Memorial Regional Medical Center, Tallahassee, Florida, United States|Pepin Heart and Vascular Institute, Tampa, Florida, United States|Emory University Hospital, Atlanta, Georgia, United States|St. Joseph's Hospital, Atlanta, Georgia, United States|University Hospital, Augusta, Georgia, United States|VA Medical Center- Atlanta, Decatur, Georgia, United States|VA Medical Center - Dubin, Macon, Georgia, United States|Straub Clinic and Hospital, Honolulu, Hawaii, United States|Kaiser Permanente Medical Center, Honolulu, Hawaii, United States|Northwestern Univ. Medical Center, Chicago, Illinois, United States|Northwestern University Medical Center, Chicago, Illinois, United States|University of Illinois - Chicago, Chicago, Illinois, United States|Evanston Northwestern Healthcare Evanston Hospital, Evanston, Illinois, United States|Indiana Ohio Heart, Fort Wayne, Indiana, United States|Community Hospital, Indianapolis, Indiana, United States|St. Vincent's Medical Center, Indianapolis, Indiana, United States|Iowa Heart Center - Laurel, Des Moines, Iowa, United States|University of Iowa, Iowa City, Iowa, United States|University of Kansas City Medical Center, Kansas City, Kansas, United States|Wesley Medical Center, Wichita, Kansas, United States|University of Louisville, Louisville, Kentucky, United States|University of Louisville, Louisville, Kentucky, United States|Cardiovascular Institute of the South, Houma, Louisiana, United States|Turuo Infirmary, New Orleans, Louisiana, United States|Methodist Hospital, New Orleans, Louisiana, United States|Alton Ochsner Medical Foundation - Brent House, New Orleans, Louisiana, United States|Cardiac Centers of Louisiana, Shreveport, Louisiana, United States|Cardiovascular Institute of the South, Thibodaux, Louisiana, United States|Sinai Hospital of Baltimore, Baltimore, Maryland, United States|Union Memorial Hospital, Baltimore, Maryland, United States|Washington Adventist Hospital, Takoma Park, Maryland, United States|Midatlantic Cardiovascular Associates, Towson, Maryland, United States|St. Joseph's Hospital, Towson, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham and Womens Hospital, Boston, Massachusetts, United States|Baystate Medical Center, Springfield, Massachusetts, United States|University of Massachusetts, Worcester, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|McLaren Regional Medical Center, Flint, Michigan, United States|Thoracic and Cardiovascular Institute, Lansing, Michigan, United States|West Shore Cardiology Research Department, Muskegon, Michigan, United States|William Beaumont Hospital, Royal Oak, Michigan, United States|Covenant Medical Center, Saginaw, Michigan, United States|St. Luke's Hospital-Duluth, Duluth, Minnesota, United States|St. Mary's Duluth Health System, Duluth, Minnesota, United States|Abbott Northwestern Hospital, Minneapolis, Minnesota, United States|Park Nicollet Medical Center, Minneapolis, Minnesota, United States|North Memorial Hospital, Robbinsdale, Minnesota, United States|Park Nicollet Health Research Center, St. Louis Park, Minnesota, United States|Mississippi Center for Clinical Research, Jackson, Mississippi, United States|St. Luke's Hospital - Mid-America Heart Institute, Kansas City, Missouri, United States|Christian North East Hospital, St. Louis, Missouri, United States|Washington University School of Medicine, St. Louis, Missouri, United States|Cardiology diagnostics, Ltd., St. Peters, Missouri, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Cardiovascular Associates of the Delaware Valley, Haddon Heights, New Jersey, United States|Garden State Cardiology, Paramus, New Jersey, United States|Albert Einstein Hospital, Bronx, New York, United States|Maimonides Medical Center, Brooklyn, New York, United States|United Health Services, Johnson City, New York, United States|New York Presbyterian Hospital, New York City, New York, United States|Rochester General Hospital, Rochester, New York, United States|University of Rochester, Rochester, New York, United States|Westchester County Medical Center, Valhalla, New York, United States|Asheville Cardiothoracic Surgeons, Asheville, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|West forest School of Medicine, Winston-Salem, North Carolina, United States|Akron General Medical Center, Akron, Ohio, United States|Summa Health Systems, Akron, Ohio, United States|Good Samaritan Hospital, Cincinnati, Ohio, United States|Sterling Research Group, Cincinnati, Ohio, United States|Good Samaritan Hospital -Seton Center, Cincinnati, Ohio, United States|Tri Health Bethesda North Hospital, Cincinnati, Ohio, United States|University Hopital of Cleveland, Cleveland, Ohio, United States|Mt. Carmel West, Columbus, Ohio, United States|Dayton Heart Center, Dayton, Ohio, United States|North Ohio Heart Center, Sandusky, Ohio, United States|Oklahoma Foundation for Cardiovascular Research, Oklahoma City, Oklahoma, United States|University of Oklahoma, Oklahoma City, Oklahoma, United States|Integris Baptist Medical Center, Oklahoma City, Oklahoma, United States|Bend Memorial Clinic, Bend, Oregon, United States|Northwest Surgical Associates, Portland, Oregon, United States|Legacy Good Samaritan Hospital, Portland, Oregon, United States|The Heart Center, Doylestown, Pennsylvania, United States|North Memorial Pain Institute, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Guthrie Clinical Research, Sayre, Pennsylvania, United States|Chester County Cardiovascular Center, West Chester, Pennsylvania, United States|The Chattanooga Heart Institute Cardiovascular Group, P.C., Chattanooga, Tennessee, United States|Baptist Memorial Hospital, Memphis, Tennessee, United States|Parkway Cardiovascular Associates, Oak Ridge, Tennessee, United States|Brackenridge Hospital, Austin, Texas, United States|Seton Medical Center, Austin, Texas, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Methodist Hospital, Houston, Texas, United States|Texas Heart Institute, Houston, Texas, United States|VA Medical Center - Houston, Houston, Texas, United States|Texas Tech University Health Center, Lubbock, Texas, United States|South Texas Cardiovascular Consultants Clinical Research Center, San Antonio, Texas, United States|South Texas VA Health Care, San Antonio, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Scott and White Memorial Hospital, Temple, Texas, United States|Fletcher Allen Health Care, Burlington, Vermont, United States|Cardiovascular and Thoracic Surgery Associates, Arlington, Virginia, United States|Inova Fairfax Hospital, Falls Church, Virginia, United States|Mary Washington Hospital, Fredericksburg, Virginia, United States|Sentara Norfolk General Hospital, Norfolk, Virginia, United States|Carillion Roanoke Hospital, Roanoke, Virginia, United States|VA-Medical Center -Seattle Cardiology, Seattle, Washington, United States|University of Washington, Seattle, Washington, United States|FHS Research Center, Tacoma, Washington, United States|Tacoma General Hospital, Tacoma, Washington, United States|Camcare Health Education & Research Institute, Charleston, West Virginia, United States|Appleton Medical Center, Appleton, Wisconsin, United States|Gundersen-Lutheran Hospital, La Crosse, Wisconsin, United States|Wisconsin Center for Clinical Research, Milwaukee, Wisconsin, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Cardiovascular Research and Education Foundation, Inc., Wausau, Wisconsin, United States|Makenzie Health Science Center, Edmonton, Alberta, Canada|Cathy Metcalfe Research Consultants, Delta, British Columbia, Canada|Vancouver General Hospital, Vancouver, British Columbia, Canada|St. Paul's Hospital, Vancouver, British Columbia, Canada|Victoria Heart Institute, Victoria, British Columbia, Canada|University of Manitoba Health Science Centre, Winnipeg, Manitoba, Canada|Health Science Centre, Winnipeg, Manitoba, Canada|New Brunswick Heart Center, St. John, New Brunswick, Canada|General Hospital Health Science Center, St. John's, Newfoundland and Labrador, Canada|Dalhousie University, Halifax, Nova Scotia, Canada|McMaster Clinic, Hamilton, Ontario, Canada|Sunnybrook & Women's College Health Science Centre, Toronto, Ontario, Canada|Toronto General Hospital, Toronto, Ontario, Canada|Montreal Heart Institute, Montreal, Quebec, Canada|University of Montreal, Montreal, Quebec, Canada|Royal Victoria Hospital, Montreal, Quebec, Canada|Hopital Laval, Quebec City, Quebec, Canada|Regina General Hospital, Regina, Saskatchewan, Canada",,"https://ClinicalTrials.gov/show/NCT00048308"
177,"NCT00040157","Safety and Antiviral Study of ACH-126, 443 (Beta-L-Fd4C) in the Treatment of Adults With HIV Infection and Modestly Detectable Viral Load.",,"Terminated","No Results Available","HIV Infections","Drug: ACH126-443 (Beta-L-Fd4C)",,"Alexion Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment","ACH443-006",,,"May 2003","June 25, 2002",,"December 30, 2015","Body Positive, Inc., Phoenix, Arizona, United States|L.a., California, United States|Pacific Horizon Medical Group, Inc., San Francisco, California, United States|Community Health Care Center One, Inc., Ft. Lauderdale, Florida, United States|South Shore Hospital, Miami Beach, Florida, United States|AIDS Research Consortium, Atlanta, Georgia, United States|Chicago, Illinois, United States|St. Lukes Roosevelt Hospital, New York, New York, United States|Stony Brook University Infectious Disease, Dept. of Medicine, Stony Brook, New York, United States|Houston, Texas, United States|Houston, Texas, United States|Hampton Road Medical Specialists, Hampton, Virginia, United States|Swedish Medical Center, Seattle, Washington, United States",,"https://ClinicalTrials.gov/show/NCT00040157"
178,"NCT00037622","Safety and Antiviral Study of ACH-126, 443 (Beta-L-Fd4C) in the Treatment of Adults With Chronic Hepatitis B Infection.",,"Terminated","No Results Available","Chronic Hepatitis B","Drug: ACH-126, 443 (beta-L-Fd4C)",,"Alexion Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ACH443-901",,,"May 2003","May 20, 2002",,"August 19, 2009",,,"https://ClinicalTrials.gov/show/NCT00037622"
179,"NCT00112983","Eculizumab in Treating Patients With Paroxysmal Nocturnal Hemoglobinuria",,"Completed","No Results Available","Leukemia","Biological: eculizumab",,"Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI)","All","18 Years and older   (Adult, Older Adult)","Phase 3",,"Other","Interventional","Allocation: Randomized|Masking: Double|Primary Purpose: Prevention","ALEXION-C04-001|UCLA-0406101-01|CDR0000409569","November 2004",,"June 2005","June 3, 2005",,"May 30, 2013","Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States",,"https://ClinicalTrials.gov/show/NCT00112983"
180,"NCT05117645","Role of Computed Tomography in Evaluation of Different Causes of Intestinal Obstruction Correlated With Operative Findings",,"Not yet recruiting","No Results Available","Intestinal Obstruction","Diagnostic Test: Computed tomography","Emphasization the role of the MDCT in the evaluation of intestinal obstruction.","Sohag University","Female","1 Year and older   (Child, Adult, Older Adult)",,"50","Other","Observational","Observational Model: Cohort|Time Perspective: Prospective","soh-med-21-11-04","December 2021","June 2022","June 2022","November 11, 2021",,"November 11, 2021","Sohag University Hospital, Sohag, Egypt",,"https://ClinicalTrials.gov/show/NCT05117645"
181,"NCT04925804","Unraveling Genetics of HypoPhosPhatasia (HPP Genetics)",,"Completed","No Results Available","Hypophosphatasia",,"Genetic analysis (WGS) of participants clinically suspected for HPP|Analysis and identification of genetic variants","CENTOGENE GmbH Rostock|Alexion Pharmaceuticals","All","Child, Adult, Older Adult",,"16","Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","HPP genetics-2020","June 2, 2021","December 2, 2021","December 2, 2021","June 14, 2021",,"December 29, 2021","Universität Würzburg - Klinische Studieneinheit, Orthopädische Klinik, Würzburg, Germany",,"https://ClinicalTrials.gov/show/NCT04925804"
182,"NCT04725812","Complement Regulation to Undo Systemic Harm in Preeclampsia","CRUSH","Recruiting","No Results Available","Preeclampsia|Severe Preeclampsia|Eculizumab|HELLP|HELLP Syndrome|HELLP Syndrome Second Trimester|Pregnancy Related|AHUS|PNH|Complement Regulatory Factor Defect|Complement Abnormality|HELLP Syndrome Third Trimester","Drug: Eculizumab","Latency (in days) from enrollment to delivery|Composite adverse maternal outcomes|Composite adverse neonatal outcomes|Changes in blood and urine concentrations of terminal complement protein C5a before and after each treatment.|Changes in blood and urine concentrations of terminal complement protein C5b-9 before and after each treatment.|Changes in blood and urine concentrations of complement protein CD59 before and after each treatment.|Aspartate and alanine transaminase concentration before and after each treatment.|Hemoglobin concentration before and after each treatment.|Platelet count before and after each treatment.|Lactate dehydrogenase concentration before and after each treatment.|Serum creatinine before and after each treatment.|Urine protein concentration before and after each treatment.|Ratio of urine protein to urine creatinine before and after each treatment.|Serum concentration of soluble fms-like tyrosine kinase 1 (sFlt-1) before and after each treatment.|Serum concentration of placental growth factor (PlGF) before and after each treatment.|Serum ratio of soluble fms-like tyrosine kinase 1 (sFlt-1) concentration to placental growth factor (PlGF) concentration (sFlt-1/PlGF) before and after each treatment.|Serious adverse events","Cedars-Sinai Medical Center|Alexion Pharmaceuticals","Female","13 Years and older   (Child, Adult, Older Adult)","Phase 2","12","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","STUDY00000039","September 13, 2021","September 13, 2023","March 13, 2024","January 27, 2021",,"September 16, 2021","Cedars-Sinai Medical Center, Los Angeles, California, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/12/NCT04725812/Prot_SAP_000.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/12/NCT04725812/ICF_001.pdf","https://ClinicalTrials.gov/show/NCT04725812"
183,"NCT04304144","A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis",,"Active, not recruiting","No Results Available","AL Amyloidosis","Drug: CAEL-101|Drug: SoC: cyclophosphamide, bortezomib, and Dexamethasone (CyBorD)|Drug: Daratumumab","Dose Toxicity","Caelum Biosciences, Inc.|Alexion Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","25","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CAEL101-203","March 18, 2020","January 23, 2023","January 23, 2023","March 11, 2020",,"January 31, 2022","Clinical Trial Site, Palo Alto, California, United States|Clinical Trial Site, Detroit, Michigan, United States|Clinical Trial Site, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT04304144"
184,"NCT03766347","Pediatric NMOSD Observational Study",,"Recruiting","No Results Available","Neuromyelitis Optica|NMO Spectrum Disorder",,"Time to relapse","Mayo Clinic|Alexion Pharmaceuticals","All","2 Years to 17 Years   (Child)",,"100","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","17-005618","February 1, 2018","February 1, 2022","February 1, 2023","December 6, 2018",,"March 9, 2021","Mayo Clinic, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03766347"
185,"NCT03723512","Non-contrast Enhanced MRI in Patients With C3 Glomerulopathy (C3G) or Immune-complex Membranoproliferative Glomerulonephritis (IC-MPGN) Enrolled in the ACH471-205 Study",,"Completed","No Results Available","C3 Glomerulonephritis|C3 Glomerulopathy|Immune Complex Membranoproliferative Glomerulonephritis|IC-MPGN|Dense Deposit Disease","Device: Non contrast-enhanced magnetic resonance imaging","Median diffusivity (D) in the kidney, renal cortex and medulla.|Renal artery blood flow and renal plasma flow.|Change in median diffusivity in the kidney, renal cortex and medulla after 12-month treatment with ACH-0144471.|Change in renal artery blood flow and renal plasma flow after 12-month treatment with ACH-0144471.","Mario Negri Institute for Pharmacological Research|Alexion Pharmaceuticals","All","17 Years to 65 Years   (Child, Adult, Older Adult)","Not Applicable","7","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","Subproject MRI ACH471-205","December 6, 2018","February 17, 2021","February 17, 2021","October 29, 2018",,"November 26, 2021","Centro di Ricerche Cliniche per le Malattie Rare Aldo e Cele Daccò, Ranica, BG, Italy",,"https://ClinicalTrials.gov/show/NCT03723512"
186,"NCT03580941","Usefulness of a Diagnostic Algorithm to Diagnose Thrombotic Microangiopathies in Pregnancy",,"Active, not recruiting","No Results Available","Hemolytic-Uremic Syndrome",,"Incidence of TMAs|Need for additional interventions|Death|Length of stay in the ICU","Fundación Grupo de Investigación en Cuidados Intensivos y Obstetricia|Alexion Pharmaceuticals","Female","14 Years to 49 Years   (Child, Adult)",,"75","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","LS30885-2","April 15, 2018","August 30, 2020","November 30, 2020","July 10, 2018",,"June 2, 2020","Gestion Salud, Cartagena, Bolivar, Colombia",,"https://ClinicalTrials.gov/show/NCT03580941"
187,"NCT03574506","Eculizumab Use in the Postpartum Period for the Treatment of Pregnancy Associated aHUS: A Case Series",,"Active, not recruiting","No Results Available","Atypical Hemolytic Uremic Syndrome|Pregnancy",,"Maternal mortality|ICU length of stay|Dosing and number of doses received","Fundación Grupo de Investigación en Cuidados Intensivos y Obstetricia|Alexion Pharmaceuticals","Female","14 Years to 49 Years   (Child, Adult)",,"50","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Retrospective","LS30885-1","April 15, 2018","August 30, 2020","November 30, 2020","July 2, 2018",,"June 2, 2020","Gestion Salud, Cartagena, Bolivar, Colombia",,"https://ClinicalTrials.gov/show/NCT03574506"
188,"NCT03418389","Evaluate and Monitor Physical Performance of Adults Treated With Asfotase Alfa for Hypophosphatasia","EmPATHY","Enrolling by invitation","No Results Available","Hypophosphatasia",,"Physical Performance|Body composition|Health related quality of life|Bone Mineral Density|Skeletal pathology|Laboratory evaluation|Safety assessment","Dr. Lothar Seefried|Alexion Pharmaceuticals|Wuerzburg University Hospital","All","18 Years and older   (Adult, Older Adult)",,"25","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Other","KLH-01-2018","September 5, 2018","December 2021","May 2022","February 1, 2018",,"October 8, 2020","Clinical Trial Unit, Orthopedic Department, Wuerzburg University, Würzburg, Germany",,"https://ClinicalTrials.gov/show/NCT03418389"
189,"NCT03329365","Paroxysmal Nocturnal Hemoglobinuria in ESUS & ETUS",,"Unknown status","No Results Available","Paroxysmal Nocturnal Hemoglobinuria|Embolic Stroke of Undetermined Source|Transient Ischemic Attack|Cerebral Vein Thrombosis",,"Frequency of PNH in ESUS/ETUS/SSS-CVTUS|Frequency of PNH in ESUS/ETUS|Frequency of PNH in SSS-CVT","Lawson Health Research Institute|Alexion Pharmaceuticals","All","18 Years to 50 Years   (Adult)",,"200","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","HSREB109061","November 1, 2018","March 29, 2020","March 29, 2020","November 6, 2017",,"March 2, 2020","London Health Sciences Centre, London, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT03329365"
190,"NCT02512562","A Study to Evaluate the Effect of ACH-3102 and Simeprevir on AL-335 Pharmacokinetics in Healthy Volunteers",,"Completed","No Results Available","Chronic Hepatitis C","Drug: AL-335|Drug: ACH-3102|Drug: Simeprevir","Multiple dose PK Profile, Cmax and AUC: effect of ACH-3102 on AL-335 and metabolites|Multiple dose PK Profile, Cmax and AUC: effect of Simeprevir on AL-335 and metabolites|Multiple dose PK Profile, Cmax and AUC: effect of ACH-3102 and Simeprevir on AL-335 and metabolites|Safety Data: Composite number and frequency of treatment emergent adverse events, physical examination findings, abnormal vital signs, 12 lead ECG and abnormal clinical laboratory results|Steady-state PK Profile from Clast, t1/2, Tmax, Tlast, CL/F, Vz/F, λz: effect of AL-335 and ACH-3102 on Simeprevir|Steady-state PK Profile from Clast, t1/2, Tmax, Tlast, CL/F, Vz/F, λz: effect of AL-335 and Simeprevir on ACH-3102","Alios Biopharma Inc.|Alexion Pharmaceuticals","All","18 Years to 60 Years   (Adult)","Phase 1","32","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AL-335-602","July 31, 2015","August 31, 2015","August 31, 2015","July 31, 2015",,"October 16, 2019","Biotrial, Rennes, France",,"https://ClinicalTrials.gov/show/NCT02512562"
191,"NCT02372513","National Lysosomal Acid Lipase Deficiency Study","LAL-D","Completed","No Results Available","Cholesteryl Ester Storage Disease",,"Frequency of Cholesteryl Ester Storage Disease in children who have unexplained transaminase elevation for more than 3 months and/or organomegaly and/or hepatosteatosis unrelated to obesity and/or cryptogenic fibrosis and cirrhosis|Identify demographic and clinical features of Cholesteryl Ester Storage Disease","Ankara University|Alexion Pharmaceuticals","All","3 Months to 18 Years   (Child, Adult)",,"810","Other|Industry","Observational","Observational Model: Cohort|Time Perspective: Prospective","LALD-TR","January 2015","January 31, 2017","March 1, 2017","February 26, 2015",,"November 13, 2017","Ankara University School of Medicine, Ankara, Turkey",,"https://ClinicalTrials.gov/show/NCT02372513"
192,"NCT02013037","The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation","DUET","Completed","Has Results","Antibody-mediated Rejection|Hyperacute Rejection of Cardiac Transplant|Left Ventricular Dysfunction|Cardiac Allograft Vasculopathy|Heart Graft Dysfunction","Drug: Eculizumab","Number of Participants of Pathologic Antibody-Mediated Rejection and Left Ventricular Dysfunction|Patient Survival at 12 Months Post Heart Transplantation|Number of Participants With Hemodynamic Compromise at 6 Months Post Transplant|Number of Participants With Hemodynamic Compromise at 1 Year Post Transplant|Number of Participants With Antibody Mediated Rejection (AMR)|Number of Participants With of Acute Cellular Rejection (ACR)|Development of Cardiac Allograft Vasculopathy (CAV) by Intravascular Ultrasound (IVUS)|Number of Participants With Evolution of DSA: Donor Specific Antibody Post Transplantation","Cedars-Sinai Medical Center|Alexion Pharmaceuticals","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","36","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CSR 205237|Pro00028970","November 2012","December 30, 2019","April 30, 2020","December 17, 2013","May 3, 2021","May 3, 2021","Cedars Sinai Medical Center, Heart Institute, Los Angeles, California, United States","""Study Protocol and Statistical Analysis Plan: Study Protocol including Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/37/NCT02013037/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT02013037"
193,"NCT01895127","Efficacy and Safety of Eculizumab for Treatment of Antibody-mediated Rejection Following Renal Transplantation",,"Terminated","Has Results","Antibody-mediated Rejection|Humoral Rejection","Drug: Eculizumab|Biological: Immunoglobulin|Procedure: Plasmapheresis","Percent Change in Estimated Glomerular Filtration (eGFR) Rate","Brigham and Women's Hospital|Alexion Pharmaceuticals","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","11","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2013P001292","November 2013","April 2016","April 2016","July 10, 2013","September 21, 2017","September 21, 2017","UCSF Medical Center, San Francisco, California, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|University of Michigan Medical Center, Ann Arbor, Michigan, United States",,"https://ClinicalTrials.gov/show/NCT01895127"
194,"NCT01716728","Identification of Undiagnosed Lysosomal Acid Lipase Deficiency",,"Unknown status","No Results Available","Lysosomal Acid Lipase Deficiency|Cholesterol Ester Storage Disease","Other: enzyme analysis","number of patients with previously undiagnosed GD identified Time Frame: up to 2 years Description: Safety Issue?: No number of patients with previously undiagnosed LALD identified","Massachusetts General Hospital|Alexion Pharmaceuticals","All","Child, Adult, Older Adult","Not Applicable","60","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic","2012P000418","August 2012","August 2014",,"October 30, 2012",,"August 13, 2013","Massachusetts General Hospital, Boston, Massachusetts, United States",,"https://ClinicalTrials.gov/show/NCT01716728"
195,"NCT01403389","A Study of the Activity of Eculizumab for Prevention of Delayed Graft Function In Deceased Donor Kidney Transplant",,"Terminated","No Results Available","Delayed Function of Renal Transplant","Drug: Eculizumab|Drug: Placebo","Composite of Delayed Graft Function and Slow Graft Function","Schroppel, Bernd, M.D.|Alexion Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","8","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","HSM 10-1600","December 1, 2011","August 6, 2013","February 6, 2014","July 27, 2011",,"May 6, 2019","Mount Sinai Recanati/Miller Transplantation Institute, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01403389"
196,"NCT01327573","Eculizumab Therapy for Chronic Complement-Mediated Injury in Kidney Transplantation",,"Completed","Has Results","Kidney; Complications, Allograft","Drug: eculizumab","Baseline eGFR (Estimated Glomerular Filtration Rate)|Estimated Glomerular Filtration Rate (eGFR) at Months 2,3,4,5,6|Group Difference Percentage Change in 6-month Estimated Glomerular Filtration Rate (eGFR)","Sanjay Kulkarni|Alexion Pharmaceuticals|Yale University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","16","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","100700716","March 2011","February 2015","February 2015","April 1, 2011","August 12, 2019","August 12, 2019","Yale University, New Haven, Connecticut, United States",,"https://ClinicalTrials.gov/show/NCT01327573"
197,"NCT01303952","Therapy of Chronic Cold Agglutinin Disease With Eculizumab","DECADE","Completed","No Results Available","Cold Agglutinin Disease","Drug: Eculizumab","LDH|Transfusion avoidance|PRBC units transfused|Change in hemoglobin levels|Haptoglobin|Hemopexin|Free hemoglobin|Reticulocytes|SF-36v2 QLQ|FACIT-F SCALE version 4|Six-Minute Walk Test|Circulatory symptoms|Thrombosis record","University Hospital, Essen|Alexion Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 2","13","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CAD01|2009-016966-97","January 2011","September 2014","June 2015","February 25, 2011",,"July 19, 2017","Department of Hematology, University Hospital Essen, Essen, Germany",,"https://ClinicalTrials.gov/show/NCT01303952"
198,"NCT01221181","Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy",,"Completed","Has Results","Dense Deposit Disease|Membranoproliferative Glomerulonephritis","Drug: Eculizumab","Number of Patients With Change in Proteinuria or Serum Creatinine Over Treatment Period","Columbia University|Alexion Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 1","6","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AAAF2403","July 2010","October 2011","October 2011","October 14, 2010","February 19, 2019","February 19, 2019","Columbia University Medical Center, Glomerular Center, New York, New York, United States|Columbia University Medical Center, Nephrology Clinical Research Center, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01221181"
199,"NCT01106027","Dosing Regimen of Eculizumab Added to Conventional Treatment in Positive Crossmatch Deceased Donor Kidney Transplant",,"Terminated","Has Results","Kidney Transplant","Drug: Eculizumab","Number of Subjects With Acute Humoral Rejection (AHR) up to One Year Post Transplant.","Mayo Clinic|Alexion Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","2","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","09-005627DD","March 2010","August 19, 2016","August 19, 2016","April 19, 2010","November 14, 2017","January 31, 2018","Mayo Clinic, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT01106027"
200,"NCT01095887","Eculizumab to Prevent Antibody-mediated Rejection in ABO Blood Group Incompatible Living Donor Kidney Transplantation","ABOi","Terminated","Has Results","Kidney Transplant","Drug: Eculizumab","Number of Subjects With Antibody-Mediated Rejection (AMR) Within 3 Months of Kidney Transplant","Mayo Clinic|Alexion Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","6","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","09-003392|UL1TR000135","May 2010","April 2014","April 2014","March 30, 2010","June 19, 2015","July 20, 2015","Mayo Clinic, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT01095887"
201,"NCT00935883","Complement Inhibition With Eculizumab for the Treatment of Non-Exudative Macular Degeneration (AMD)","COMPLETE","Completed","Has Results","Age-Related Macular Degeneration","Drug: Eculizumab|Drug: Saline","Growth of Geographic Atrophy|Decrease in Drusen Volume|Change in Visual Acuity for Drusen Group|Change in Visual Acuity for Geographic Atrophy Group","Philip J. Rosenfeld, MD, PhD|Alexion Pharmaceuticals|University of Miami","All","50 Years and older   (Adult, Older Adult)","Phase 2","60","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20090055","July 2009","June 2012","August 2013","July 9, 2009","January 26, 2015","May 30, 2017","Bascom Palmer Eye Institute, Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT00935883"
202,"NCT00904826","An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica",,"Completed","Has Results","Neuromyelitis Optica|Devic's Disease","Drug: Eculizumab","Median Number of Neuromyelitis Optica (NMO) Attacks Per Year|Number Subjects Experiencing an NMO Attack in 12 Months of Eculizumab Treatment|Change in Expanded Disability Status Scale (EDDS) Score|Number of Subjects With Change in Visual Acuity in at Least One Eye by at Least One Point|Number of Subjects With Change in Ambulation by at Least 1 Point|Mean Serum Concentration of Eculizumab|Percentage Hemolysis|Mean Eculizumab Concentration in Cerebrospinal Fluid (CSF)|Mean Complement Protein 5 (C5) Concentration in CSF","Mayo Clinic|Alexion Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","14","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","09-001240","April 2009","December 2011","December 2011","May 20, 2009","November 3, 2013","November 3, 2013","Mayo Clinic, Scottsdale, Arizona, United States|Mayo Clinic, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT00904826"
203,"NCT00670774","Dosing Regimen of Eculizumab Added to Conventional Treatment in Positive Cross Match Living Donor Kidney Transplant",,"Completed","Has Results","Kidney Transplant","Drug: Eculizumab","Number of Subjects With Antibody-Mediated Rejection (AMR) in the First 3 Months After Living Donor Kidney Transplantation|Number of Patients Developing High DSA Levels at Less Than or Equal to 3 Months|Number of Patients Requiring Splenectomy|Graft Dysfunction in First Month Post Transplant|Length of Follow-up|Number of Subjects With Graft Survival at One Year|Number of Subjects Receiving Posttransplant Plasma Exchange (PE)|Transplant Glomerulopathy Incidence at One Year","Mark Stegall|Alexion Pharmaceuticals|Mayo Clinic","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","31","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","07-007208","March 2008","May 2017","August 2017","May 2, 2008","June 26, 2018","June 26, 2018","Mayo Clinic, Rochester, Minnesota, United States","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/74/NCT00670774/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT00670774"
204,"NCT02093533","Eculizumab in Primary MPGN","EAGLE","Completed","No Results Available","Membranoproliferative Glomerulonephritis","Drug: Eculizumab","24hours proteinuria|Terminal complement complex (sC5b-9) levels|Glomerular filtration rate (GFR) measured by iohexol plasma clearance and estimated.|Time to disease progression.","Mario Negri Institute for Pharmacological Research|Alexion Pharma Italy s.r.l.","All","up to 75 Years   (Child, Adult, Older Adult)","Phase 2","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EAGLE|2013-003826-10","March 2014","December 2017","December 2017","March 21, 2014",,"January 17, 2018","Ospedale Pediatrico ""Giovanni XXIII"" - U:O Nefrologia, Bari, BA, Italy|A.O. Papa Giovanni XXIII - U.O. Nefrologia e Dialisi/IRCCS IRFMN - Centro di Ricerche Cliniche per le Malattie Rare Aldo e Cele Daccò, Bergamo, BG, Italy|Policlinico Sant'Orsola -Malpighi - U.O.S. Nefrologia e dialisi pediatrica, Bologna, BO, Italy|Policlinico ""G.Martino"" - U.O. Nefrologia e Dialisi, Messina, ME, Italy|Policlinico Universitario di Padova - U.O. Nefrologia Pediatrica, Padova, PD, Italy|Ospedale Centrale, Bolzano, Italy|Policlinico ""Federico II"" - U.O. Nefrologia, Napoli, Italy|Ospedale degli Infermi - U.O. Nefrologia e Dialisi, Rimini, Italy|C.I. Columbus-Università Cattolica del S.Cuore - UOC Nefrologia e Dialisi, Roma, Italy|Ospedale Pediatrico ""Bambin Gesù"" - U.O. Nefrologia, Roma, Italy|Presidio Ospedaliero O.I.R.M. ""Sant'Anna"" - U.O. Nefrologia, Torino, Italy|Ospedale ""Santa Chiara"" - U.O. Nefrologia, Trento, Italy|Ospedale Cà Foncello - U.O. Nefrologia, Treviso, Italy",,"https://ClinicalTrials.gov/show/NCT02093533"
205,"NCT04390464","mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R)","TACTIC-R","Recruiting","No Results Available","COVID19","Drug: Ravulizumab|Drug: Baricitinib|Other: Standard of care","Time to incidence of the composite endpoint of: Death, Mechanical ventilation, ECMO, Cardiovascular organ support, or Renal failure|Change in clinical status as assessed on 7-point ordinal scale compared to baseline|Proportion of patients with adverse events of special interest in each treatment arm|Time to Sp02 >94% on room air|Time to first negative SARS-CoV2 PCR|Duration of oxygen therapy|Duration of hospitalisation|All cause mortality at day 28|Time to clinical improvement","Cambridge University Hospitals NHS Foundation Trust","All","18 Years and older   (Adult, Older Adult)","Phase 4","1167","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TACTIC-R","May 8, 2020","May 7, 2021","May 1, 2022","May 15, 2020",,"May 18, 2020","Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire, United Kingdom",,"https://ClinicalTrials.gov/show/NCT04390464"
206,"NCT01919346","Eculizumab for Prevention of Delayed Graft Function (DGF) in Kidney Transplantation",,"Terminated","No Results Available","Delayed Graft Function|Kidney Transplantation|Complement Activity","Drug: Eculizumab|Drug: Normal Saline","Hemodialysis|Estimated Glomerular Filtration Rate (GFR)|Primary Non-function|Graft Rejection|Patient Survival|Graft Survival|Serum Creatinine|Urine Output|Biomarkers|Qualified Delayed Graft Function (qDGF)","Heeger, Peter, M.D.|Alexion Pharmaceuticals|Icahn School of Medicine at Mount Sinai","All","18 Years and older   (Adult, Older Adult)","Phase 2","21","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","13-0920","August 2013","December 2017","December 2017","August 9, 2013",,"February 27, 2018","Yale - New Haven Hospital, New Haven, Connecticut, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Montefiore Medical Center, New York, New York, United States|University Hospitals Case Medical Center, Cleveland, Ohio, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States",,"https://ClinicalTrials.gov/show/NCT01919346"
207,"NCT03468140","Pilot Trial of Eculizumab Therapy to Reduce Preservation Injury in Human Macrosteatotic Liver Transplantation",,"Withdrawn","No Results Available","End Stage Liver Disease","Drug: Eculizumab|Other: No intervention","Degree of Hepatocellular Injury|Alanine transaminase (ALT) recovery time|Seven-day peak post-transplant (GCT)|Gamma-glutamyl transpeptidase (GCT) recovery time|International Normalized Ratio (INR) recovery time|Seven-day peak post-transplant creatinine","Yale University|Ochsner Health System|Alexion Pharmaceuticals","All","18 Years and older   (Adult, Older Adult)","Early Phase 1","0","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2000021373","October 1, 2021","April 30, 2023","December 31, 2023","March 16, 2018",,"April 8, 2021","Ochsner Clinic Foundation, New Orleans, Louisiana, United States",,"https://ClinicalTrials.gov/show/NCT03468140"
208,"NCT02796885","Characterisation of Adult-Onset Hypophosphatasia",,"Unknown status","No Results Available","Hypophosphatasia","Other: no intervention - observational study","ALP and PLP|ALP:PINP ratio|prevalence of imaging-confirmed musculoskeletal pathology in patients with HPP|short physical function battery score","Sheffield Teaching Hospitals NHS Foundation Trust|National Institute for Health Research, United Kingdom|Alexion Pharmaceuticals","All","16 Years and older   (Child, Adult, Older Adult)",,"250","Other|Industry","Observational","Observational Model: Case-Control|Time Perspective: Cross-Sectional","STH18683|16/NW/0385|202179","November 2016","December 31, 2019","December 31, 2019","June 13, 2016",,"June 4, 2019","Nuffield Orthopaedic Research, Oxford, United Kingdom|University of Sheffield, Sheffield, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02796885"
209,"NCT02113891","Eculizumab Therapy for Subclinical Antibody-mediated Rejection in Kidney Transplantation","TAMARCIN","Withdrawn","No Results Available","Subclinical Acute Antibody-mediated Rejection in Kidney Transplantation","Drug: Eculizumab","Microcirculation inflammation|Transplant glomerulopathy|Measured Glomerular Filtration Rate (Iohexol clearance)|Incidence of adverse effects|Incidence of biopsy-proven acute rejection|CH50|Endothelial Microparticles and Progenitors|Molecular diagnosis of AMR|Donor Specific Antibody titers (Luminex SA)","Assistance Publique - Hôpitaux de Paris|Institut National de la Santé Et de la Recherche Médicale, France|Alexion Pharmaceuticals","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","0","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P101004","February 2015","July 2017","November 2017","April 15, 2014",,"February 25, 2015",,,"https://ClinicalTrials.gov/show/NCT02113891"
210,"NCT01275287","Targeting Complement Activation in Antineutrophil Cytoplasmic Autoantibodies (ANCA)-Vasculitis - Eculizumab",,"Withdrawn","No Results Available","Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis","Drug: Standard of care treatment|Drug: eculizumab","Birmingham Vasculitis Activity Score (BVAS)|Complement levels elevation|Birmingham Vasculitis Activity Score(BVAS)|Normalisation of complement activation|Change in complement levels|change in complement levels 2|Birmingham Vasculitis Activity Score (BVAS) 2","University of North Carolina, Chapel Hill|Alexion Pharmaceuticals|National Institutes of Health (NIH)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","0","Other|Industry|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","10-2218|P01DK058335","May 2011","December 2012","December 2012","January 12, 2011",,"February 23, 2017","UNC Kidney Center, Chapel Hill, North Carolina, United States",,"https://ClinicalTrials.gov/show/NCT01275287"
